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ABSTRACT
Background: Hepatic inflammation has a variety of causes and is a common health
care problem world-wide. Although much work has been undertaken on the
pathogenesis of hepatitis, the underlying cytokine networks involved have remained
elusive. In addition, the recently described family of small molecular weight
chemoattractant cytokines, chemokines, have not been studied in relation to their
potential role in the pathogenesis of liver disease.
Aims of the thesis: To study the mechanisms of chemokine production that may occur
during hepatic disease, the role of chemokines in hepatic injury and repair following
paracetamol poisoning and hepatic expression of chemokines in patients with liver
disease. In addition, the role of tumour necrosis factor alpha (TNF) and stem cell factor
(SCF) were also studied following paracetamol poisoning.
Materials andMethods: Human hepatoma cell line chemokine production was studied
during co-culture with human monocytes and following tumour necrosis factor
stimulation using enzyme linked immunoassay and reverse transcriptase PCR (RT-
PCR). RT-PCR was used to determine the expression of CXC and CC chemokines in
liver biopsy tissue from patients with hepatitis of various aetiologies. The role of
chemokines in hepatic repair following paracetamol poisoning was studied in a murine
model, using 300mg/kg paracetamol administered by intraperitoneal injection (IP).
Repair was quantitated histologically using the AXIO-HOME microscope. Hepatic
16
chemokine expression was inhibited by IP injection of blocking anti-chemokine
antibodies and augmented with an adenovirus MIP2 expression vector. Hepatic TNF
expression was measured following paracetamol poisoning and inhibited with anti-TNF
antibodies, soluble TNF receptor, interleukin (IL) 10 or dexamethasone. Hepatic injury
was measured by serum transaminase concentrations and histologically using H&E
sections. Hepatic SCF expression and role in hepatic regeneration was also determined
following paracetamol poisoning using methods described above.
Results: Both CXC and CC chemokines were produced during monocyte adhesion
with human hepatoma cell lines. EL-8 production was dependent on proinflammatory
cytokine production. In contrast, CC chemokine production appeared to be dependent
on free radical activation of NF-klB. Direct TNF stimulated IL-8 production was
mediated by TNF RI receptors via a protein kinase C pathway and was inhibited by
dexamethasone. Both CXC and CC chemokines were detectable in human liver
biopsies in patients with hepatitis C, hepatic allograft rejection and alcoholic hepatitis.
Hepatic CXC and CC chemokines were also induced following paracetamol poisoning,
inhibition of MIP2 and MIP1 alpha increased 3 day mortality and augmenting MEP2
expression was associated with accelerated hepatic regeneration. Hepatic TNF
expression was not induced following paracetamol poisoning and inhibiting TNF was
not associated with protection from hepatic injury. SCF was present within the liver at
high concentration and located in both hepatocytes and bile ducts. Paracetamol
poisoning was associated with reduced hepatic SCF concentrations and inhibiting SCF
was associated with delayed hepatic regeneration.
17
Conclusions: Both adhesion mediated and direct proinflammatory cytokine stimulation
induce hepatic chemokine production. Chemokines are expressed in liver tissue from
patients with hepatitis and therefore may be implicated in the pathogenesis of hepatic
inflammation. The data regarding the role of chemokines in hepatic regeneration
suggest that these cytokines have much wider biological functions than just
chemoattraction. SCF may also play a role in hepatic regeneration, but TNF is not
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1.1. CYTOKINES: A DEFINITION.
A basic definition for most cytokines would classify these mediators as soluble
hormone-like proteins produced by a variety of cells following stimulation with a
variety of inducers, therefore lipid based inflammatory mediators such as platelet
activating factor (PAF) and leukotrienes, which are not the focus of this thesis, will not
be discussed further (reviewed by Imaizumi et al 1995, Goetzl et al 1995). In contrast
to hormones which are synthesised by specific endocrine tissues, cytokines are
produced by a variety of organs or cells. Historically, the term interleukin (EL) was
proposed to describe proteins produced by lymphocytes acting on lymphocytes and
further classified as monokines or lymphokines, depending upon whether their source
of synthesis was a monocyte/macrophages or lymphocytes, respectively. However, the
cellular source and biological targets of these proteins are not restricted to cells of the
immune system, as endothelial cells, stellate (Ito cells, fat storing cells, myofibroblasts)
cells and hepatocytes are all capable of producing and responding to a number of
different cytokines. Cytokines can broadly be grouped according to their structure or
function into interkeukins, growth factors, interferons, tumour necrosis factors and
chemokines (Table 1.1). However, inclusion in one group does not exclude a cytokine
from membership of another, for example IL-8 is both an interleukin and a chemokine.
In addition, many of the interleukins are also growth and differentiation factors for
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to to
Cytokines are most distinguished for their activities associated with inflammation,
immune reactivity, tissue injury or repair and organ dysfunction. Evidence for the
crucial role of cytokines in the evolution of the inflammatory response comes from the
demonstration that certain viruses encode the genetic information for soluble receptors
for some cytokines, which when expressed by an infected cell inactivates a particular
cytokine and allows the virus to evade the immune system. In addition, certain viruses
may utilise cytokines or cytokine receptors to gain entry into cells, eg. human
immunodeficiency virus (HIV) 1 and chemokine receptors, CCR-5 and CXCR-4
(Kozak et al 1997), or interfere with cellular functions, eg. hepatitis B and IL-6
(Neurath et al 1992). However, many cytokines also play important roles in the
modulation of normal physiological and biochemical functions of cells.
1.2. INTERLEUKINS
As mentioned above, it was originally considered that interleukins were produced by
leukocytes and acted on leukocytes. However, it has become increasingly clear that
these cytokines are produced by cells other than leukocytes and they act on a wide
variety of cells. At present there are 18 different interleukins, as this thesis concentrates
on the roles of tumour necrosis factor a (TNFa) and chemokines in the pathobiology
of liver disorders, the cell source, targets, types of cell receptor and actions of the
interleukins have been summarised in table 1.2.
1.3. INTERFERONS
The interferons (IFN) were first identified by their anti-viral properties, but they have
many other effects, serving as potent immunoregulatory and immunostimulatory
factors. This group of cytokines are divided structurally into three, IFNa, IFN(3 and
23
IFNy. The cellular source, targets, types of cell receptor and actions of the interferons
have been summarised in table 1.3.
1.4. GROWTH FACTORS
Growth factors are proteins that act on other cells to induce proliferation. Often this
function and the target cell can be concluded from the cytokines name, such as
granulocyte-monocyte colony stimulating factor. The cell source, targets, types of cell
receptor and actions of the growth factors have been summarised in table 1.4.
However, many other cytokines possess growth enhancing activity and these will be
discussed under the appropriate sub-headings.
1.5. TUMOUR NECROSIS FACTORS
TNFa (cachectin) and TNF{3 (lymphotoxin) have similar amino acid sequences (30%
homology), bind to the same receptors and produce a wide range of similar effects.
Not least of these is their ability to induce the necrosis of certain tumour cells
(Carswell et al 1975), an effect from which they derive their name.
TNFa (reviewed by Vilcek & Lee 1991) is produced mainly from monocytes and tissue
resident macrophages, but can be synthesised by other cells including neutrophils,
activated lymphocytes, natural killer (NK) and lymphokine activated killer (LAK) cells,
endothelial cells smooth muscle cells and hepatocytes. In contrast, TNFP is produced
by lymphocytes. The primary sequence of TNFa contains both hydrophobic and
hydrophilic areas, thus TNFa is initially expressed as a biologically active 26-kDa
transmembrane protein which is then cleaved to form the 17-kDa, 157 amino acid
mature secreted protein. TNFp can also be expressed in a biologically active
24
Table 1.2. INTERLEUKINS.
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Table 1.4. GROWTH FACTORS.
CYTOKINE SOURCE TARGETS RECEPTORS ACTIONS
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transmembrane form and is cleaved to produce the 171 amino acid, 25-kDa mature
protein. The cleavage of membrane bound TNF can be inhibited by metalloproteinase
inhibitors. Secreted TNFa and TNFp combine to form active non-covalently linked
homotriamers. Single TNFp molecules can also triamerise with two membrane bound
TNFp molecules. This triamer of membrane bound and soluble TNFP binds a specific
TNF receptor, TNF-Rrp (LT-pR).
The two TNFs are induced following endotoxin (lipopolysaccaride, LPS) stimulation
and are responsible for almost all of the clinical symptoms and signs of septic shock.
These cytokines have wide ranging (pleiotropic) effects on multiple cell types, through
their ability to induce the expression of other cytokines, such as growth factors,
interleukins and chemokines. TNFs can also regulate the expression of cell surface
receptors, transcription factors and acute phase proteins. In addition to inducing
tumour necrosis, TNFs can also induce apoptosis of certain cell types.
There are two TNF receptors, TNF-R55 (also referred to as TNFR1, TNFRp, p55 or
CD120a) and TNF-R75 (TNFR2, TNFRa, p75 or CD120b), which are expressed on
all cell types (reviewed by Bazzoni & Beutler 1996). The TNF receptors are encoded
by two different genes, which are differentially regulated. TNFR1 appears to be
constitutively expressed, while TNFR2 can be induced by a variety of external stimuli,
including mitogens, cAMP, lipopolysaccaride and interleukins. Structure/functional
studies have shown that the TNF receptors are only able to bind triamers of TNFa or
TNFp. The intracellular domains of TNFR1 and TNFR2 are different suggesting that
they induce different intracellular signalling pathways. There is also evidence that both
receptors have different biological functions; depending on the cell type studied,
TNFR1 translates the cytotoxic signals of the TNFs and TNFR2 the proliferative and
regulatory signals. Although TNFR2 is constitutively phosphorylated, neither TNFR
has intrinsic kinase activity. Recently several elegant studies have elucidated the novel
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family of TNFR associated proteins that are essential for signal transduction (Figure
1.1.). Binding of TNFs with their receptors can subsequently induce a wide variety of
intracellular signalling pathways which are listed in Table 1.5.
1.6. CHEMOKINES
The chemokines are a recently characterised family of chemoattractant cytokines that
are structurally divided into at least three different groups (Table 1.6) depending on the
arrangement of the first two cysteine residues in the amino acid sequence (reviewed by
Adams & Lloyd 1997, Baggiolini et al 1997). The CXC chemokines, for example IL-8
or Growth related gene (Gro), have a non-conserved amino acid between the cysteine
residues. In contrast, the CC chemokines, for example monocyte chemoattractant
protein (MCP) 1 or macrophage inflammatory protein 1 alpha (MlPla), have no amino
acid between the cysteine residues. Two recently characterised chemokine molecules
have a different primary structure, lymphotactin has only a single cysteine at the N-
terminus and neurotactin has 4 amino acids between the first two cysteine residues.
The genes for the CXC chemokines are clustered on chromosome 4, and the genes for
the CC chemokines are found on chromosome 17. Stromal cell derived factor (SDF) a
recently characterised CXC chemokine is encoded on the long arm of chromosome 10.
Most cell types can synthesise the CXC chemokines, while the cells able to express the
CC chemokines are more limited. MlPla, for example, is only produced by immune
cells. The nomenclature of the chemokine family is some what confusing, however a
comparison of human, murien and rat chemokines is shown in table 1.6.
The early response cytokines, TNFa and IL-ip, are primary stimuli to the production
of chemokines. Many other stimuli exist, including other cytokines such as IFN-y,
oxidant stress, bacterial or viral infection. Chemokines were originally described
30













TNFR = tumour necrosis factor receptors, TRADD = TNFR associated proteins with death domains,
FADD = Fas assocaited proteins with death domains, TRAF = TNF associated factors.
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Table 1.5. TNFa intracellular signalling pathways.
Activation of phospholipases;
Neutral and acidic sphingomyelinase,
Phospholipase C (phosphatidylcholine and phosphatidylinositol specific),
Phospholipase A,
Phospholipase D.




c-jun N-terminal protein kinase,
c-raf-1 serine/threonine kinase.
Induction of free radical generation.
Increased intracellular calcium concentration.
Induction of nitric oxide production.
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regarding their chemoattractant properties. In general, CXC chemokines are neutrophil
chemoattractants and CC chemokines are monocyte chemoattractants. However, some
recently described members of the CXC chemokines, interferon inducible protein 10
(IP-10) and monokine induced by interferon gamma (MIG), are not biologically active
on neutrophils. Both IP-10 and MIG do not have the amino acid sequence Glu-Leu-
Arg (ELR) at the N-terminal side of the CXC motif, which is essential for binding and
activation of the neutrophil IL-8 receptors that induce chemotaxis. Both CXC and CC
chemokines act as lymphocyte chemoattractants with some selectivity on certain
lymphocyte subsets. Chemokines are also growth factors for haemopoietic cells,
activating factors for a variety of cell types, are able to induce angiogenesis and inhibit
entry of human immunodeficency virus into permissive cells.
There are several chemokine receptors characterised, including several orphan
receptors which have no characterised ligand at present The chemokine receptors and
their ligands are detailed in Table 1.7. Chemokine receptors are members of the seven
transmembrane domain G-protein signalling family of cull surface receptors, and as
such are sensitive to inhibition by pertussis toxin. There is evidence that some of the
specificity of chemokine action is dependent on the interaction with different G-protein
isoforms, the IL-8 receptors can bind Gai2, Gai3, Gal4, Gal5 and Gal6 while
CCR1 can couple Gal4 but not Gal6. Coupling of the receptor and ligand induces
phospholipase C hydrolysis of phosphatidylinositol 4,5-bisphosphate into two
potentially active products, inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG).
IP3 mobilises intracellular calcium and activates calmodulin dependent protein kinases.
Both DAG and the elevated intercellular calcium can also activate the serine/threonine
protein kinase C. Protein kinase C comprises a family of at least 7 different but
structurally related enzymes which have different substrate specificity. G proteins can
also associate with adenylate cyclase, cGMP phosphodiesterase and Ras, with the
activation of other intracellular signalling pathways. For example, the IL-8 receptor,
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CCR1 MlPla, MIPip, RANTES, MCP-2,
MCP-3, MCP-4
CC R2a/b MCP-1, MCP-2, MCP-3, MCP-4
CCR3 Eotaxin, RANTES, MCP-3, MCP-4,
MlPla, MIPip
CCR4 RANTES, MlPla, MCP-1
CC R5 RANTES, MEPla, MIPip
CC R6 Liver and activation regulated
chemokine (LARC)
CC R7 EBIl-ligand chemokine
CC R 8 1-309
Duffy Antigen CXC chemokines (IL-8, Gro, ENA-
78) and CC chemokines (RANTES,
MlPla, MIPip, MCP proteins)
Orphan chemokine receptors Unknown
Viral chemokine receptors Various
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CXCR1, is able to increase intracellular calcium, activate phospholipase D and induce
free radical generation. Both IL-8 receptors can phosphorylate the p42/p44 mitogen
activated protein kinase (MAP-kinase) and phosphatidylinositol 3-kinase. The former
kinase can also be induced by MCP-1 stimulation of the CCR2 chemokine receptor.
1.7. CYTOKINE PRODUCTION: The importance of intercellular
networking.
The liver is an important organ in the metabolism of cytokines, with the capacity both
to produce and remove cytokines. Hepatic uptake of circulating cytokines is inhibited
by alcohol (Deaciuc et al 1996) and this may contribute to the elevated levels of TNFa
and EL-6 that are observed in such patients. Ail cells normally resident in the liver have
the capacity to produce cytokines which by stimulating surrounding cells (paracrine
effect) or themselves (autocrine effect) lead to further cytokine production and
amplification of an inflammatory response. While some cytokines are released by
resting cells, the concentrations and variety of cytokines released is considerably
increased following stimulation by a variety of inducers.
1.7.1. Hepatic injury during sepsis.
The production of cytokines within the liver often depends upon the initial
induction of early response cytokines released from tissue resident macrophages
(Kupffer cells). A good example of this complex network of cytokine signals, leading
to the amplification of an immune response, follows the injection of
lipopolysaccaride/endotoxin. In the liver, lipopolysaccaride binds to CD 14 and other
cell surface molecules on the Kupffer cell and stimulates the production of both TNFa
and IL-ip. These early response proinflammatory cytokines activate macrophages via
an autocrine effect and recruit the stromal cells of the liver (endothelial cells, stellate
cells and hepatocytes) to participate in the inflammatory response (paracrine effect) by
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inducing expression of cytokines and chemokines by these cells (Thornton et al 1990,
1992). TNFa and EL-1P can also induce the expression of adhesion molecules, such as
intercellular adhesion molecule 1 (ICAM-1), on the endothelial surface and the
corresponding ligand Mac-1 on circulating inflammatory cells. Adhesion between
circulating mononuclear cells and activated endothelium via ICAM-1 induces both
CXC and CC chemokine expression (Lukacs et al 1994, 1995a), which attract and
activate circulating inflammatory cells and further amplifies an inflammatory response.
In addition to inducing and amplifying a local inflammatory response, TNFa may
induce both necrosis and apoptosis of hepatocytes via a direct mechanism and through
the induction of nitric oxide expression by the hepatocytes themselves (Kurose et al
1996). Cell damage may also be mediated via free radical and elastase production
induced by TNFa.
1.7.2. Ischaemia reperfusion injury
Another example of the importance of cytokine networks in the development of
hepatic injury occurs consequent to ischaemia/reperfiision (I/R). This important clinical
problem can occur following hepatic resection or surgery and after hypotension and
resuscitation. There are two phases of hepatic injury following I/R; an initial phase (1-3
hours post reperfusion), which is associated with free radical generation and KupfFer
cell activation and a later phase (6-24 hours post reperfusion) associated with
neutrophil influx into the liver. The accumulation of neutrophils following I/R occurs in
both experimental animal models and patients with cirrhosis and are important effectors
of hepatic damage. The cascade of events leading to neutrophil accumulation is now
better understood following the publication of several recent studies. Free radicals
released following reperfusion stimulate the production of PAF and TNFa (Suzuki et
al 1994, Serizawa et al 1996) from Kupffer and endothelial cells. Hepatic expression of
IL-la, another early response cytokine, is also elevated following I/R (Shito et al
1997). Both PAF and TNFa can stimulate the production of each other and therefore
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further amplify the inflammatory response. Neither TNFa, PAF or IL-la are
chemoattractant for neutrophils, but these cytokines can stimulate the release of
neutrophilic chemoattractants, such as epithelial neutrophil activating peptide (ENA-
78) and cytokine induced neutrophil chemoattractants (CINC), from parenchyma and
non-parenchyma cells of the liver (Colletti et al 1996a, Deutschman et al 1996).
Inhibition of early response or chemoattractant cytokines and increasing circulating IL-
1 receptor antagonist attenuates hepatic neutrophil accumulation and damage in animal
models of I/R. Hepatic neutrophil infiltration and damage also occurs following 70%
hepatectomy and similar cytokine/chemokine networks have been reported with
increased TNFa expression inducing local production of the neutrophil
chemoattractant, ENA-78 in the liver (Colletti et al 1996b). LPS stimulated TNFa
release from monocytes is also increased in patients after partial hepatectomy and
therefore similar mechanisms of hepatic damage may occur in humans (Sato et al
1996).
1.7.3. Other stimuli to cytokine production
Reactive oxygen intermediates are produced by hepatocytes during the
metabolism of ethanol, paracetamol and a variety of other drugs. Free radicals can
activate the transcription factor, NF-kB, which can induce the transcription of a variety
of cytokines and chemokines (Sen & Packer 1996). Hepatitis B viral infection
stimulates the production of TNFa (Larapezzi et al 1996) and human herpesvirus 6
may induce IL-8 expression (Inagi et al 1996) in Hep G2 hepatoma cells. Ethanol
induces IL-8 (Shiratori et al 1993) and Gro (Shiratori et al 1994) production in rodent
primary hepatocyte cultures and supernatants from ethanol treated hepatocytes can
induce the production of CINC from rat Kupffer cells (Mawet et al 1996). This latter
effect is dependent on hepatocyte ethanol metabolism and is inhibited by 4-
methylpyrazole. Cytokine production in the liver is also affected by hormones (Van
Gool et al 1990), adrenaline increases LPS induced IL-6 production, but reduces TNF
39
a synthesis. Low concentrations of corticosterone, similar to those found in vivo,
enhance the production of IL-6 and TNFa by LPS, but higher concentrations of
corticosterone inhibit cytokine production.
Unopposed amplification of the immune response could lead to the development of
autoimmune disease or massive release of proinflammatory mediators with multiorgan
failure and death, as is seen during sepsis. Several negative immune modulators exist
including anti-inflammatory cytokines (eg. IL-10 and IL-4), soluble cytokine receptors
(soluble TNF receptors) and cytokine antagonists (IL-1 receptor antagonist). IL-10 for
example down regulates endotoxin mediated IL6 release from Kupffer and sinusoidal
endothelial cells (Knolle et al 1997). However, not all soluble cytokine receptors are
inhibitory, soluble IL-6R (p80) can induce IL-6 effects on cells not normally expressing
this component of the IL-6 receptor by binding to the ubiquitously expressed gpl30
signal transduction polypeptide (Fernandezbotran et al 1996).
1.8. CYTOKINE RECEPTORS.
The functions of cytokines are mediated by binding to specific receptors expressed on
the surface of target cells (Foxwell et al 1992). Cytokine receptors can be classified
structurally into 5 different groups (Table 1.8). The immunoglobulin superfamily
contain several extracellular immunoglobulin like domains and include other cell
surface molecules such as MHC, the T cell receptor and ICAM-1. The haematopoietic
growth factor family have a conserved amino acid sequence (tryptophan-serine-X-
tryptophan-serine or WSXWS) usually located on the extracellular domain just
proximal to the transmembrane region of the receptor. The TNF receptor family also
includes the CD40 antigen on B cells and Fas (Van den Abeele et al 1995). There are 2
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The interferon receptor family comprises of the receptors for IFN-cc/p and IFN-y.
Lastly is the chemokine receptor family, characterised by 7 transmembrane alpha-
helical structures, which are discussed in detail above. (Horuk 1994). Some cytokine
receptors are hybrids, for example the IL6R contains both immunoglobulin and
WSXWS domains and most cytokine receptors are not single polypeptide chains, but
complexes of two or more. One polypeptide chain binds the cytokine ligand which then
diamerises with a signal transducing polypeptide generating a receptor with greater
ligand affinity. Signal transducing polypeptides may bind to a number of different
cytokine binding chains; for example, gpl30, the signal transducing portion of the IL-6
receptor can also interact with the receptors binding leukaemia inhibitory factor (LIF),
oncostatin M and ciliary neurotrophic factor (CNTF).
1.8.1. Intracellular signalling.
Binding of cytokines to their receptors, stimulates a complex system of
intracellular signals ultimately leading to the biological effect of the cytokine on its
target cell (Foxwell et al 1992, Horuk 1994, Schindeler & Darnell 1995, Van den
Abeele et al 1995, Diehl & Rai 1996, Mufson 1997, Darnay & Aggarwal 1997). Some
of the growth factor receptors, eg. monocyte colony stimulating factor (M-CSF),
platelet derived growth factor (PDGF) and epidermal growth factor (EGF), have
intrinsic tyrosine kinase activity. Ligand binding induces receptor diamerisation,
autophosphorylation and attracts cytosolic proteins with Src homology which
subsequently activate the MAP-kinase pathway. Other intracellular signalling pathways
may also be activated by receptors with intrinsic tyrosine kinase activity, including
phosphoinositol, protein kinase C and Ras-GTPase. Most cytokine receptors do not
posses intrinsic tyrosine kinase activity but associate with soluble cytoplasmic protein
tyrosine kinases such as those of the Janus (Jak) or Tyk tyrosine kinase families. Jak
phosphorylates members of the STAT (signal transduction and activator of
transcription) protein family, which associate with other cytoplasmic phosphorylated
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STAT proteins, translocate to the nucleus and activate gene transcription by binding to
specific sequences in target genes. STAT proteins can also be phosphorylated directly
by the membrane bound receptor tyrosine kinases. The specificity of the intracellular
signals activated by different cytokines is dependent on the activation of specific STAT
proteins (Table 1.9) and the different target gene sequences recognised by the different
STAT protein diamers. Phosphorylation dependant activation of cytosolic protein
phosphatases by tyrosine kinases also affects the degree of protein tyrosine
phosphorylation and hence activation of these enzyme systems. Signal transduction of
the interferon receptors is also mediated via the Jak/Tyk STAT pathway. TNFa
induces a wide variety of intracellular second messengers including NF-kB,
serine/threonine (stress activated protein kinase, SAPK) and tyrosine kinases,
ceramide/sphingomyelin, reactive oxygen species and phosphoinositols. Intracellular
signalling induced by chemokine receptor binding has been discussed above.
1.8.2. Intracellular signalling in liver cells
Most studies regarding cytokine intracellular signalling have been conducted in
cells of the immune system rather than hepatocytes or the nonparenchymal cells of the
liver. Increased intracellular cGMP is involved in the production of TNFa by Kupffer
cells during sepsis (Harbrecht et al 1995). Phosphorylation of Jakl and to a lesser
extent Jak2 with STAT phosphorylation, Ras and MAPK activation has been recently
reported following IL-4 stimulation of hepatocytes (Chuang et al 1996). IFN-y and IL-
6, but not EL-ip, TNFa and EGF, activate STAT3 in rat hepatocytes and human
hepatoma cells (Kordula et al 1995). In contrast with IL-6, which produces rapid and
transient activation of STAT1 and STAT3 in HepG2 cells, hepatocyte growth factor
(HGF) induces delayed and sustained activation of STAT3 only (Schaper et al 1997).
Insulin inhibits hepatocyte IL-6 induced acute phase response by transcriptional
inhibition of STAT3 expression (Campos et al 1996). IL-ip induces the SAPK
pathway in HepG2 cells, but does not activate Ras or MAP-kinase (Bird et al 1994).
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4 Interleukin 12 GAS
5 Interleukin 2, 3,
5, 7, 15, GM-
CSF, SCF, Epo.
GAS
6 Interleukin 3, 4,
13, PDGF
GAS
ISRE = interferon stimulated response element, GAS = gamma
activated sequence. These are palindromic DNA sequences (GAS =
TT N(i) AA, binding of STAT 1 and STAT 4 is best when N(i) = 5,
binding of STAT 3 is best when N(i) '= 4 and binding of STAT 6 is
best when N(i) = 6).
Oxidative stress can also induce the MAP-kinase which via phosphorylation of protein
phosphatases can dephosphorylate and inactivate hepatic p38, a phosphoprotein
constitutively active in the liver (Mendelson et al 1996). In addition TNFa can induce
specific hepatocyte phosphatase expression and hence modulate signalling via
cytoplasmic or membrane bound protein kinases (Ahmad et al 1997).
1.9. CYTOKINES AND HEPATIC METABOLISM.
The functions of cytokines are diverse and clearly include a role in normal physiologic
functions and homeostasis. Body temperature fluctuation during the day, appetite
regulation and lethargy/sleep patterns are all controlled at least in part by cytokines.
The normal metabolic functions of the liver, including gluconeogenesis, lipid and
protein metabolism are affected by cytokines. TNFa increases hepatic HMG CoA
reductase activity, lipid synthesis and secretion and expression of LDL receptors (Laio
& Floren 1994) but reduces both hepatic and plasma LCAT activity. Transforming
growth factor (3 (TGFP) inhibits LCAT activity in Hep G2 cells {Skeltering et al 1995).
EL-4 induces the expression of cytochrome P450 2E1 and glutathione S-transferases.
In contrast, IL-2, TNFa, IL-ip and IL-6 can inhibit the induction of certain
cytochrome P450 isoforms. Endocytosis of hepatocytic mannose and scavenger
receptors is enhanced by TNFa and IL-ip (.Asumendi et al 1996), but these cytokines
inhibit the activity of bile acid transporters on the biliary canalicular membrane
(Moseley et al 1996, Green et al 1996). The biological effect of cytokines, such as
TNFa is dependent on the effective concentration; low concentrations are involved in
homeostasis, increasing local concentration of TNFa is associated with local
inflammatory response and focal hepatic necrosis and massive release ofTNFa into the
circulation results in systemic activation with adult respiratory distress syndrome and
multiple organ failure.
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1.10. CYTOKINES AND THE ACUTE PHASE RESPONSE.
The acute phase response is characterised by increased circulating concentrations of
several different plasma proteins, including C-reactive protein (CRP), serum amyloid A
(SAA) protein, haptoglobin, fibrinogen and a2 macroglobulin (positive acute phase
proteins), and the reduction in others, such as albumin, alpha fetoprotein, fibronectin
and transferrin (negative acute phase proteins). The altered serum concentrations of
these proteins is the direct result of changes in protein synthesis and release from
hepatocytes under the influence of cytokines. The effects of cytokines on the hepatic
acute phase response has been the subject of several recent reviews (Baumann &
Gauldie 1994, Koj 1996, Moshage 1997).
IL-6 affects the synthesis and secretion of a wide range of acute phase proteins from
cultured rodent and human primary hepatocytes, hepatoma cell lines and in vivo in
animal models and man (Banks et al 1995). The synthesis of positive acute phase
proteins is induced by IL-6, while the production of negative acute phase proteins is
inhibited. Other cytokines utilising the common gpl30 signal transducing receptor
(LIF, oncostatin M, CNTF and cardiotropic 1) can also induce similar changes in acute
phase protein production by cultured hepatocytes. The importance of gpl30 in signal
transduction during the acute phase response in vivo is supported by the inhibition of
IL-6 stimulated acute phase protein production by monoclonal anti-gpl30 antibodies
(Harrison et al 1996). Many other cytokines, eg. TNFa, IL-ip, EL-4, IL-8, EL-10, IL-
13 and EFN-y, and growth factors, such as TGFp and HGF can induce an acute phase
response or modulate the effects of EL-6. Hep G2 cells also express G-protein
receptors for the chemoattractants, C5a and FMLP, which are also able to induce
production of the positive acute phase proteins and inhibit negative acute phase protein
production (Buchner et al 1995, McCoy et al 1995). Classic hormones, eg.
corticosteroids, can also modulate the cytokine stimulated acute phase response.
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1.11. CYTOKINES, HEPATIC INJURY AND INFLAMMATION.
Many animal models of hepatic inflammation exist, two well studied examples are
lipopolysaccaride administration to rodents sensitised with galactosamine (LPS/GalN)
and Concanavallin A injection. Serum cytokines are not elevated following LPS/GalN,
however hepatocyte apoptosis is followed by inflammatory cell infiltration, hepatic
necrosis, and elevated serum transaminases. The histological changes in the liver and
elevated serum transaminases occurring following LPS/GalN administration are
prevented by prior administration of anti-TNF antibodies, soluble TNF receptors,
exogenous recombinant EL-10, cyclosporin or dexamethasone (Santucci et al 1996,
Louis et al 1997). Phosphodiesterase inhibitors can also inhibit hepatic injury in this
model by altering the cytokine balance in favour of anti-inflammatory cytokines, such
as EL-10 (Gantner et al 1997). Recently, transcriptional blockers other than GalN, such
as actinomycin D and alpha amanitin were also shown to induce apoptosis, hepatic
inflammation and necrosis which could be prevented by anti-TNF antibodies {Leist et
al 1997). TNFa dependant hepatocyte apoptosis appears to signal via the EL-1
converting enzyme (ICE) like protease pathway and can also be prevented in vitro and
vivo by specific ICE-protease inhibitors (Knustle et al 1997). Pretreatment with EL-1(3,
by inducing tolerance, can also inhibit hepatocyte apoptosis induced by TNFa in the
LPS/GalN model (Bohlinger et al 1995).
Concanavallin A (Con-A) injection induces massive T cell activation, infiltration of the
liver with neutrophils, CD4+ and CD8+ lymphocytes and focal hepatic necrosis. Serum
elevation of EL-2, TNFa and EFN-y have been reported. In vitro studies have
implicated perforin mediated hepatocyte injury, observing that TNFa is not directly
cytotoxic to Con-A treated hepatocytes (Watanabe et al 1996). In contrast, others
have shown ConA is directly cytotoxic to cultured hepatocytes (Leist & Wendel 1996).
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However, in vivo administration of anti-TNF antibody, anti-EFN-y antibody or
recombinant IL-6 prevents hepatic damage without affecting IL-2 release or hepatic
infiltration of inflammatory cells (Mizuhcira et al 1996). Soluble TNF receptor is also
effective in preventing liver damage in this model (Bruck et al 1997)
The advent of transgenic technology has lead to its use in the study of hepatic
inflammation. IFN-y transgenic mice develop a chronic hepatitis, which appears
mediated by TNFa (iOkamoto et al 1996). The HBV transgenic mouse has improved
greatly the understanding of the pathogenesis of hepatic damage in HBV infection
(Chisari & Ferrari 1995). The observed reduction in HBV transcription following
infection with other hepatotropic viruses or bacteria in HBV transgenic mice appears
secondary to the local production of IFN-y and TNFa by macrophages and cytotoxic
lymphocytes (Guidotti et al 1996). An inhibitory effect on HBV replication in these
mice can also be induced by exogenous recombinant EL-12 administration via the
induction of IFN-y (Cavanaugh et al 1997). IFN-y can induce apoptotic cell death in
primary hepatocyte culture (Morita et al 1995) and this mechanism may be important
in clearance of viral infected cells in vivo. Adenovirus transfection or liposomal
encapsulation, the latter with or without retrovirus infection (Wu & Zern 1996), have
been used to study the transient expression of cytokines in the liver. For example,
adenovirus mediated expression of CINC, a CXC chemokine, in the liver is associated
with the development of a neutrophilic hepatitis (Maher et al 1997).
1.11.1. Clinical studies of cytokines and hepatic inflammation
The serum or plasma concentrations of a variety of cytokines and cytokine
antagonists are elevated in patients with liver disease. However, the potential
pathogenic role of elevated circulating cytokines to the development of hepatic
inflammation is not clear. Increased circulating proinflammatory cytokines can
contribute to the multiorgan failure seen in some patients with liver disease. Elevated
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circulating TNFa or EL-ip have been observed in patients with alcoholic liver disease,
especially those who are malnourished, and have been correlated with survival (Means
et al 1996). Increased circulating TNFa has been reported in patients with the HELLP
syndrome (Haeger et al 1996) and others with acute liver failure (Keane et al 1996).
EFN-y is found in the serum of patients with viral hepatitis and acute cellular rejection
(Cacciarelli et al 1996). Increased circulating TNFa and M-CSF have been reported in
patients with viral hepatitis (Spengler et al 1996). Increased circulating IL-6 occurs in
patients with HCV infection and is correlated with hepatic inflammatory activity and
serum HCV-RNA levels (Malagnarnera et al 1997). In addition to increased TNFa,
elevated EL-8 has been reported in patients with alcoholic liver disease (Sheron et al
1993). Increased circulating IL-8 may have a suppressive effect on neutrophil function
as has been reported in IL-8 transgenic mice; these mice are unable to mount a
neutrophil response to intraperitoneal injection of bacteria {Simonet et al 1994).
Cytokine production from peripheral blood mononuclear cells have also been studied in
a variety of liver conditions, but again their importance in understanding the pathogenic
mechanisms within the liver are unclear. LPS induced TNFa expression is increased in
blood monocytes from patients with alcoholic liver disease due to a decreased
responsiveness to the anti-inflammatory effects of EL-10 (Lemoine et al 1995).
Monocyte production of proinflammatory cytokines is increased in patients with
hepatitis C virus (HCV) infection, although others have shown impaired phorbol-12-
myristate-13-acetate (PMA) stimulated TNFa and IL-ip release (Mendoza et al
1996). Mitogen and HCV peptide stimulated T cells, derived from peripheral blood,
produce TNFa and EFN-y but little EL-4. In contrast, spontaneous IL-10 production
and HCV peptide stimulated IL-12 production was similar in patients with HCV
infection compared with patients with liver cirrhosis and controls (Kakumu et al 1997).
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Many studies using reverse transcriptase, polymerase chain reaction (RT-PCR), in-situ
hybridisation or immunohistochemistry have demonstrated hepatic expression of a
variety of different cytokines in patients with liver disease. Hepatic expression of TNF
a has been reported in hepatitis B, hepatitis C, autoimmune liver disease and alcoholic
hepatitis (Llorente et al 1996, Fang et al 1996). Recent interest has focused on
differentiating the T helper (Th) cell responses in various inflammatory conditions into
Thl, characterised by IFNy and IL-2 expression and a cell-mediated response, or Th2,
characterised by IL-4 and EL-5 expression and an antibody mediated immune response.
ThO denotes a mixed response. A Th2 response may be associated with fibrosis and
viral persistence, in contrast a vigorous Thl response may damage surrounding
hepatocytes (a bystander effect). Hepatic expression of Thl cytokines has been
reported in patients with hepatitis C infection, in addition, T cell clones prepared from
liver tissue produce Thl cytokines following stimulation with recombinant HCV
proteins (Napoli et al 1996, Lohr et al 1996). Chronic cellular rejection following
hepatic transplantation is also associated with the expression of Thl cytokines in the
liver (Gorczynski et al 1996). In contrast with HCV infection the situation in patients
with hepatitis B infection is more complicated. Patients infected with HBV express
both IL-4 and IFN-y (ThO) when the liver is severely inflamed (Bertoletti et al 1997).
Others have shown hepatic expression of Thl cytokines in patients with acute HBV
and active inflammation and Th2 cytokines in patients with chronic infection and low
levels of hepatic inflammation (Fukuda et al 1995). However, it is not clear if this
latter finding is related to switching of the immune response from Thl to Th2, as has
been reported in the natural evolution of immune responses in mice. The T helper
response in hepatitis B may be dependent on the antigen expressed at a particular time.
Hepatitis B core antigen can induce a Thl response and hepatitis B e antigen induces
Th2 or ThO helper T cells in vivo, this effect can also be modulated by exogenous IFN
a (Milich et al 1997). Differentiation of the immune response into Thl or Th2 like
responses in patients with primary biliary cirrhosis (PBC) is more confused. Mitogenic
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stimulation of liver infiltrating T cells from patients with PBC and some with
autoimmune hepatitis produce Th2 cytokines (Lohr et al 1994). However others,
studying the intrahepatic expression of IFN-y and EL-4, have suggested a
predominance of a Thl phenotype in PBC {Hcirada et al 1997). Defective purified
protein derivative (PPD) stimulated Thl and Th2 cytokine production by peripheral
blood cells has also been reported in patients with PBC {Jones et al 1997)
In some conditions the cellular infiltrate in the liver has been correlated with hepatic
expression of chemoattractant cytokines. Hepatic neutrophil infiltrates are prominent in
alcoholic hepatitis and have been correlated with the local expression of the CXC
chemokines, EL-8 {Sheron et al 1993) and Gro (Maltby et al 1996). In addition, a
hepatotoxic effect of the murine Gro homologue, macrophage inflammatory protein 2
(MEP2), has also been implicated in the pathogenesis of alcoholic liver disease
(Bautista 1997). Hepatic expression of IL-5, a potent eosinophil chemoattractant, has
been reported in conditions such as PBC {Martinez et al 1995) and acute cellular
rejection following liver transplantation {Martinez et al 1993), which can both be
associated with hepatic eosinophilia. Acute cellular rejection is also characterised by
lymphocytic inflammation and hepatic expression of the CC chemokines, MlP-la and
MIP-lp {Adams et al 1996).
1.12. CYTOKINES AND HEPATIC FIBROSIS.
The stellate cell plays a central role in the development of hepatic fibrosis and cirrhosis.
The effect of cytokines on stellate cell biology have been reviewed recently by several
authors {Davis & Kresina 1996, Alcolando et al 1997). In summary, stellate cell
proliferation and collagen synthesis can be influenced by Kupffer cell (eg. TGF0 and
TNFa), endothelial cell (eg. PDGF) and hepatocyte (eg. insulin like growth factor and
IGF-binding protein) derived factors {Gressner et al 1995). Stellate cell derived PDGF
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also has an autocrine effect on the producing cells. IL-ip, IL-4 and EL-6 can also
modulate stellate cell collagen and cytokine synthesis. Another example of cytokine
networking involving hepatic stellate cells (Benyon et al 1997) is their recently
reported ability to secrete stem cell factor (SCF). SCF activates mast cells and
prolongs their survival by inhibiting apoptosis. Recent reports have correlated the
degree ofmast cell infiltration with the severity of hepatic fibrosis (Farrell et al 1995).
Hepatic SCF mRNA and protein concentration is increased in fibrotic liver diseases in
patients and following bile duct ligation in experimental animals (Omori et al 1997a).
Interestingly, human hepatic stellate cells proliferate when exposed to human mast cell
tryptase (Benyon et al 1997). Therefore, both mast cells and stellate cells may interact
via SCF and tryptase to promote fibrogenesis within the liver.
In addition to its importance in the pathophysiology of hepatic fibrosis, the stellate cell
is also the major source of the CC chemokine, MCP-1, in patients with acute liver
disease (Czaja et al 1994). The expression of stellate cell MCP-1 is induced by reactive
oxygen species and the early response cytokines, TNFa and EL-1(3 (Xu et al 1996).
Interestingly, MCP-1 is also chemoattractant for mast cells and basophils.
1.13. CYTOKINES AND HEPATIC REGENERATION.
The role of cytokines in hepatic regeneration has also been the subject of several recent
reviews (Hoffman et al 1994, Fansto & Webber 1994, Diehl & Rai 1996b). Many
cytokines are hepatocyte mitogens in vitro, but their relative importance in vivo
remains unclear. EGF, TGFa and HGF are complete hepatocyte mitogens, but recent
studies have suggested a central role for TNFa, in hepatic regeneration following both
toxic and partial, 70%, hepatectomy (PH). Exogenous TNFa stimulates hepatic DNA
synthesis in rodents and accelerates recovery of liver weight following PH. Although
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serum TNFa concentrations are not elevated following PH, anti-TNF antibodies inhibit
regeneration in this model and following toxic liver injury (Bruccoleri et al 1997).
Hepatic regeneration following PH is also impaired in TNFR1 knock-out mice
(Yamada et al 1997). In addition, Kupffer cell blockade augments hepatic regeneration
following PH secondary to impaired EL-10 release from these cells allowing sustained
unopposed TNFa production from endothelial cells (Rai et al 1997). Anti-TNF
antibodies have an even greater inhibitory effect on hepatic regeneration following PH
in chronic ethanol fed rats. TNFa released following PH has also been implicated in the
activation of several intracellular signalling pathways (e.g. STAT 3) and transcription
regulators (e.g. API, C/ERB, NF-kB) which may control the expression of proto-
oncogenes and the progression of hepatocytes through the cell cycle during
regeneration (Cressman et al 1995, Diehl et al 1995, Taub 1996). Lead nitrate induces
liver cell hyperplasia and increases hepatic TNFa concentrations but two other
inducing agents, cyproterone acetate or nafenopin, are not associated with increased
hepatic TNFa expression (Menegazzi et al 1997). Dexamethasone, a relatively non¬
specific anti-inflammatory agent, reduces TNFa concentrations, without affecting HGF
expression, and inhibits hepatocyte proliferation induced by lead nitrate .
1.14. CYTOKINES AND HEPATIC CANCER.
Certain cytokines have been implicated in the development of hepatic cancer. TGF{3
over expression in trangenic mice is associated with a 60% incidence of spontaneous
hepatoma, however the incidence in HGF/TGFp double transgenics is only 30%,
suggesting coexpression of HGF may protect against hepatocarcinogenesis.
Hepatoblastomas are often associated with extramedullary haematopoiesis within the
liver and can express the haematopoietic cytokines, erythropoietin, stem cell factor,
granulocyte colony stimulating factor (G-CSF) and granulocyte-monocyte colony
stimulating factor (GM-CSF). Carcinoembryonic antigen can induce Kupffer cell
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production of TNFa and EL-lp (Gangopadhyay et al 1996), these proinflammatory
cytokines may induce endothelial cell adhesion molecule expression and thus enhance
the potential for metastasis. Elevated circulating concentrations of IL-8 have been
reported in patients with hepatoma (Sakamoto et al 1992) and may contribute to the
immunodeficiency of such patients. Transcatherter arterial embolisation is a commonly
used therapy for hepatoma. Tumour embolisation is often followed by fever and an
inflammatory response, this has been associated with increased circulating IL-6
concentrations, systemic TNFa or EL-1(3 are unaffected (Matsuda et al 1994).
TNFa, IL-ip, IL-6 and IFN-y production have been implicated in the weight loss and
cachexia induced by malignant tumours (.Argiles & Lopez Soriano 1997). Implantation
of Morris 7777 hepatoma cells in severe combined immunodeficiency (SCED) mice
induces TNFa, EL-ip and IL-6 production from spleen cells and is associated with
profound weight loss (Murray et al 1997). In contrast, transplantation of MCA
sarcoma was not associated with loss or increased proinflammatory cytokine
expression (Murray et al 1997). Rats bearing the Yoshida AH-130 ascites hepatoma
have a hypercatabolic state with increased circulating TNFa concentrations. Anti-TNF
antibodies normalise the muscle protein synthesis abnormalities and disturbances in
hormone balance, but are unable to prevent weight loss in this model (Costelli et al
1993, 1995).
1.15. THERAPEUTIC POTENTIAL OF CYTOKINES.
Use of interferon alpha in the viral hepatitis is the most widely used cytokine in the
treatment of liver disease (Tilg 1997). TNFa, GM-CSF and IL-12 have also been used
to treat patients with viral hepatitis, IL-12 may be especially efficacious in chronic
HBV infection which appears characterised by a Th2 type cytokine response. Prior
inhibition of macrophage function with gadolinium chloride or liposome encapsulated
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diphosphonates has been shown to inhibit liver injury in a number of experimental
models of toxic liver injury. As noted above inhibition of TNFa with a variety of
agents inhibits liver injury in these models. Inhibition of cytokine production by
steroids can explain their efficacy in treating hepatic allograft rejection, alcoholic
hepatitis and autoimmune hepatitis.
Cytokine therapy has been used to prevent hepatic tumour metastasis or tumour
growth in a variety of animal models, but the use of cytokines in the management of
patients with hepatoma is much more limited and often disappointing. Conventional
antitumour therapies, such as mitomycin C and adriamycin, are able to activate Kupffer
cells and induce the antitumoral activity of these cells (Adachi et al 1992). IFN-y
administration activates hepatic Kupffer cells and protects rodents against hepatic
metastasis from intrasplenic hepatoma cell injection (Karpoff et al 1996). Using a
similar model, injection of irradiated hepatoma cells transfected with vectors expressing
GM-CSF or IL-2 to induce T cell activation also prevented hepatic tumour metastasis.
Combination treatment with GM-CSF or IL-2 expressing cells and EFN-y was more
effective in preventing tumour growth than either therapy alone. Reinjection of tumour
cells incubated in vitro with cytokines that upregulate MHC and adhesion molecule
expression is also effective in inducing cytotoxic T cell responses and protects against
parenteral tumour cell injection (Guo et al 1997). In vivo transfection of primary and
metastatic hepatoma with adenovirus-IL-2 expressing vectors can cure upto 75% of
tumour bearing animals (Huang et al 1996). Direct injection of IL-2 into hepatomas
can also induce an effective anti-tumoural systemic T cell response in animals with
implanted tumours (Balemans et al 1993). An alternative strategy is to induce
lymphokine activated killer cells from peripheral blood mononuclear cells and reinfuse
these cells, this has been found safe and effective in a small pilot study of patients with
advanced carcinoma (Yeung et al 1993). Ultrasound guided injection of LAK and IL-2,
combined with subcutaneous IL-2 has also been used safely in patients with primary
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and secondary liver tumours (Ferlazzo et al 1997). Intratumour injection of TNFa is
effective in animal hepatoma models. Development of closed perfusion techniques has
allowed the use of local TNFa, in conjunction with conventional cytotoxic therapy, in
patients with hepatic malignancy. Intra-arterial TNFa and IFN-y can also significantly
improve the response to hepatic artery ligation in a rodent model of hepatoma (Yang et
al 1995). In a small pilot study, thymostimulin has been shown to be effective in
treating patients with hepatoma. The antitumoral activity of thymostimulin appears
secondary to Kupffer cell TNFa production (Balach et al 1997).
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TNFoc STIMULATED CHEMOKINE PRODUCTION FROM
HUMAN HEPATOMA CELLS
2.1. INTRODUCTION
The cellular composition of the liver includes tissue resident macrophages (Kupffer
cells), endothelial cells, biliary epithelial cells and lipocytes. However, hepatocytes
form the largest cell mass within the liver. Although stromal cells have not been
classically considered as immune cells, there is increasing evidence that these cells can
play an active role in the development and maintenance of an inflammatory response
through their ability to produce cytokines, including proinflammatory cytokines and
chemokines. Relatively little is known regarding the production of chemokines by
hepatocytes. Studies have shown that cultured rodent liver cells can produce EL-8
{Shiratori et al 1993) and Gro {Shiratori et al 1994) when exposed to ethanol and
more recently human hepatoma cell lines (Thornton et al 1990) and primary human
hepatocytes (Rowell et al 1997) have been shown to produce both CXC and CC
chemokines following proinflammatory cytokine stimulation. However, contamination
of the primary cultures with Kupffer cells, which are potent sources of chemokines,
may produce confounding results in studies using primary cell cultures. In addition, no
data exists on the potential intracellular pathways induced by proinflammatory
cytokines resulting in hepatocyte chemokine production. Knowledge of signalling
mechanisms may direct development of specific therapy to modulate chemokine
production from this large mass of cells, preventing their recruitment into the
inflammatory response.
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In view of the problems of supply and purity of preparation of primary human
hepatocytes, the studies in this chapter focused on chemokine production from human
hepatoma cells (Hep G2 and SK-Heps lines) induced by TNFa (in view of the potential
importance of this early response cytokine in the pathogenesis of hepatic disease),
although preliminary data is presented on the few experiments undertaken using normal
human hepatocytes (Clonetics Inc). The aims were as follows;
• to determine which chemokines were produced by cultured human hepatoma cells.
• to assess the effect of soluble TNF receptors and other cytokines on TNFa induced
chemokine production.
• Using specific inhibitors and inducers to investigated the intracellular pathways
involved in hepatoma cell chemokines production.
• To measure the effect of drugs previously used in the treatment of liver disease, on
hepatoma cell chemokine production.
2.2. METHODS
2.2.1. Cell culture and stimulation.
Human hepatoma cells (SK-Heps and Hep G2) from the American Type
Culture Collection, were cultured in Dulbecco's modified Eagles medium (DMEM) in 6
or 24 well plates. Normal human hepatocytes (a kind gift from Dr S Kamil, Clonetics
Inc, CA) were cultured in 6 well matrigel coated plates in Hepato-STIM (Becton
Dickinson, Bedford, MA). In the majority of experiments, TNFa was added at 5ug/ml
and the cells cultured for a further 20 hours. The supernatants were recovered and
stored at -20°C for ELISA and guanidine isothiocyanate added to the cells before
freezing at -20°C and subsequent RNA extraction. The inhibitors (purchased from
Sigma and Fugisawa), dexamethasone (10~4 mol/L), cyclosporin (5 ug/ml), FK 506
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(100 ug/ml), staurosporine (100 ng/ml) genistein (10 umol/L), calphostin C (1 umol/L),
and anti-TNF receptor antibodies (from R&D Systems Inc, 20 ng/ml) were
preincubated with the culture human hepatoma cells at 37°C for 30 minutes before
addition of TNFa. The antioxidant, N-acetylcysteine (Sigma, 10 mmol/L), and the NF-
kB inhibitor, pyrrolidine dithiocarbamate (Sigma, PDTC, 1 mmol/L), were
preincubated with the hepatoma cells for 6 hours prior to addition of TNFa. Soluble
TNF receptors (R&D Systems Inc) were added at the time of TNFa stimulation.
Phorbol-12-myristate-13-acetate, (PMA, 2.5 umol/L) stimulation of Flep G2 cells and
SK-Heps was continued for 4 hours before the media was replace and the hepatoma
cells cultured for a further 20 hours.
2.2.2. Enzyme linked immunoassay (ELISA).
Flat bottomed 96-well microtitre plates (Nunc Immunoplate I 96-F,
Copenhagen, Denmark) were coated with 50 ul/well of anti-chemokine antibody for 16
hours at 4°C and then washed with phosphate buffered saline (PBS), pH 7.5 and
0.05% Tween-20 (wash buffer). Nonspecific binding sites were blocked with 2%
bovine serum albumin in PBS and incubated for 90 minutes at 37°C. Plates were rinsed
four times with wash buffer, and 50 ul of supernatant (neat and at 1/10 dilution) added
in duplicate, followed by incubation for 1 hour at 37°C. Plates were washed four
times, followed by addition of 50 ul/well of biotinylated anti-murine antibody (3.5
ug/ml in PBS, pH 7.5, 0.05% Tween-20, and 2% fetal calf serum), and then incubated
at 37°C for 30 minutes. Plates were washed as before, streptavidin-peroxidase
conjugate (Bio-Rad Labs) was added, and the plates incubated for 30 minutes at 37°C.
Plates were then washed four times and chromogen substrate (Bio-Rad Labs) added,
the reaction was terminated with 50 ul/well of 3 M H2SO4 and the plates read at 490
nm in an ELISA reader. Standards were V2 log dilutions of human chemokines from 1
pg/ml to 100 ng/ml. The ELISA methods used consistently detected chemokine
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concentrations > 30 pg/ml and were specific without detectable cross-reaction with
other CXC or CC chemokines, IL-6, IL-1 or TNFa.
2.2.3. RNA extraction, cDNA synthesis and PCR.
Cultured cells were scraped from the culture plates and homogenised in 1 ml of
4.2 mol/L guanidine isothiocyanate, 25 mmol/L Tris (pH 8.0), 0.5% Sarkosyl and 0.1
mol/L 2-mercaptoethanol. An equal volume of 100 mmol/L Tris (pH 8.0), 10 mmol/L
ethylenediamine tetraacetic acid (EDTA) and 1.0% sodium dodecyl sulphate (SDS)
was added and total RNA prepared following phenol-chloroform and chloroform-
isoamyl alcohol extraction. The isolated RNA was quantitated by spectrophotometric
analysis at 260 nm and 5ug reverse transcribed into cDNA using oligo (dT)12-18
primers and AMV reverse transcriptase. The cDNA was amplified using specific
primers for the chemokines detected by ELISA using cyclophylin as control
(cyclophylin sense CATCTGCACTGCCAAGAC, cyclophylin antisense
CTGCAATCCAGCTAGGCATG). The amplification reaction was incubated initially
at 94°C for 5 minutes followed by 35 cycles at 93°C for 45 seconds, 52°C for 45
seconds and 72°C for 90 seconds. The amplification products were visualised under
UV light following separation in a 2% agarose gel containing 0.3 mg/ml ethidium
bromide.
2.2.3. Statistical analysis
Results are presented as mean + standard error of at least 3 separate
experiments. Statistical significance was determined by analysis of variance and
students t-test as appropriate, with p < 0.05 considered significant.
2.3. RESULTS
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2.3.1. Hepatoma cells produce CXC and CC chemokines following
proinflammatory cytokine stimulation.
Both Hep G2 cells (Figure 2.1) and SK-Heps produced IL-8 immunoreactive
protein following stimulation with TNFa, in a concentration and time dependent
fashion and this was associated with induction of mRNA expression. Hep G2 cells
produced none of the other CXC chemokines measured, ie. Gro, ENA-78, IP 10 or
MIG. In contrast, SK-Heps constitutively produced low concentrations of the CXC
chemokine, Gro (0.120 + 0.023 ng/ml, mean + SEM, n = 12), which were not induced
further by TNFa (0.176 + 0.022, n = 16). SK-Heps produced the CC chemokines
MCP-1 and RANTES during stimulation with TNFa, and the production of these
chemokines was induced in a time and concentration dependent manner. Induction of
MCP-1 and RANTES immunoreactive protein was associated with increased
expression of the mRNA.
2.3.2. Cultured human hepatocytes produce CXC and CC chemokines.
Normal human hepatocytes (Figure 2.2) stimulated with TNFa produced
significantly (P < 0.05) increased immunoreactive EL-8 (control 1.692 + 0.252 ng/ml,
mean + SEM, n = 6, TNFa stimulated 7.773 + 0.230, n = 4), Gro (control 0.190 +
0.033 ng/ml, n = 6, TNFa stimulated 0.771 + 0.099, n = 4), ENA-78 (control 0.694 +
0.157 ng/ml, n = 6, TNFa stimulated 1.655 + 0.136, n = 4) and IP-10 (control 0.134 +
0.060 ng/ml, n = 6, TNFa stimulated 0.933 + 0.239, n = 4). Low concentrations of
MIG were also detectable (0.089 + 0.021 ng/ml, n = 6), but TNFa stimulation had no
significant effect on MIG expression (0.045 + 0.028, n = 4). No immunoreactive MIP1
alpha or beta were detectable following TNFa stimulation, however TNFa
significantly increased MCP-1 production (control 0.229 + 0.058 ng/ml, n = 6, TNFa
0.461 + 0.038, n = 4). Unfortunately RANTES production was not studied in these
experiments.
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In preliminary experiments (n = 2), a similar pattern of chemokine production was
induced in human primary hepatocytes by IL-ip, with the suggestion that this early
response cytokine was more potent in inducing chemokine expression. In addition,
these preliminary experiments revealed that IFNy (5 ng/ml) was generally inhibitory in
regard to human hepatocyte chemokine production, reducing chemokine concentration
below basal expression. However significant production of both IP-10 (12.996 ng/ml, n
= 2) and MIG (1.196 ng/ml, n = 2) was noted following IFNy stimulation.
2.3.3. TNFa signals via TNFR1 to induce chemokine production.
Preincubation of hepatoma cells with anti-TNFRl antibody resulted in
significant reduction (p < 0.05) in the production of IL-8 (4.12 + 0.43 ng/ml, n = 10),
MCP-1 (0.17 + 0.04 ng/ml, n = 10) and RANTES (0.05 + 0.03 ng/ml, n = 8) from SK-
Heps following TNFa stimulation compared with controls (IL-8, 22.28 + 2.46, n = 10,
MCP-1, 0.63 + 0.10, n = 10, RANTES, 0.85 ± 0.21, n = 10). The concentration of IL-
8 induced by TNFa stimulation of Hep G2 cells (2.58 •+ 0.42, .n = 16) was also
significantly reduced by anti-TNFRl antibodies (0.58 + 0.08, n = 13). Anti-TNFR2
antibodies had no effect on TNFa stimulated IL-8 production from Hep G2 cells
(control 2.58 + 0.42, n = 16, anti-TNFR2 antibody 2.54 + 0.39, n = 13) and MCP-1
(control 0.63 + 0.10, n = 10, anti-TNFR2 antibody 0.66 + 0.13, n = 10) or RANTES
(control 0.85 + 0.21, n = 10, anti-TNFR2 antibody 0.62 + 0.05, n = 8) released by SK-
Heps. Interestingly, IL-8 production by SK-Heps was significantly enhanced by anti-
TNFR2 antibodies (40.11 + 5.24, n = 10), compared with controls (IL-8, 22.28 + 2.46,
n = 10). These data suggest that TNFa stimulated chemokine production from human
hepatoma cells, signals via TNFR1, rather than TNFR2.
2.3.4. Soluble TNFR inhibits chemokine production.
Inclusion of either soluble TNFR1 or TNFR2 in the culture media did not affect
chemokine synthesis induced by TNFa. However, when both soluble TNFRs were
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combined in the culture media, there was a dose dependent inhibition of chemokine
production by both the SK-Heps and Hep G2 cells (figure 2.3). Soluble TNFR1 and
TNFR2 (1000 ng/ml) also completely inhibited RANTES production (TNFa
stimulated 0.85 + 0.21 ng/ml, mean + SEM, n = 8, TNFa and soluble TNFR 0, n = 4)
and significantly inhibited MCP-1 expression (TNFa stimulated 0.63 + 0.10 ng/ml,
mean + SEM, n = 10, TNFa and soluble TNFR 0.14 + 0.06, n = 6).
2.3.5. Other cytokines modulate TNFa stimulated chemokine production.
IFN-y significantly inhibited TNFa stimulated, IL-8 production from Hep G2
cells (TNFa alone 2.94 + 0.33 ng/ml, mean + SEM, n = 12, TNFa + IFN-y 1.84 +
0.25, n = 8, figure 2.4). IL-10 and IL-4 had no effect on either basal or TNFa
stimulated IL-8 production from Hep G2 cells (figure 2.4). In contrast, these cytokines
had no effect on IL-8 expression in SK-Heps (figure 2.5), but IFN-y significantly
increased the TNFa stimulated RANTES (TNFa alone 0.90 + 0.17 ng/ml, n = 12,
TNFa + IFN-y 1.85 + 0.48, n = 8) and TNFa stimulated MCP-1 (TNFa alone 0.51 +
0.05 ng/ml, n = 12, TNFa + IFN-y 1.09 + 0.17, n = 8) production in these cells.
2.3.6. Dexamethasone inhibits TNFa stimulated, IL-8 expression.
High dose dexamethasone significantly reduced the production of IL-8 by Hep
G2 (TNFa stimulated IL-8 production 2.94 + 0.33 ng/ml, mean + SEM, n = 10, TNFa
+ dexamethasone 1.45 + 0.08, n = 8) and SK-Heps (TNFa stimulated IL-8 production
19.61 ± 2.74, n = 10, TNFa + dexamethasone 10.11 + 1.16, n = 8) following TNFa
stimulation (figure 2.6 & 2.7). Cyclosporin and FK 506 had no effect on EL-8
production by either cell line, and the synthesis of RANTES and MCP-1 by SK-Heps
was unaffected by dexamethasone, cyclosporin and FK 506.
2.3.7. TNFa induced IL-8 production is mediated via protein kinase C.
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The phorbol ester, PMA, significantly induced the expression of IL-8 (figure
2.8 & 2.9) by SK-Heps (control 2.928 + 0.195 ng/ml, mean + SEM, n = 12, PMA
15.489 ± 1.477, n = 6) and Hep G2 cells (control 0.733 ± 0.083, n = 12, PMA 6.874 ±
0.579, n = 6). Staurosporine (0.lug/ml), a non-specific protein kinase inhibitor, and
calphostin C (1 umol/L), a specific protein kinase C inhibitor, significantly inhibited
TNFa stimulated IL-8 production (figure 2.8 & 2.9) from both Hep G2 (TNFa
stimulated IL-8 production 2.689 + 0.346, n = 12, TNFa + staurosporine 0.556 +
0.427, n = 6, TNFa + calphostin C 1.307 ± 0.186, n = 8) and SK-Heps (TNFa 19.479
+ 2.680, n = 12, TNFa + staurosporine 1.672 + 0.481, n = 6, TNFa + calphostin C
5.837 + 0.820, n = 8). Staurosporine at lower concentrations (lOng/ml and lng/ml)
also significantly reduced IL-8 production in both SK-Heps and Hep G2 cells
compared with controls. Genistein (lOumol/L), a protein tyrosine kinase inhibitor, had
no effect on IL-8 production (figure 2.8 & 2.9) by Hep G2 cells, but significantly
reduced IL-8 expression in SK-Heps (TNFa + genistein 8.138 + 1.438, n = 8).
Therefore, IL-8 production in human hepatoma cell lines is mediated via protein kinase
C, however, in SK-Heps other protein tyrosine kinases are also implicated.
2.3.8. TNFa induced CC chemokine production is mediated via protein
kinases.
PMA significantly induced the expression of RANTES (0.393 + 0.159 ng/ml,
mean + SEM, n = 6, figure 2.10) compared with controls (0.135 + 0.057, n = 12).
Staurosporine completely abolished the production of RANTES induced by TNFa
(TNFa stimulated RANTES production, 0.899 + 0.174, n = 12, TNFa + staurosporine
0, n = 6), but calphostin C and genistein had no effect on RANTES expression in SK-
Heps (figure 2.10). PMA did not significantly induce the expression of MCP-1 in SK-
Heps, compared with controls (figure 2.11). Staurosporine and calphostin C
significantly inhibited the production ofMCP-1 (TNFa alone 0.509 + 0.051 ng/ml, n =
12, TNFa + staurosporine 0.077 + 0.030, n = 6, TNFa + calphostin C 0.104 + 0.027,
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n = 8) induced by TNFa (figure 2.11). In addition, MCP-1 expression in SK-Heps was
inhibited by genistein (0.171 + 0.047, n = 8, figure 2.14).
2.3.9 TNFa induced chemokine production is unaffected by antioxidants and
pyrrolidine dithiocarbamate.
In contrast with data presented in chapter 3, regarding adhesion mediated
chemokine production, N-acetylcysteine (NAC) did not alter TNFa stimulated
chemokine production by Hep G2 or SK-Heps. Pyrrolidine dithiocarbamate (PDTC)
significantly enhanced IL-8 expression induced by TNFa in SK-Heps and Hep G2 cells
(table 2.1).
2.3.10. Figures for Chapter 2.
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Figure 2.1c. Induction ofHep G2 EL-8 gene expression following TNFa stimulation. 1
= 3 hours, 2=12 hours, 3 = 24 hours, 4 = 5 ng/ml TNF alpha, 5 = 0.1 ng/ml TNF
alpha, 6 = 0.01 ng/ml TNF alpha.
68
Figure 2.2. TNFa (5 ng/ml) induced chemokine production by normal human
hepatocytes. # = significantly different (P< 0.05, n = 4) from unstimulated controls (n=
6).
Figure 2.3 a. Effect of soluble TNF receptors (sTNFRl and sTNFR2) on IL-8
production by SK-Heps, # = significantly different (P < 0.05) v control.
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sol TNFR (ng/ml)
Figure 2.3b. Effect of soluble TNF receptors (sTNFRl and sTNFR2) on EL-8
production by Hep G2 cells. # = significantly different (P < 0.05) v control.
Figure 2.4. Effect of other cytokines on TNFa induced IL-8 expression in Hep G2
cells, # = significantly different (P < 0.05) from controls.
Figure 2.5. Effect of other cytokines on TNFa induced IL-8 expression in SK-Heps,
no significant differences were noted.
NO TNF +TNF TNF + DEX TNF+CyA TNF + FK506
Figure 2.6. Effect of dexamethasone, cyclosporin and FK 506 on TNFa induced IL-8
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Figure 2.7. Effect of dexamethasone, cyclosporin and FK 506 on TNFa induced EL-8
production by SK-Heps, # = significantly different (P < 0.05) from control.
*
Figure 2.8. Effect of protein kinase inhibitors on IL-8 production by Hep G2 cells
following TNFa stimulation. Stauro = staurosporine, calp C = calphostin C and geni =
genistein. * = significantly different (P < 0.05) compared with no TNF, # =
significantly different compared with TNF stimulated (+ TNF).
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Figure 2.9. Effect of protein kinase inhibitors on IL-8 production by SK-Heps
following TNFa stimulation. Stauro = staurosporine, calp C = calphostin C and geni
genistein. * = significantly different (P < 0.05) compared with no TNF, # =










Figure 2.10. Effect of protein kinase inhibitors on RANTES production by SK-Heps
following TNFa stimulation. Stauro = staurosporine, calp C = calphostin C and geni
genistein. * = significantly different (P < 0.05) compared with no TNF, # =













Figure 2.11. Effect of protein kinase inhibitors on MCP-1 production by SK-Heps
following TNFa stimulation. Stauro = staurosporine, calp C = calphostin C and geni =
genistein. # = significantly different (P < 0.05) compared with TNF stimulated (+
TNF).
2.3.11. Table 2.1. Effect ofN-acetylcysteine and pyrrolidine dithiocarbamate
on TNFa stimulated chemokine production in human hepatoma cell lines.
TNFa alone TNFa + NAC (10 TNFa + PDTC (1
mmol/L) mmol/L)
Hep G2 1I8 2.722 + 0.681 1.561 +0.322 12.051 + 0.795#
SK-Hep IL-8 9.731 + 0.955 9.417 + 0.811 21.486 + 3.886#
SK-Hep MCP-1 1.453 ±0.394 1.069 + 0.396 0.945 ±0.413
SK-Hep
RANTES
0.455 + 0.094 0.184 + 0.074 0.584 + 0.155




In this chapter the production of CXC and CC chemokines following TNFa
stimulation was studied. Both SK-Heps and Hep G2 cell lines produced EL-8
constitutively and the expression of IL-8 was induced by TNFa. SK-Heps also
expressed Gro, RANTES and MCP-1, although TNFa stimulation only induced the
expression of the latter two CC chemokines and not Gro. Chemokine expression
induced by TNFa was mediated via TNFR1 and inhibited by soluble TNF receptors.
Although dexamethasone inhibited IL-8 expression in both cell lines other drugs used
in the treatment of hepatic disorders, FK 506 and cyclosporin, had no effect on
chemokine production by Hep G2 cells or SK-Heps. The effect of other cytokines had
a different effect on IL-8 production in Hep G2 cells compared with SK-Heps. EFN-y
inhibited Hep G2, TNFa stimulated IL-8 expression, but had no effect on IL-8
expression induced in SK-Heps. Induction of IL-8 expression by PMA and inhibition of
EL-8 expression induced by TNFa after treatment with the protein kinases C inhibitors,
staurosporine and calphostin C, implicate this intracellular pathway in TNFa stimulated
IL-8 production in this cell line. Similar results were observed regarding TNFa
stimulated EL-8 production in SK-Heps. However, the tyrosine kinase inhibitor,
genistein, also inhibited TNFa stimulated IL-8 production in this cell line, thus
implicating protein tyrosine kinases in IL-8 production by this cell line. These data
regarding the intracellular pathways involved in CC chemokine production by SK-Heps
is less clear. MCP-1 production induced by TNFa, like IL-8, is inhibited by
staurosporine, calphostin C and genistein, but PMA has no effect. In contrast, PMA
stimulated RANTES expression in SK-Heps, but TNFa induced RANTES production
was only inhibited by staurosporine. Calphostin C and genistein had no effect on TNFa
induced RANTES production. These data implicate intracellular pathways utilising
protein kinases in TNFa induced CC chemokine production by SK-Heps, but do not
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clarify further which pathways may be involved. Thus, although TNFa signals via
TNFR1 to induce chemokine production by human hepatoma cells, divergent
intracellular pathways lead to the expression of CXC and CC chemokines.
In these studies human hepatocytes and hepatoma cell lines were found to secrete a
variety of CXC and CC chemokines. The pattern of chemokine production in normal
human hepatocytes was most similar to the SK-Hep cell line and is similar to other
epithelial cells. Hep G2 cells in contrast produced only IL-8 following TNFa
stimulation. It is not surprising that the human hepatoma cell lines secrete different
chemokines in view of their different origins. Hep G2 cell were derived from a
hepatoblastoma and therefore may be more "immature" compared with SK-Heps,
which were derived from ascitic fluid cells in a patient with a hepatoma. These data
contrast with the study of Rowell and colleagues (1997), who found expression of a
variety of CXC chemokines by Hep G2 cells and absence of MCP-1 expression in any
of the hepatoma cell lines or human hepatocyte cultures tested. In addition, they found
an inverse relationship in the concentration of chemokines produced and the age of the
donor; foetal liver cells were more potent producers of IL-8 and Gro than normal
human hepatocytes from an elderly donor.
Previous studies have shown that the majority of the neutrophilic chemoattractant
activity in hepatocyte conditioned media is dependent on IL-8 (Thornton et al 1990,
Rowell et al 1997). The production of other CXC chemokines, such as Gro and ENA-
78, may contribute the residual neutrophil chemoattractant activity observed in
hepatocyte conditioned media after neutralisation of IL-8 with blocking antibodies. The
role of CXC chemokine production in the pathogenesis of liver disorders is becoming
clearer. Both IL-8 and Gro expression in hepatocytes can be induced by ethanol
(Shiratori et al 1993, 1994). These CXC chemokines are expressed in liver tissue from
patients with alcoholic liver disease and are correlated with the degree of neutrophilic
76
infiltrate (Sheron et al 1993, Maltby et al 1996). Recently, hepatic over expression of
Gro/CINC, using adenovirus expression vectors, was found to induce a neutrophilic
hepatitis (Maker et al 1997). However, CXC chemokines can also function as
lymphocyte chemoattractants, with some subset specificity (Baggiolini et al 1997).
Presumably whether a certain proinflammatory stimulus induces a neutrophilic or
lymphocytic infiltrate may depend on expression of other immunomodulatory
cytokines, adhesion molecules or the activation state of the circulating inflammatory
cells. ELR negative, CXC chemokines (eg. IP-10 and MIG) can inhibit the biological
functions of the ELR positive CXC chemokines (eg. IL-8 and ENA-78). Thus the
cellular composition of an inflammatory infiltrate may also be influenced by the relative
local concentrations ofELR negative and ELR positive CXC chemokines.
The data presented in this chapter clearly show that TNFa stimulation of hepatocyte
chemokine production is mediated via TNFR1, rather than TNFR2. This confirms
previous data showing that IL-8 expression in HeLa cells was mediated via TNFR1
(Boldin et al 1995). The inhibitory effect of soluble TNF receptors, at physiological
concentrations, on cellular chemokine production, suggests that these soluble receptors
may have an immunomodulatory role in vivo. These data presented in this chapter also
suggest that TNFa signals via intracellular protein kinase C, at least in regard to IL-8
production. Staurosporine is a broad spectrum inhibitor of protein kinases but has
other effects such as the induction of apoptosis in some cell lines. In view of the
general inhibitory nature of staurosporine on chemokine production and because cell
death was not directly studied, a direct toxic effect of staurosporine on the hepatoma
cells cannot be excluded. However, the concentrations of staurosporine necessary to
induce apoptosis in sensitive cell lines were in excess of those used in this study and no
detachment of adherent hepatoma cells into the culture media were observed after
incubation with staurosporine. Calphostin C and genistein can also induce apoptosis in
certain cells, but their differential effect on TNFa stimulated chemokine production is
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evidence against a direct toxic effect on the hepatoma cells used in these studies. In
addition, no detachment of the hepatoma cells was observed after incubation with these
kinase inhibitors. Genistein is an inhibitor of protein kinases and calphostin C can also
inhibit protein tyrosine kinases and other protein kinases such as PKA and PKG.
However the latter effect of calphostin C occurs at concentrations 5-50 fold those used
in the experiments reported. In addition, studies in other cell types have implicated
several intracellular cellular signalling pathways, such as protein tyrosine kinases,
protein kinase C and phosphatases, in the modulation of proinflammatory cytokine
stimulation of chemokine production (Jordan et al 1995, Jordan et al 1996, Alonso et
al 1996, Beales & Calam 1997).
In summary, the stimulatory effect of TNFa on hepatoma cell lines has been studied.
These data show that hepatocytes can produce a variety of CXC and CC chemokines
following proinflammatory cytokine stimulation. Chemokine expression induced by
TNFa is modulated by soluble TNF receptors, IFNy and dexamethasone and involves
the activation of intracellular protein kinases.
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ADHESION MEDIATED CHEMOKINE PRODUCTION
3.1. INTRODUCTION
Recent studies have shown an intimate association between adhesion molecules and
chemokines, with MIPip, a member of the C-C chemokine family, binding to CD44
and thereby activating pi integrin binding to vascular cell adhesion molecule 1
(VCAM-1) adhesion molecules, resulting in the attachment and chemotaxis of CD8+ T
cells (Tcmaka et al 1993). In addition, monocyte adhesion to plastic and tissue matrix is
sufficient for the expression of various cytokine genes (Haskill et al 1988, Eierman et
al 1989, Kasahara et al 1991, 1993). Lymphocytes activated via CD3 and ICAM-1 or
VCAM-1 receptor (CD1 la and VLA 4, respectively) have shown induced proliferative
and cytokine responses (Van Seventer et al 1990, Damle et al 1992). Adhesion
between monocytes and human umbilical endothelial cells (HUVEC) via ICAM-1, but
not VCAM-1, can induce the production of MlPla (Lukacs et al 1994). MlPla, a
member of the C-C chemokine family, is chemoattractant for monocytes, T
lymphocytes and natural killer cells (Davatelis et al 1988, Wolpe et al 1988, Taub et al
1993, Maghazachi et al 1994). Thus, MlPla may be important in attracting these cells
to sites of malignant disease. Both MCP-1 and IL-8 are produced during monocyte
adhesion with IFN-y treated HUVEC (Lukacs et al 1995). In addition to its
chemoattractant properties, IL-8 is a potent angiogenic factor which may promote
tumour growth through its angiogenic properties (Strieter et al 1995) and inhibition in
vivo of EL-8 in SCID mice results in reduced non-small cell lung cancer tumour size
and tendency to metastasis (Arenberg et al 1996).
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The aims of the studies presented in this chapter study were to determine if monocyte
interaction with the human hepatoma cell lines, SK-Heps and Hep-G2, induced the
production of chemokines in an adhesion dependent manner, to determine the cellular
origin of the chemokines and the specific adhesion molecules important in the
monocyte/hepatoma cell interaction, and to assess the potential role of reactive oxygen
intermediates as a mechanism for chemokine expression in this model.
3.2. MATERIALS AND METHODS
3.2.1. Mononuclear cell isolation
Peripheral blood was drawn into a heparinised syringe from healthy volunteers,
diluted 1:1 with normal saline and mononuclear cells separated by density gradient
centrifugation. The recovered cells were washed three times with normal saline and
layered onto a density gradient (1.068 g/ml) for the enrichment of monocytes (Ficol-
lite, Atlanta Biologies, Atlanta, GA). The isolated cells were then washed, cytospun
onto a glass slide, stained with Diff-Quik and differentially counted. The purity of the
monocytes from the gradient was consistently above 80% monocytes, with the
remainder lymphocytes.
3.2.2. Hepatoma:moiiocyte co-culture.
SK-Heps and Hep-G2 were grown in DMEM to confluence in 6 or 24 well
plates and the enriched monocyte population (1 x 106 cell/ml) layered on top. Culture
supernatants were collected at 24 hours of co-culture, peak chemokine production was
detected at this time point in previous studies (Lukacs et al 1994). To determine if cell
contact was obligatory for chemokine production, experiments were conducted in
which the monocyte population was separated from the hepatoma cells using a
transwell system (Costar, Kennebunkport, ME). Hepatoma cells and monocytes were
fixed by addition of 1% paraformaldehyde as previously described (Takafuji et al
1996). Normal human hepatocytes (a kind gift from Dr S Kamil, Clonetics Inc, CA)
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were cultured in 6 well matrigel coated plates in Hepato-STIM (Becton Dickinson,
Bedford, MA).
Monoclonal antibodies (5ng/ml) to TNF, IL1 beta and adhesion molecules (R&D
Systems, Minneapolis, MN) were preincubated with the hepatocytes for 15 minutes
before addition of the monocytes and the supernatants recovered at 24 hours. N-
acetylcysteine (NAC), pyrrolidine dithiocarbamate (PDTC) and 3'-aminobenzamine
(ABZ) were added to the co-cultures with the monocytes, NAC was preincubated with
the hepatocytes for 6 hours prior to the addition of the monocytes.
3.2.3. Chemokine ELISA.
Extracellular immunoreactive chemokines were measured as described
previously in chapter 2, using human anti-chemokine antibodies raised in New Zealand
white rabbits by multiple site injection. Chemokine gene expression was determined by
RT-PCR as previously described in chapter 2, using human primers for the genes of
interest.
3.2.4. Statistics.
Data are presented as mean + standard error. If the data was noted to be
skewed then non-parametric statistical tests were used (Wilcoxons rank sum test or
Kruskal-Wallis test). Statistical significance between groups was determined using the
unpaired Students t-test and comparison between multiple groups was performed by
one-way ANOVA. P < 0.05 was considered significant.
3.3. RESULTS
3.3.1. Monocyte interaction with human hepatoma cell lines induces
chemokine production.
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Unstimulated cultures of SK-Heps or monocytes produce minimal amounts of
MlPla (SK-Heps, 0.030 + 0.01 ng/ml, mean + SEM, n = 8; monocytes, 0.010 + 0.010,
n = 8), IL-8 (SK-Heps, 0.030 + 0.01, n = 8, monocytes 0.420 + 0.020, n = 8) or MCP-
1 (SK-Heps, 0.528 + 0.034 ng/ml, n = 8, monocytes 0.228 + 0.068, n = 8). In addition,
Hep G2 cells cultured alone in 6 well plates produced some IL-8 (0.030 + 0.01, n = 8)
but no background MlPla and MCP-1.
Enriched monocytes co-cultured with the hepatoma cells (Figure 3.1) produced
significant concentrations ofMIPla (SK-Heps & monocytes 3.480 + 0.580, Hep G2 &
monocytes 3.638 + 0.160, n = 8), IL-8 (SK-Hep & monocytes, 362.0 + 80.8, n = 8,
Hep G2 & monocytes, 19.58 + 2.50, n = 8) and MCP-1 (SK-Hep & monocytes, 2.334
+ 0.207, n = 8, Hep G2 & monocytes, 0.968 + 0.142, n = 8). Increased chemokine
protein concentration was associated with increased expression of mRNA (Figure 3.2).
Separation of the monocytes and hepatocytes using transwell plates showed significant
reduction in the production of both MlPla (SK-Heps & monocytes 0.303 + 0.060, Hep
G2 & monocytes 0.395 + 0.029, n = 8) and IL-8 (SK-Hep & monocytes 47.9 + 7.6, n =
8; Hep G2 & monocytes 5.66 + 0.43, n = 8), indicating a requirement for cell-to-cell
contact (Figure 3.1). In contrast, MCP-1 production was significantly reduced when the
SK-Heps were separated from the mononuclear cells by an insert (0.968 + 0.163, n =
8), but not when the Hep G2 hepatoma cells were cultured with the monocytes in
transwell plates (0.813 + 0.183, n = 8). These data implicate adhesion as essential in the
production of MCP-1 during monocyte adhesion with SK-Heps, but not in MCP-1
production during monocyte interaction with Hep G2 cells. In contrast with previous
studies (Lukacs et al 1994,1995), adhesion mediated chemokine production was not
dependent on the preactivation of the hepatoma cells with the proinflammatory
cytokines, TNFa, IL-lp, IFN-y or LPS (Table 3.1).
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Unstimulated normal human hepatocytes produced no MlPla either spontaneously or
when co-cultured with monocytes. In contrast, small amounts of IL-8 were produced
by normal human hepatocytes (1.692 + 0.252, n = 6), with increased IL-8
concentration (4.026 + 0.544, n = 6) during monocyte:hepatocyte co-culture. MCP-1
production was similar in cultures of hepatocytes alone (0.229 + 0.058, n = 6)
compared with cultures of hepatocytes and monocytes (0.359 + 0.037, n = 6).
In summary, both CXC and CC chemokines are produced during monocyte:hepatoma
cell co-culture by an adhesion dependent mechanism and does not require preactivation
of the hepatoma cells. In contrast, normal human hepatocytes and mononuclear cells
only produce the CXC chemokine, IL-8, during co-culture.
3.3.2. Both monocytes and hepatoma cells produce chemokines during
adhesion.
To examine which cell populations were producing the chemokines during the
co-cultures individual cell populations were fixed with paraformaldehyde before
culture. No MlPla was produced (Figure 3.3) when paraformaldehyde fixed
monocytes were co-cultured with Hep G2 hepatoma cells and low concentrations were
observed when paraformaldehyde fixed monocytes were cultured with SK-Heps (0.144
+ 0.049 ng/ml, n = 6). In contrast, culture of normal monocytes with paraformaldehyde
fixed hepatoma cells resulted in significant production of MlPla (fixed SK-Heps &
normal monocytes 1.348 + 0.273, fixed Hep G2 & normal monocytes 1.276 + 0.125, n
= 6), indicating that the monocytes and not the hepatoma cells were the source of
MlPla.
Paraformaldehyde fixed monocytes co-cultured with paraformaldehyde fixed
hepatocytes (either SK-Hep or Hep G2) produced no IL-8. Normal monocytes co-
cultured with fixed SK-Heps (31.42 + 4.44, n = 6) and paraformaldehyde fixed
monocytes co-cultured with normal SK-Heps (24.08 + 6.47, n = 6) synthesised IL-8,
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suggesting that the IL-8 produced during monocyte-SK Hep interaction is derived
from both cell populations. IL-8 was also produced in the Hep G2 cultures (fixed Hep
G2 & normal monocytes 5.87 + 0.93, n = 6; Hep G2 & fixed monocytes 0.56 + 0.06, n
= 6). However, the significantly higher production of IL-8 during monocyte interaction
with fixed Hep G2 cells, implies that the monocytes are the major source of IL-8 in this
culture system.
MCP-1 production during adhesion was significantly reduced when either fixed
monocytes (0.105 + 0.017, n = 4) or fixed hepatocytes (0.056 + 0.019, n = 4) were co-
cultured with the respective unfixed cell populations, compared with the adhesion
between unfixed monocytes and unfixed SK-Heps (0.260 + 0.030, n = 4). Although
MCP-1 production during monocyte interaction with Hep G2 cells did not appear to be
adhesion mediated, co-culturing normal monocytes with fixed Hep G2 cells did not
affect MCP-1 production and MCP-1 production was completely abolished when fixed
mononuclear cells were used. This suggests the monocytes produced the MCP-1 in the
Hep G2:monocyte co-cultures, but that both the monocytes and SK-Heps were the
source ofMCP-1 in this co-culture system.
In summary, MlPla production during monocyte adhesion with human hepatoma cells
is from the former cell type. In contrast, the production of IL-8 and MCP-1 during
monocyte:hepatoma cell co-culture is from both cell types, suggesting that adhesion
can activate both cell populations.
3,3.3. Inhibition of IL-8 production by neutralising antibodies to TNFot or IL1
P-
The proinflammatory cytokines, TNFa and IL-lp, are potent stimuli for the
production of chemokines in many different cell types. In co-culture supernatants, both
TNFa (SK-Heps & monocytes 0.128 + 0.018 ng/ml, Hep G2 & monocytes 0.207 +
0.015, n = 8) and IL-ip (SK-Heps & monocytes 0.781 + 0.050, Hep G2 & monocytes
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0.253 + 0.014, n = 8) were detected. The concentrations of IL-ip (0.192 + 0.056, n =
8) were lower in supernatants from monocytes cultured alone, in contrast, TNFa
(0.276 + 0.094, n = 8) concentrations were similar in supernatants from monocytes
cultured alone compared with the co-cultures of monocytes with hepatoma cells. No
IL-6 was produced during monocyte.hepatoma cell co-culture.
To further study the potential role of proinflammatory cytokine stimulation in the
production of chemokines, neutralising antibodies to either IL-ip or TNFa were
included in the cultures (Figure 3.4). Production of IL-8 was significantly reduced
when anti-TNFa (87.98 ± 16.79, n = 12) or anti-IL-lp (80.74 ± 11.62, n = 12)
antibody were included in monocyte:SK Hep co-cultures. However, IL-8 production
was not significantly reduced when anti-TNFa (10.96 + 1.63, n = 8) or anti-EL-ip
(7.63 + 1.58, n = 8) antibody were included in monocyte:Hep G2 co-cultures. MlPla
and MCP-1 production were also unaffected by anti-TNFa or anti-IL-ip antibodies.
In summary, IL-8 production during adhesion appears dependent on proinflammatory
cytokine release during monocyte adhesion with SK Hep cells, but not Hep G2 cells.
MlPla and MCP-1 production was not dependent on proinflammatory cytokine
production with either cell population.
3.3.4. Inhibition of MEPla and MCP-1 production by neutralising antibodies
to beta integrins.
To determine which adhesion molecules are involved in the monocyte adhesion
with hepatoma cells leading to chemokine production, neutralising monoclonal
antibodies for specific adhesion molecules were included in the co-cultures. Inclusion
of ICAM-1 blocking antibodies in the co-cultures did not affect the production of
MlPla, MCP-1 or IL-8 (Figure 3.5, 3.6). In contrast, monoclonal antibodies directed
against VCAM-1 or its pi integrin ligand, resulted in significant reduction in the
production ofMlPla during monocyte adhesion with either hepatoma cell line (Figure
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3.5). Inclusion of monoclonal antibodies directed against E-selectin and (33 integrin
also resulted in significant reduction in the production ofMlPla (Figure 3.5). Similar
data were observed regarding the effect of anti-adhesion molecule antibodies on the
production of MCP-1, during monocyte adhesion with SK-Heps (Figure 3.6). As the
production of MCP-1 in the Hep G2 cultures with monocytes was not adhesion
dependent, this interaction was not studied with blocking adhesion molecules. The
production of IL-8 was unaffected by the inclusion of any of these neutralising
antibodies in cultures of monocytes and SK-Heps or Hep G2 cells. Therefore, in
contrast with the CXC chemokine IL-8, adhesion dependent production of the CC
chemokines, MTPla and MCP-1, occurs via selectin and (31 and (33 integrin mediated
adhesive interactions.
3.3.5. Effect of antioxidants on MlPla production.
Cross linking of beta integrins has previously been shown to lead to an
intracellular oxygen burst and free radical formation. Many chemokine genes, including
MlPla and IL-8, contain a NF-kB binding site in their 5' noncoding region which may
be activated by reactive oxygen species via NF-klB. To study the potential role of this
pathway, N-acetylcysteine (NAC) and the specific inhibitor of oxidant mediated NF-kB
activation, PDTC, or an AP-1 inhibitor, ABZ, were included in the co-cultures.
Inclusion of either NAC (Figure 3.7) or PDTC (Figure 3.8) resulted in a dose
dependent inhibition ofMlPla production in cultures of monocytes with SK-Heps or
Hep G2 cells. In contrast, the AP-1 inhibitor, ABZ had no effect on MEPla
production. Similar results were obtained for MCP-1 production during monocyte
adhesion with SK-Hep cells (SK-Heps + monocytes, 2.40 + 0.30 ng/ml, mean + SEM,
n = 9, SK-Heps + monocytes + NAC 10 mmol/L, 0.67 + 0.11, n = 8, SK-Heps +
monocytes + PDTC 1 mmol/L, 0.60 + 0.19, n = 8, SK-Heps + monocytes + ABZ 1
mmol/L, 1.95 + 0.12, n = 6). The production of IL-8 during monocyte adhesion with
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SK-Hep or Hep G2 hepatoma cells was unaffected by the inclusion of NAC, PDTC
and ABZ in the culture media.
This specific effect of NAC and PDTC on adhesion mediated CC chemokine
production implicates the intracellular production of reactive oxygen intermediates and
subsequent activation of the nuclear transcription factor, NF-kB in the synthesis of
MCP-1 and MlPla during monocyte adhesion with hepatoma cell lines and contrasts
with the expression of IL-8, a CXC chemokine.
3.3.6. Figures for Chapter 3.
Figure 3.1a. Adhesion mediated MlPla expression. * = significantly different from
hepatoma cells alone, # significantly different from hepatoma cells co-cultured with
monocytes in transwell plates.
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Figure 3.1b. Adhesion mediated IL-8 expression. * = significantly different from
hepatoma cells alone, # significantly different from hepatoma cells co-cultured with
monocytes in transwell plates.
Figure 3.1c. Adhesion mediated MCP-1 expression. * = significantly different from
hepatoma cells alone, # significantly different from hepatoma cells co-cultured with
monocytes in transwell plates
89
Ml 2 3 4 5 6
MIP1 alpha
Figure 3.2. Adhesion mediated chemokine production is associated with enhanced
gene expression. 1 = SK-Heps alone, 2 = SK-Heps + monocytes, 3 = SK-Heps +
monocytes + insert, 4 = Hep G2 alone, 5 = Hep G2 + monocytes, 6 = Hep G2 +
monocytes + insert. M = molecular weight markers. Data for MCP-1 is not shown but
similar results were obtained.
Figure 3.3a Effect of paraformaldehyde fixation on MlPla production during
adhesion. N = unfixed cells, F = paraformaldehyde fixed cells, M = monocytes. # =
significantly different (P < 0.05) compared with controls.
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Figure 3.3b Effect of formaldehyde fixation on IL-8 production during adhesion. N =
unfixed cells, F = fixed cells, M = monocytes. # = significantly different (P < 0.05)
compared with controls.
Figure 3.4. Effect of blocking TNFa or IL-ip on IL-8 production during monocyte




































Figure 3.5a. Effect of blocking anti-adhesion molecule antibodies on MlPla
production during adhesion using SK-Heps. # = significantly different (P < 0.05)
compared with controls.
Figure 3.5b. Effect of blocking anti-adhesion molecule antibodies on MlPla
























Figure 3.6. Effect of blocking anti-adhesion molecule antibodies on MCP-1 production
during adhesion using SK-Heps. # = significantly different (P < 0.05) compared with
control.
Figure 3.7. Effect of N-acetylcysteine on MlPla production during adhesion. # -
significantly different (P < 0.05) compared with controls.
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Figure 3.8. Effect of pyrrolidine dithiocarbamate on MlPla production during
adhesion. # = significantly different (P < 0.05) compared with controls.
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3.3.7. Table 3.1. Effect of cytokine prestimulation on chemokine production








unstimulated 0.676 ± 1.993 + 0.040 + 2.699 +
0.122 0.073 0.013 0.365
TNFa 1.32 ± 1.588 + 0.130 + 3.078 +
0.044 0.110 0.012 0.373
IL-ip 0.784 + 1.476 + 0.065 + 2.757 +
0.092 0.076 0.009 0.500
IFN-y 0.540 + 1.478 + 0.150 + 4.697 +
0.006 0.118 0.063 0.606
LPS 0.390 + 1.240 + 0.025 + 2.061 +
0.006 0.082 0.003 0.316
Hep G2
unstimulated 0 1.052 + 0 5.363 +
0.092 0.592
TNFa 0 1.002 + 0 4.540 +
0.111 0.430
IL-IP 0 1.158 + 0 4.506 +
0.088 0.178
IFN-y 0 1.596 + 0 5.778 +
0.322 0.372
LPS ND ND ND ND
IL-8 was not measured in these studies. ND = not determined. No significant differences were
noted between unstimulated and cytokine stimulated hepatoma cells in the chemokine
concentration produced following adhesion.
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3.4. DISCUSSION.
These data presented in this chapter show that monocyte adhesion to hepatoma cells
induces the production of the potent inflammatory chemokines, MlPla, MCP-1 and
IL-8. The mononuclear cells, rather than the hepatocytes, appeared to be the source of
the MlPla. In contrast, both cell populations synthesised IL-8 and MCP-1. Chemokine
production was dependent on adhesion between the two cell populations, except in the
case of MCP-1 production induced by monocyte interaction with Hep G2 cells,
because the addition of monocytes to hepatoma cells in transwell separated culture
dishes significantly reduced the IL-8 and MlPla concentrations. IL-8 production
during monocyte adhesion with the SK-Hep hepatoma cell line was dependent on
release of TNFa and EL-1(3, but inhibition of these proinflammatory cytokines had no
effect on MlPla or MCP-1 production nor production of IL-8 during monocyte
adhesion with Hep G2 cells. MlPla and MCP-1 production, but not IL-8, was
inhibited by neutralising monoclonal antibodies directed against VCAM-1 and the (31
integrin component of its ligand (VLA 4, a4(31) and also antibodies directed to (33
integrins and E-selectin. Adhesion mediated IL-8 production during the Hep
G2:monocyte co-culture could not be inhibited by the anti-adhesion molecule
antibodies used. Studies of the potential intercellular pathways implicated release of
intracellular reactive oxygen intermediates with the subsequent induction of NF-kB in
the production of the CC chemokines studied, but not in CXC chemokine (IL-8)
expression.
The results of this study support previous reports of adhesion mediated chemokine
production (Lukacs et al 1994, 1995) during monocyte adhesion with human umbilical
endothelial cells (HUVEC). However there are several important differences.
Pretreatment of either Hep G2 or SK-Hep cells with IFN-y was unnecessary to induce
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chemokine production during adhesion, preincubation of the HUVEC cultures with
EFN-y was essential to induce expression ofMlPla, MCP-1 and IL-8. TNFa and IL-1
(3 were not produced during monocyte adhesion with HUVEC and chemokine
production was unaffected by anti-TNFa and anti-IL-ip antibodies, in contrast with
the IL-8 produced during monocyte:SK-Hep co-culture. In addition, during the
monocyte:HUVEC interaction, MlPla production was inhibited by monoclonal anti-
ICAM-1 antibodies (Lukacs et al 1994). This may be explained by investigations in
other laboratories which found no expression of ICAM-1 on human hepatoma cell lines
(Volpes et al 1992, Kvale et al 1993). However, MlPla production was not inhibited
by anti-ICAM-1 antibodies but by neutralisation of interaction with E-selectin, VCAM-
1 and the pi component of its integrin ligand VLA-4 (a4pi), and p3 integrin. Thus,
following transendothelial migration, non-ICAM-1 dependent adhesive interactions,
namely with E-selectin and pi and P3 integrins, may be important in stimulating
chemokine production from the mononuclear cells. A recent study has reported
induction of hepatoma cell pi and P4 integrin expression following adhesion with
endothelial cells and HGF treatment. E-selectin expression occurs on inflammed
hepatic endothelium, but not normal endothelium, but the expressionof selectins on
human hepatoma cells has not been reported. However, in a small study of 10
hepatomas, none expressed VCAM-1 or E-selectin.
Immunohistochemical studies have not demonstrated E-selectin, ICAM-1 or VCAM-1
expression on normal human hepatocytes. In addition, the lack of MCP-1 and MlPla
production during monocyte adhesion with normal human hepatocytes suggests that
CC chemokine production from non-proinflammatory cytokine stimulated cells is
specific for transformed cells. Interestingly, it has previously been shown that IL-8 and
MCP-1 production by monocyte:HUVEC adhesion was inhibited by soluble collagen
and fibronectin (Lukacs et al 1995), both of these extracellular matrix proteins are
potential ligands for P1 and P3 integrins.
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It has been proposed that reactive oxygen intermediates are the common pathway
through which differing stimuli induce NF-kB activation and gene expression (Schreck
et al 1991), although this may be dependent on the cell type studied (Brennan et al
1995). Intracellular signalling via |31, P2 or $3 integrins may trigger a respiratory burst
and the formation of reactive oxygen species in a variety of inflammatory cells,
including mononuclear cells (Nagata et al 1995, Berton et al 1992, Zhou et al 1993).
In addition, selectin cross-linking significantly increases the oxidative burst induced in
neutrophils by either formyl-Met-Leu-Phe or TNFa (Waddell et al 1994). A NF-kB
site is located in the 5' region of several chemokine genes and is important in the
transcriptional regulation of these genes. Therefore the effects of antioxidants on
chemokine production during monocyte hepatoma cell interaction were studied. In this
study, NAC induced a dose dependent inhibition ofMlPla production in monocytes
co-cultured with either Hep G2 or SK-Heps cells and inhibited MCP-1 production
during monocyte adhesion with SK-Heps. In contrast, IL-8 production was unaffected,
thus excluding a toxic or anti-adhesive effect of NAC on the cells in the co-culture.
NAC increases intracellular thiols and interacts directly with oxygen free radicals
(Aruoma et al 1989) and hence can inhibit NF-kB activation and gene transcription
(Staal et al 1990). PDTC is a specific inhibitor of oxidant mediated NF-kB activation,
while other transcription factors, such as SP1, AP-1 and C/ERP are unaffected
{Schreck et al 1992, Ziegler-Heitbrock et al 1993). PDTC also inhibited adhesion
mediated MlPla and MCP-1 production, but not IL-8 synthesis, in a dose-dependent
fashion. Although both NAC and PDTC may affect AP-1 binding in certain cells
{Meyer et al 1993, Bergelson et al 1994), another AP-1 inhibitor, 3'-aminobenzamine,
had no effect on either IL-8, MCP-1 or MlPla production in the studies presented
here. Although the activation ofNF-kB was not directly demonstrated, inhibitors were
used to assess the differential effect of inhibiting this transcription factor on adhesion
mediated chemokine expression. Therefore, these data indirectly implicate intercellular
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free radial mediated NF-kB activation as the mechanism inducing CC chemokine
production during adhesion.
Previous studies have shown a relationship between monocyte adhesion and chemokine
production (Lukacs et al 1994, 1995). Such studies have focused on adhesion mediated
chemokine expression in the setting of inflammation. This is the first study to report
monocyte adhesion to transformed human hepatoma cell lines also induces the
production of chemokines. In the context of malignant disease this finding may have
several potential biological effects. The activation of mononuclear cells during contact
with tumour cells would allow the local deposition of MlPla, intensifying the
chemotactic gradient, and increasing both the numbers and activational status of the
infiltrating inflammatory cells. IL-8 is a potent angiogenic factor in vivo (Strieter et al
1995) and IL-8 inhibition reduces tumour size and frequency of metastasis in SCID
mice (Arenberg et al 1996). Interferon inducible protein 10 (IP-10), a non-ELR CXC
chemokine is an angiostatic factor both in vitro and in vivo {Strieter et al 1995).
However negligible production of IP-10, in comparison with the concentrations of IL-
8, were noted during monocyte adhesion with either SK-Heps or Hep G2 cells (data
not shown). Therefore, IL-8 production during adhesion, through its angiogenic
properties, could enhance tumour cell growth and metastatic potential. This effect
would be further amplified by the inflammatory cells recruited to the site of a tumour
via adhesion mediated CC chemokine production. Thus, tumours may not just evade
the body's immune response, but may potentially turn the host defence systems to its
own advantage. Adhesion ofmonocytes with normal human hepatocytes did not induce
MEPla or MCP-1 expression and therefore adhesion mediated chemokine production
and subsequent immune amplification is unlikely to occur in normal uninflammed non-
transformed liver. These data suggest that CXC chemokine production is mediated via
proinflammatory cytokine production and CC chemokine expression via integrin
mediated free radical production and subsequent NF-tcB activation. Therefore, targeted
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anti-cancer therapies may enhance local inflammatory chemokine production, but
inhibit angiogenic chemokine expression. However, with the observed minor
differences in adhesion mediated chemokine production between SK-Heps and Hep
G2, suggest that individual tumours may respond in slightly differing ways.
In summary, monocyte adhesion with hepatoma cells induces the production ofMlPla,
MCP-1 and IL-8. IL-8 production during monocyte adhesion with SK-Hep cells was
dependent on proinflammatory cytokine induction. Integrins, pi and P3, VCAM-1 and
E-selectin are important adhesion molecules involved in CC chemokine, MCP-1 and
MlPla, production, which was not dependent on classical proinflammatory cytokine
stimulation, but appears to follow upon free radical mediated activation of NF-kB.
Thus, adhesion between monocytes and hepatoma cells may induce the production of
potent chemoattractant and angiogenic chemokines resulting in enhanced tumour cell
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ROLE OF TNFa IN HEPATIC INJURY POST
PARACETAMOL POISONING
4.1 INTRODUCTION.
Paracetamol is metabolised to the highly reactive compound N-acetyl-p-
benzoquinonone-imine (NAPQI), which is normally inactivated by intracellular
glutathione. Intracellular NAPQI accumulates following overdose and binds to
intracellular enzymes ultimately leading to hepatocyte cell death (Mitchell et al 1973).
This understanding of the metabolic fate of paracetamol does not explain the
observations that inhibition of macrophage function will prevent paracetamol induced
hepatic necrosis in experimental models. A recent report has shown that pretreatment
with gadolinium chloride, to block Kupffer cell function, does not alter the metabolic
fate of paracetamol in vivo and has implicated a direct contribution of Kupffer cells in
the pathogenesis of hepatic necrosis following paracetamol overdose (Laskin et al
1995). Kupffer cells are primary sources of tumour necrosis factor alpha (TNFa)
which has been shown to induce hepatocyte apoptosis and necrosis after hepatotoxin
exposure (Leist et al 1995, Kimura et al 1997). In addition, toxic liver injury following
administration of carbon tetrachloride (Czaja et al 1995), cadmium (Kayama et al
1995), galactosamine/lipopolysaccaride (Louis et al 1997) and Concanavallin A
(Gantner et al 1995) can be inhibited by blocking hepatic TNFa expression or Kupffer
cell function (Edwards et al 1993).
The aims of these studies were to;
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• determine ifTNFa expression was induced by paracetamol poisoning
• measure the effect of inhibiting TNFa on hepatic necrosis in this experimental
model.
4.2 MATERIALS AND METHODS.
4.1. Experimental model.
Six week old female CBA/J mice were fasted, but with free access to water, for
8 hours prior to intraperitoneal (I.P.) injection of paracetamol 300 mg/kg, dissolved in
normal saline. After injection, the animals were allowed free access to laboratory chow.
Rabbit anti-murine TNFa antibodies were prepared by multiple site immunisation of
New Zealand White rabbits with recombinant murine TNFa, serum IgG was purified
using a protein A column and 0.5 ml of immune serum injected IP, 1 hour prior to
paracetamol administration. Non-immune serum was used as control. Many previous
studies have shown the efficacy of the immune serum in inhibiting the in vivo effects of
TNFa (Remick et al 1990, Eskcmdari et al 1992, Hewett et al 1993, Colletti et al
1995). Mice were also injected IP. with interleukin 10 (5 ug) soluble TNF receptor
(200ug) and dexamethasone (4 ug) or saline as control, 1 hour prior to paracetamol
administration, which have also been shown to inhibit the in vivo effects of TNFa in
experimental animals (Standiford et al 1995, Walley et al 1996, Lukacs et al 1995,
Chensue et al 1990). In addition, soluble interleukin 1 receptors (200ug/animal) were
injected I.P. 1 hour prior to paracetamol administration.
4.2. TNFa expression.
Samples of liver were weighed and homogenised in 1 ml of phosphate buffered
saline containing 0.5% Nonidit P40 and the supernatant recovered following
centrifugation. Measurements of antigenic TNFa from serum and liver homogenate
were made using a double ligand ELISA specific for murine TNFa as previously
described (Walley et al 1996). Liver was also "snap frozen" in liquid nitrogen and
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homogenised in 1 ml of 4.2 mol/L guanidine isothiocyanate, 25 mmol/L Tris (pH 8.0),
0.5% Sarkosyl and 0.1 mol/L 2 mercaptethanol. An equal volume of 100 mmol/L Tris
(pH 8.0), 10 mmol/L EDTA and 1.0% SDS was added and total RNA prepared
following phenol-chloroform and chloroform-isoamyl alcohol extraction. The isolated
RNA was quantitated by spectrophotometric analysis at 260 nm and 5ug reverse
transcribed into cDNA using oligo (dT) 12-18 primers and AMV reverse transcriptase.





The amplification reaction was incubated initially at 94°C for 5 minutes followed by 35
cycles at 93°C for 45 seconds, 52°C for 45 seconds and 72°C for 90 seconds. The
amplification products were visualised under UV light following separation in a 2%
agarose gel containing 0.3 mg/ml ethidium bromide.
4.3. Assessment of hepatic injury.
Hepatic injury was measured by serum aspartate aminotransferase activity
determined using a standard calorimetric assay (Sigma Chemical Co, St Louis,
Missouri, USA) and by histological assessment of H & E stained sections of liver
tissue. The histological assessment was conducted by two independent investigators
(Drs Simpson and Harrison) without prior knowledge of what if any anti-TNFa
treatment the animal had received. Hepatic necrosis was scored as follows; +, less than




A two way analysis of variance was used to test for differences in serum and
hepatic TNFa concentrations and serum aspartate aminotransferase activities. A Chi
square test was used to test for significant differences in mortality. Both analysis of
variance and Chi square tests were used to test for differences in hepatic histology. A
result of p < 0.05 was chosen as significant. All data are presented as mean + standard
error.
4.3 RESULTS.
To determine the time course of hepatic injury we measured the serum concentration
of the enzyme, aspartate aminotransferase, and scored hepatic necrosis on H&E stained
histological sections. Three hours following paracetamol administration a significant
increase in serum aspartate aminotransferase (control 22.5 + 2.6 IU/L, n = 6,
paracetamol treated 2726 + 629 IU/L, n = 6, p < 0.05) and the appearance of severe
hepatic necrosis was observed (Figure 4.1 & 4.2). These changes were completely
prevented by the prior injection of 300 mg/kg, N-acetylcysteine (Figure 4.3). Thus the
murine model used in these experiments, is similar to the liver damage induced in
humans.
Induction of TNFa by paracetamol in vivo was determined by measuring serum and
hepatic TNFa protein and gene expression. Serum TNFa (figure 4.4) increased 3
hours following paracetamol injection (20.4 + 0.6 pg/ml, mean + SEM, n = 5, p <
0.05) and remained elevated for 24 hours compared with control (2.4 + 2.4 pg/ml, n =
7). Hepatic TNFa protein concentration (figure 4.5) was similar at all time points
following paracetamol administration (range 0.498-4.818 ng/gm wet weight) and was
not significantly different compared with controls (0.941 + 0.114 ng/gm wet weight, n
= 7). Hepatic TNFa gene expression was not induced following paracetamol (Figure
4.6). Therefore, although a small, but significant increase in serum TNFa protein was
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observed, there was no induction of hepatic TNFa protein or gene expression
following paracetamol poisoning.
To further determine the role ofTNFa in the pathogenesis of hepatic injury induced by
paracetamol, we inhibited the biological effects of TNFa in vivo using anti-TNF
antibodies, soluble TNF receptors, interleukin 10 and dexamethasone. Mortality (Table
4.1) following paracetamol poisoning was minimally increased in mice pre-treated with
blocking anti-TNFa antibodies (12.5%), soluble TNF receptor (8.3%), interleukin 10
(12.5%) and dexamethasone (0%) compared with controls (0%). Serum aspartate
(Table 4.1) was also similar in all groups. Histological assessment of the extent of
hepatic necrosis (Figure 4.7, Table 4.2), determined 20 hours post paracetamol
injection, was also similar in controls (2.0 + 0.2, mean score + SEM, n = 16) and mice
pretreated with blocking anti-TNFa antibodies (2.5 + 0.3, n = 8), soluble TNFa
receptor (2.3 + 0.3, n = 10), interleukin 10 (2.43 + 0.2, n = 7) and dexamethasone (2.1
+ 0.2, n = 8). Soluble interleukin 1 receptors had no effect on hepatic injury post-
paracetamol as determined by serum transaminases (7378 + 1092, n = 8), death rate
(0%) or histological score (2.5 + 0.2).
4.3.1. Figures for Chapter 4.
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3hou"s 6hOLrs 12hars 24hars control
Figure 4.1. Serum aspartate aminotransferase post-paracetamol poisoning. N = 5 in
each group, except control n = 7.
CONTROL 1 HOUR POST PARACETAMOL
3 HOURS POST PARACETAMOL 24 H0URS POST PARACETAMOL
Figure 4.2. Hepatic histology (H&E stained sections x 10) control, 1 hour, 3 hours and
24 hours following paracetamol poisoning.
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Figure 4.3. Hepatic histology (H&E stained sections x 10) 24 hours post-paracetamol
poisoning, with and without pretreatment with N-acetylcysteine (300 mg/kg).
LT 30
1 HOUR 3 HOURS 6 HOURS 12 HOURS 24 HOURS CONTROL
Figure 4.4. Serum TNFa following paracetamol poisoning. # = significant difference
(p < 0.05) compared with saline injected controls, n = 5 in each group except the
control group in which n = 7.
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1 HOUR 3 HOURS 6 HOURS 12 HOURS 24 HOURS CONTROL
Figure 4.5. Hepatic TNFa following paracetamol poisoning. No significant
differences (p < 0.05) were noted compared with saline injected controls, n = 5 in




1 3 6 12 24 C N
Figure 4.6. Hepatic TNFa mRNA expression following paracetamol poisoning.
Cyclophylin was used as control. 1, 3, 6, 12, 24 = hours post-paracetamol, C =
control, N = negative control. Images are negatives ofpolaroid photographs.
CYCLOPHYLIN
12 24 C N
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Figure 4.7. Hepatic histology following paracetamol poisoning, the effect of anti-TNF
a therapies. Representative sections from control animals and mice preinjected with
anti-TNFa antibodies, soluble TNF receptor and interleukin 10 prior to paracetamol
injection are presented. No difference in hepatic histology was observed. The data
from dexamethasone treated animals is not shown, but no improvement in hepatic
histology was observed.
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4.4 DISCUSSION.
In this study, an increase in serum TNFa at 3 hours post paracetamol was observed,
but there was no increase in hepatic TNFa protein or gene expression. In addition,
treatment with anti-TNFa antibodies, soluble TNF receptor, interleukin 10 and
dexamethasone did not protect against paracetamol induced hepatic necrosis as
determined 20 hours post paracetamol poisoning. The concentrations of anti-TNFa
therapies used were sufficient to inhibit the high serum concentrations observed during
sepsis, for example the anti-TNFa antibodies reduce TNFa serum concentrations of
80,000 pg/ml observed following caecal ligation and puncture, to undetectable levels
(Eskandari et al 1992). Therefore, the anti-TNFa therapies employed in this paper
should have been more than adequate to completely inhibit circulating concentrations
ofTNFa observed following paracetamol poisoning (maximum 30 pg/ml).
Kupffer cells have been implicated in the development of hepatic necrosis following
paracetamol poisoning. Cultured hepatocytes exposed to paracetamol release
unidentified mediators that activate Kupffer cells in vitro (Laskin et al 1986a).
Activated Kupffer cells have been identified in liver tissue following paracetamol
poisoning in experimental animals {Laskin et al 1986b). Gadolinium chloride
pretreatment blocks Kupffer cell function and inhibits hepatic necrosis in a rat model of
paracetamol poisoning, without affecting the metabolism of paracetamol {Laskin et al
1995). Interestingly, pretreatment with lipopolysaccaride, a macrophage activator, also
prevented hepatic necrosis in this model {Laskin et al 1995). Goldin and colleagues
{1996), using dichloromethylene diphosphonate containing liposomes, found Kupffer
cell blockade only delayed, but did not prevent, hepatic necrosis following paracetamol
poisoning in a murine model. Kupffer cells are potent sources of TNFa, which may
induce hepatocyte death in vivo and in vitro {Hill et al 1995, Leist et al 1996).
Previous studies have shown anti-TNFa antibodies {Hewett et al 1993), soluble TNF
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receptors (Czaja et al 1995) or interleukin 10 (Louis et al 1997) can inhibit liver injury
induced by other nonparacetamol hepatotoxic agents. Gadolinium chloride
pretreatment is associated with hepatic release of TNFa (Ruttinger et al 1996). This
may protect the liver from the subsequent toxic effects of TNFa through the induction
of tolerance. In addition, elevated circulating TNFa has been reported in patients with
fulminant liver failure from a variety of causes (Muto et al 1988, Sekiyama et al 1994,
Haeger et al 1996).
In contrast with the results presented here, other workers have shown an increase in
serum TNFa using a bioassay from 6 hours to 48 hours and increased hepatic TNFa
expression at 8 hours following paracetamol administration (Blazka et al 1995). Serum
transaminases and hepatic histological damage were also reduced but not inhibited by
anti-TNFa antibodies {Blazka et al 1996). It is likely that the differences between the
two studies are due to differences in the strain of mice used and the dosage of
paracetamol (500 mg/kg). Interestingly, no effect of blocking TNFa on mortality was
reported in these previous studies and the serum transaminases at 24 hours were
returning to normal {Blazka et al 1995, 1996), in contrast with this study in which the
aspartate aminotransferase was 2000-11,000 IU/L.
The role of TNFa in the pathogenesis of toxic liver injury has been studied in other
models, including carbon tetrachloride (CC14) or lipopolysaccaride/galactosamine
(LPS/GalN) administration. Although serum or hepatic TNFa concentrations were not
reported, administration of soluble TNF receptors inhibited liver injury in rats following
CC14 (5ml/kg) {Czaja et al 1995). However in another study, using a murine model,
injection of anti-TNFa antibodies did not prevent CC14 (0.1 ml/kg) induced hepatic
injury, despite increased concentrations of serum and hepatic TNFa {Bruccoleri et al
1997). Interestingly, the reported concentrations of serum TNFa (30 pg/ml), were
similar to those observed in this study. LPS/Galn administration induces hepatic
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necrosis in mice and elevated serum and hepatic TNFa concentrations. The increased
TNFa expression and toxic liver injury in this model can be prevented by anti-TNFa
therapies (Louis et al 1997, Santucci et cil 1996).
TNFa can also play an important role in hepatic regeneration (Diahl & Rai 1996).
Liver regeneration following partial hepatectomy is delayed by inhibiting the biological
effects of TNFa in vivo and hepatic proliferation induced by lead nitrate is also
prevented by anti-TNF antibodies. In addition, liver regeneration following partial
hepatectomy is impaired in mice lacking the TNF p55 receptor (Yamada et al 1997).
However, following toxic liver injury, TNFa may have two diametrically opposing
pathogenic roles. One the one hand, TNFa can induce hepatic apoptosis and necrosis
following toxin exposure, both in vivo and in vitro and on the other hand TNFa may
also initiate and potentate hepatic regeneration. It is not clear from published data,
whether this is a species difference (ie. rat v mouse), related to the route or dose of
hepatotoxin administration or degree of hepatic injury induced, (ie. TNFa inhibition
prevents injury following high dose hepatotoxin or induction of extensive hepatic
necrosis; TNFa inhibition delays regeneration following lower dose hepatotoxin
administration or induction of milder hepatic damage).
Kupffer cells are also potent sources of interleukin 1. Interleukin I can induce the
production of TNFa from hepatocytes in vitro (Freda et al 1996) and pretreatment of
animals with interleukin 1 does not induce hepatic damage, but prevents direct TNFa
induced hepatic necrosis (Bohlinger et al 1995). However, no protective effect of
administering soluble interleukin 1 receptors on hepatic necrosis induced by
paracetamol poisoning was identified, suggesting that Kupffer cell derived interleukin 1
does not play a pathogenic role in this model. Another Kupffer cell derived cytokine,
macrophage inflammatory protein 2 (MIP2), has recently been implicated in hepatic
necrosis following chronic alcohol ingestion (Bautista 1997). Although hepatic
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expression of the CC chemokine monocyte chemoattractant protein 1 (MCP1) is
increased in toxic liver injury (Czaja et al 1994), the production of other chemokines,
such as MIP2, has not been studied.
In summary, the data presented in this chapter does not implicate TNFa in the
pathogenesis of hepatocyte necrosis following paracetamol poisoning. Therefore
therapies directed against TNFa are unlikely to be clinically effective. However, TNFa
may play a central role in hepatic regeneration following toxic liver injury and partial
(70%) hepatectomy. Therefore, although no role for TNFa in the acute necrosis
following paracetamol poisoning was identified, this multifunctional cytokine may play
a central role in initiating hepatic regeneration in this model.
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ROLE OF CHEMOKINES IN HEPATIC REGENERATION
FOLLOWING PARACETAMOL POISONING
5.1. INTRODUCTION AND AIMS
At present most of the published data regarding hepatic regeneration has been derived
from studying the rat 70% hepatectomy model and much important data have been
obtained from these studies regarding the role of cytokines in hepatic regeneration.
Following 70% hepatectomy there is some infiltration of the parenchyma with
neutrophils, which may induce some hepatocyte damage, but this animal model
essentially investigates the regeneration of normal hepatocytes in an undamaged liver.
This situation is rarely encountered in the clinical setting. Although other animal
models of toxic liver injury exist and have been discussed above, the major cause of
toxic liver injury in medical practice follows paracetamol poisoning. In this chapter the
regeneration of the liver following paracetamol poisoning was investigated, particularly
the potential role of chemokines.
The specific aims of this chapter were to
• Determine if chemokine production was induced in the liver after paracetamol
poisoning.
• Subsequently, to examine the effect on liver regeneration of inhibiting or enhancing




The murine model of paracetamol poisoning was described previously in
chapter 4.
5.2.2. Modulation of hepatic chemokine expression in vivo.
Rabbit anti-murine chemokine blocking antibodies were raised in New Zealand
White rabbits with recombinant chemokines. Antiserum was administered by
intraperitoneal injections, one hour prior to paracetamol poisoning, and every second
day there after. Non-immune serum was used as control.
The adenovirus was a kind gift from Professor J Gauldie. Rat MIP-2 cDNA was
inserted into the E3 region of the genome of recombinant human type 5 adenovirus,
made replication deficient by deleting the El region. Rat MIP-2 is 90% homologous in
base sequence with murine MIP-2. A human cytomegalovirus promoter and SV40
polyadenylation sequence inserted upstream and downstream of the MIP-2 cDNA
respectively. Replication deficient type 5 adenovirus with Escherichia coli (3-
galactosidase (lacZ) inserted into the E3 region of the viral genome served as control.
Adenovirus (2.5 x 10^ plaque forming units) was injected via tail vein injection 24
hours before paracetamol administration.
5.2.3. Murine chemokine ELISA.
Hepatic chemokine expression was measured as described in chapter 4.
5.2.4. Assessment of hepatic regeneration.
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Hepatic repair was measured using an AXIO-HOME microscope. Sections of
liver tissue (2 from each animal) were stained with haematoxylin and eosin, the area of
hepatic necrosis was quantitated and expressed as % total area.
5.2.5. Statistical analysis.
Results are presented as mean + SEM. Statistical significance was determined
by analysis of variance and students t-test as appropriate, with p < 0.05 considered
significant.
5.3. RESULTS
5.3.1. Hepatic chemokine expression is induced following paracetamol
poisoning.
To determine if chemokine expression was induced during hepatic injury and
regeneration following paracetamol poisoning, the concentration of immunoreactive
MIP-2, JE, MlPla and MIP1(3 was measured in liver homogenate supernatants.
Preliminary experiments identified 300 mg/kg as a dose which induced extensive
hepatic necrosis, elevated serum transaminases and a mortality rate of upto 30%.
Paracetamol administration at concentrations (ie. 200 mg/kg and less) were not
associated with histological hepatic damage and only mild elevation of serum aspartate
aminotransferase (ie. < 50 IU/L). Injection of paracetamol at these sub-necrotic
concentrations did not alter hepatic chemokine expression. In contrast, protein
concentrations of the CXC chemokine, MIP-2, were significantly increased compared
with controls from 12 hours to 48 hours post-paracetamol poisoning using 300 mg/kg
(Figure 5.1). Although hepatic congestion and necrosis are histologically evident from
3 hours post-paracetamol, the increased MIP-2 at 12 hours corresponds with the
increasing serum aspartate aminotransferase concentrations over the first 24 hours.
Hepatic MIP-2 concentrations are similar to controls by 3 days after paracetamol
poisoning, at which time the liver histology has not returned to normal (Figure 5.2).
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Despite the dense mononuclear inflammatory infiltrate surrounding the necrotic areas
of liver tissue, although these was some increase in hepatic CC chemokines, JE, MIP1
a and MIPip (Figure 5.3-5.5), post-paracetamol, these changes did not reach
statistical significance.
5.3.2. Modulation of hepatic chemokine expression alters liver
regeneration.
Intraperitoneal injection of neutralising anti-chemokine antibodies was
associated with a significantly delayed liver regeneration (Figure 5.6) on day 6 in
animals treated with neutralising antibodies directed against the CXC chemokine,
ENA-78 (8.67 + 2.50, mean + SEM, n = 9, mean of 2 experiments) compared with
controls (0.8 + 0.67, n = 8, mean of 2 experiments). In contrast, neutralisation ofMEP-
2, JE (MCP-1), MlPla or administration of neutralising anti-ICAM-1 antibodies, was
not associated with delayed liver regeneration on day 6 (Figure 5.6). During these
experiments the observed mortality rate in the animals treated with anti-ICAM-1
(35%), anti-MIP-2 (31.6%) and anti-MIPla (25%) was noted to be increased
compared with control animals (10.5%) and those treated with anti-JE (10%) and anti-
ENA-78 (10%) antibodies (n = 19 or 20 in each group, mean of 2 experiments).
An adenovirus expression vector was used to study the effect of enhancing hepatic
expression of the CXC chemokine, MIP-2, on liver regeneration following paracetamol
poisoning. Both control and MIP-2 adenovirus treated animals had similar histological
damage 24 hours post-paracetamol injection. In addition, a significant neutrophilic
infiltrate was not observed in the MIP-2 adenovirus injected animals compared with
controls (Figure 5.7). All animals treated with the MIP-2 expressing adenovirus had
complete liver regeneration four days following paracetamol poisoning, compared with
controls, where almost 50% of the liver remained necrotic (Figure 5.8, 5.9). Therefore,
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remained necrotic (Figure 5.8, 5.9). Therefore, increasing hepatic MIP-2 expression
accelerates hepatic regeneration following paracetamol poisoning.
5.3.3. Figures for Chapter 5.
Figure 5.1. Hepatic expression ofMIP 2 post-paracetamol poisoning. # = significantly
different from controls, n = 5 in each group.
Figure 5.2. Hepatic histology (H&E stained sections) showing dense mononuclear
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Figure 5.3. Hepatic JE (MCP-1) expression post-paracetamol.
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Figure 5.6. Effect of inhibiting hepatic chemokine expression on the resolution of the
necrotic areas of liver, following paracetamol poisoning. # = significantly different from
controls.
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Figure 5.7. Effect of adenovirus MIP 2 on hepatic histology 4 days after paracetamol
poisoning (FI&E stained sections, x 10). Complete resolution of the hepatic damage in
the MIP 2 treated animals was noted.
OrtrdadaD AfcroMR2
Figure 5.8. Quantitation of the area of hepatic necrosis at day 4 in animals treated with
adenovirus MIP 2 compared with controls. # = significantly different from controls.
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Control adenovirus
Figure 5.9 Hepatic histology (H&E stained sections, x ?) 24 hours post paracetamol in
control and adenovirus MIP 2 treated animals, no significant neutrophilic hepatitis
was noted in the adenoMIP 2 treated animals.
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5.4. DISCUSSION
These experiments have shown paracetamol poisoning in hepatotoxic doses induces the
hepatic expression of the CXC chemokine, MIP-2, blocking the effects of MIP-2
increases post-poisoning mortality rates and augmenting hepatic MIP-2 expression
enhances regeneration following paracetamol induced liver injury. Intravenous injection
of adenovirus expression vectors is associated with a high level of gene expression in
the liver compared with other tissues (Jaffe et al 1992). Although blocking MEP-2
antibodies did not delay liver regeneration, neutralisation of another CXC chemokine,
ENA-78, significantly inhibited liver regeneration after paracetamol poisoning. These
data suggest that CXC chemokines may play a permissive role in vivo in liver
regeneration following toxic liver injury and, that augmenting the hepatic expression of
these chemokines may accelerate regeneration. In contrast, although a dense
mononuclear infiltrate was observed surrounding the necrotic areas of liver, hepatic
expression of CC chemokines was not induced by lethal doses of paracetamol.
However, the observation that mortality rates are increased in mice treated with anti-
ICAM-1 and anti-MIPla antibodies suggests that pathways utilising these molecules
may also be important in the response to paracetamol poisoning.
Correlation of increased protein expression with increased mRNA, potential stimuli or
cells expressing MIP-2 were not determined in this study. Kupffer cells are potent
sources ofMIP-2 following stimulation with proinflammatory cytokines, such as TNFa
and ILlp. Both these stimuli and bacterial infection can induce the production of Gro,
the human MIP-2 homologue, from primary human hepatocytes (.Rowell et al 1997)
and the production of Gro from human hepatoma cell lines was noted to be
constitutive and was not induced by proinflammatory cytokine stimulation (presented
in chapter 2). Biliary epithelial cells (Morland et al 1997), sinusoidal endothelial cells
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and fat-storing cells (Xu et al 1996) can all be induced to produce chemokines,
including Gro or MIP-2 by proinflammatory stimuli. Studies reported in the previous
chapter, using the murine model of paracetamol poisoning, did not find induction of
TNFa expression. The effect of neutralising TNFa on hepatic expression of MIP-2
following paracetamol poisoning was not examined, but the lack of TNFa induction
post-paracetamol poisoning would suggest that this cytokine is not the proximal
stimulus to MIP-2 expression. Oxidative stress has also been implicated in the
production of chemokines (Xu et al 1996). Hepatocyte metabolism of paracetamol
metabolism results in free radical generation and oxidative stress (Arnaiz et al 1995),
which may be the stimulus to MIP-2 production observed in this study. In a recent
study, primary rat hepatocytes released Gro (a rat MIP-2 homologue) following
exposure to paracetamol (10-50 mmol/L) or hydrogen peroxide (1-10 mmol/L) and
was correlated with hepatocyte damage as determined by leakage of lactate
dehydrogenase (Horbach et al 1997).
There are no studies published on chemokine expression following any form of toxic
liver injury. A recent paper implicated MIP-2 in the hepatic injury following alcohol
ingestion, but MIP-2 was not directly toxic to primary cultures of normal rat
hepatocytes (Bautista 1997). These data presented in this chapter would suggest that
the CXC chemokines have the opposite effect on the liver following paracetamol
poisoning. The increased mortality rate in the anti-MIP-2 antibody treated group
compared with controls suggests that MIP-2, expressed during paracetamol induced
hepatic damage, may play a protective role. This clearly needs to be further studied
both in vivo, assessing the effect of neutralising MIP-2 on hepatic injury, and in vitro
using cultured primary murine hepatocytes.
The potential role of chemokines as mediators of hepatic regeneration have not
previously been reported. In a rather unfocused study, 70% partial hepatectomy was
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noted to induce the hepatic expression of IP-10, KC and chemokine genes, as well as
67 other genes (Haber et al 1993). Partial hepatectomy also increases the hepatic
expression of Gro/CINC in rats, and this has been implicated in the neutrophilic
infiltrate that occurs in the liver remnant post-resection (Ohtsuka et al 1997). Although
there is still some confusion in the literature, human Gro a is homologus with rat
CINC1 and murine KC. Murine MIP-2 is most similar to rat CINC 2 and CINC 3 and
human Gro P and Gro y. In humans Gro a, P and y bind to the same receptor, CXCR2
which can also bind all the other ELR positive CXC chemokines (Ahuja & Murphy
1996). In mice the Gro homologues, KC and MIP-2, also bind the same IL-8 like
receptor. All members of the Gro family can act as neutrophil chemoattractants and
can also induce a respiratory burst and Mac 1 expression in neutrophils {Shibata et al
1995). However, depending on the cell type studied Gro or its rodent homologues can
induce cell proliferation. Gro is alternatively known as melanoma growth stimulatory
activity because of its properties as an autocrine growth factor for human melanoma
cells (Norgauer et al 1996), Gro induces DNA synthesis in human melanoma cells. Gro
is expressed following injury to the skin (Nanney et al 1995, Tsuruta et al 1996) and
plays a role in healing via induction of keratinocyte proliferation (Retmekampff et al
1997). MIP-2/CINC and KC/CINC1 induce proliferation of cultured rat alveolar
epithelial cells and it has been suggested that the proliferative effects of IL1 are
induced via Gro production (Rangnekar et al 1991). In contrast, MIP-2 may inhibit the
proliferation of myeloid progenitors (Broxmeyer et al 1996) and Gro a and P can
inhibit endothelial cell proliferation and angiogenesis (Cao et al 1995). Proliferation
can be induced by MIP-2 and ENA-78 in rat primary hepatocyte cultures and this
effect can be inhibited by the non-ELR CXC chemokines, IP-10 and MIG (L Colletti,
personal communication). Therefore the enhanced regeneration induced by the MIP-2
expressing adenovirus may be mediated via the induction of hepatocyte cell division.
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In summary, hepatotoxic doses of paracetamol were found to induce the production of
the CXC chemokine, MIP-2. Inhibition of another CXC chemokine ENA-78 was
associated with delay in liver regeneration following paracetamol induced hepatic
necrosis and augmenting MIP-2 expression accelerated regeneration in this model. It is
tempting to speculate therefore, that adenovirus transfection of chemokine genes may
be a novel therapy to augment liver regeneration following toxic liver injury.
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. FACTOR AND TOXIC LIVER INJURY.
6.1. INTRODUCTION AND AIMS.
Hepatic regeneration following paracetamol poisoning is likely to involve a number of
cytokines and growth factors. In the previous chapter MIP-2 was implicated as a
cytokine with the potential to accelerate hepatic regeneration following paracetamol
poisoning. Stem cell factor (SCF) is best known as a haemopoetic growth factor which
induces leukocyte maturation and differentiation (Zsebo et al 1990). However, recent
evidence would suggest that SCF may serve an important role in tissue repair and
protection from injury in certain disease states. SCF is a growth factor for dermal
melanocytes and is essential for mast cell survival, proliferation and maturation (Tsai et
al 1991, Mitsui et al 1993). In addition, SCF and its receptor, c-kit, have been shown
to be expressed on numerous tumour cells, including neuroblastomas, small cell lung
adenocarcinoma, and hepatoblastomas (Vonschweinitz et al 1995). Finally, SCF has
been shown to attenuate radiation-induced injury in several cell populations (Leigh et
al 1993), indicating that it may have an protective role during cell injury. Previous
studies have demonstrated SCF expression in the liver (Rowell et al 1997, Omori et al
1997a), the aims of these studies were therefore to
• Quantitate the expression on SCF in murine liver.
• Assess the effect of toxic liver injury on hepatic SCF expression.
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• Determine the role of SCF in hepatic regeneration following paracetamol
poisoning.
6.2. MATERIALS AND METHODS.
6.2.1. Animal model.
The model of paracetamol induced hepatic necrosis has been described
previously in Chapter 4. To inhibit the effect of SCF in vivo, rabbit anti-murine SCF
immune serum (0.5ml) was injected 1 hour prior to paracetamol injection and daily
thereafter.
6.2.2. Stem cell factor ELISA.
Immunoreactive SCF was measured in serum and hepatic extracts using a
specific murine SCF ELISA, which was similar to those described in previous chapters.
6.2.3. Immunohistochemistry.
Paraffin embedded sections were rehydrated in xylene and graded alcohol,
treated with acetone for 2 minutes and 1:1 F^C^methanol for 30 minutes at room
temperature. After rinsing the slides were blocked with normal goats serum for 30
minutes at 37°C, then rabbit anti-murine SCF antibody or control antibody added
(1:100 dilution) and the slides incubated for a further 30 minutes at 37°C. The slides
were washed with PBS and overlaid for 30 minutes with biotinylated goat anti-rabbit
IgG (Biogenex, CA, supersensitive reagent, 1:20). After further washing, the slides
were incubated with streptavidin-peroxidase (Biogenex, 1:1000) in PBS for 30 minutes
at 37°C and the colour developed with 3'-amino-9-ethylcarbazole (AEC) solution
containing 0.3% hydrogen peroxide. The slides were counter-stained with Mayers
haematoxylin and photographed.
6.2.4. Assessment of hepatic regeneration.
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Hepatic repair was quantified as described in chapter 5.
6.2.5. Statistical analysis.
Results are presented as mean + SEM. Statistical significance was determined
by analysis of variance and students t-test as appropriate, with p < 0.05 considered
significant.
6.3. RESULTS.
Very high concentrations of SCF were observed in control mouse liver (1000-2000
ng/gm wet weight). Immunohistochemical studies showed SCF staining in the biliary
epithelial cells (Figure 6.1), although staining was also observed in hepatocyte
cytoplasm and nuclei.
A significant reduction in hepatic immunoreactive SCF protein was noted at 12 and 24
hours following a non-necrotic dose (200 mg/kg) of paracetamol (Figure 6.2). This
dose of paracetamol did not induce any histological damage, but serum AST was
mildly elevated upto 2 times controls. This reduction in hepatic concentration of SCF
was not associated with any alteration in serum SCF concentration (Figure 6.3). In
contrast, hepatic SCF concentrations following 300 mg/kg paracetamol significantly
increased at 1 hour following paracetamol injection. At this dose of paracetamol
extensive hepatic damage is observed, but the increase in hepatic SCF concentrations in
this model preceded any biochemical or histological evidence of liver necrosis (as
presented in chapter 4). To further study the potential role of SCF in this model of
paracetamol induced hepatic damage, anti-SCF antibodies were injected IP. before
paracetamol poisoning and daily thereafter. A significant delay in hepatic repair was
observed (Figure 6.5, 6.6), at 4 days post-paracetamol injection, in animals treated with
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anti-SCF antibodies (25.7 + 8.5 % total area necrotic, mean + SEM, n = 5) compared
with controls (11.6 + 5.3, n- 5).
6.3.1. Figures for Chapter 6.
a*
Control antibody
Figure 6.1. Immunohistochemistry of hepatic SCF expression (x 40). Cell were
counterstained with haematoxylin.
Figure 6.2. Hepatic SCF protein post-paracetamol 200 mg/kg. # = significantly
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Figure 6.3. Hepatic SCF protein post-paracetamol 300 mg/kg. # = significantly
different (P < 0.05) compared with controls.
6 HR 12 HR 24 HR 48 HR 72 HR CONTROL





Figure 6.5. Hepatic necrotic area at 4 days post-paracetamol poisoning, effect of
blocking SCF in vivo. # = significantly different (P < 0.05) compared with controls.
Figure 6.6. Hepatic histology, control antibody or anti-SCF antibody treated animals
post-paracetamol (H&E staining, x 20).
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6.4. DISCUSSION.
In this chapter high concentrations of hepatic SCF were detected, which increased
early (1 hour) following hepatotoxic doses of paracetamol. In contrast, lower doses
were associated with significant reduction in hepatic SCF concentrations 12 and 24
hours post-paracetamol poisoning. Hepatic SCF expression was noted in the biliary
epithelial cells and hepatocytes, but SCF distribution was unaffected by paracetamol
poisoning. Interestingly, in vivo inhibition of SCF was associated with significant delay
in hepatic regeneration, 4 days following paracetamol injection.
These data regarding the role of SCF in the pathophysiology of liver damage following
paracetamol poisoning may be interpreted in two ways. Firstly, SCF may protect the
liver from paracetamol induced liver injury. SCF has been shown to attenuate radiation
induced cellular damage in both hematopoietic and non-hematopoietic stem cell
populations (Leigh et al 1993, 1995). Reactive oxygen intermediates have been
implicated in cell injury induced by both radiation or paracetamol poisoning. In
addition, SCF reduces apoptosis in mast cells and primordial germ cells from foetal
gonads (Pesce et al 1993). Paracetamol can induce hepatocyte apoptosis both in vivo
and in vitro (DJ Harrison, personal communication). However, the effect of SCF on
paracetamol induced apoptosis or necrosis has not been studied to date .in this model.
SCF may have an alternative effect of augmenting hepatocyte proliferation and
regeneration following toxic liver injury, but like the hypothesised effects on injury this
was not studied directly in the experiments discussed in this chapter. SCF has a well
recognised role in controlling cell proliferation and differentiation in hematopoietic
cells, germ line cells and melanocytes. Observational studies have also implicated SCF
in controlling hepatic regeneration from the oval cell compartment following partial
hepatectomy and acetylaminofluorene administration (Fujio et al 1994). SCF has also
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been implicated in the development of differentiated hepatocytes in the pancreas of rats
subjected to copper depletion and repletion and in the bile ductular proliferation
induced in immature rats following bile duct ligation {Rao et al 1996). Therefore SCF
may also play a permissive role in hepatocyte proliferation and differentiation following
paracetamol poisoning. Hepatoblastomas are able to produce SCF {Vonschweinitz et al
1995). This may explain the extramedullar erythropoiesis that may occur within the
liver in such patients, but the role of SCF in hepatoblastoma proliferation has not been
studied. In addition, SCF can synergise with hepatocyte growth factor, a potent
hepatocyte mitogen, in proliferation of bone marrow stem cells (Galimi et al 1994).
SCF can also synergise with erythropoietin {Jacobs Helber et al 1997) and the flt-flt-3
tyrosine kinase signalling system, the latter has also been implicated in bile ductular
proliferation following bile duct ligation {Omori et al 1997b). Therefore the interaction
of SCF with these other cytokine systems in the paracetamol model would be worthy
of further study.
In addition to the potential role of SCF in hepatic proliferation and repair, SCF may
also be an important cytokine in the pathogenesis of liver fibrosis. Intrahepatic mast
cells have been correlated with the degree of hepatic fibrosis in chronic liver disease
{Farrell et al 1995). Systemic mastocytosis is associated with hepatic fibrosis, portal
hypertension and death from bleeding oesophageal varices {Mican et al 1995). SCF is
an essential factor for mast cell survival. Recent data has shown production of SCF
from transformed stellate cells when exposed to mast cell conditioned media, possibly
due to mast cell derived TNFa {Benyon et al 1997, Brito & Borojevic 1997)
These data presented in this chapter have implicated SCF in the pathogenesis of liver
injury or repair following paracetamol poisoning. The mechanism underlying this effect
is not clear at present, but it is tempting to speculate that this cytokine, in addition to
MIP 2, may be clinically useful in treating toxic liver injury.
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HEPATIC CHEMOKINE EXPRESSION IN
PATHOLOGICAL STATES.
7.1. INTRODUCTION AND AIMS.
In previous chapters the role of chemokines and cytokines in the pathogenesis of liver
disorders has been studied using in vitro cell culture and in vivo animal studies. When
this work was initiated in 1995, there was little data regarding the hepatic expression of
chemokines in the patients with liver disease, although this has changed more recently.
Most inflammatory liver diseases are characterised by infiltration of the liver with
lymphocytes, for example viral hepatitis and allograft rejection following liver
transplantation. However, granulocytes, such as eosinophils in acute cellular rejection
and neutrophils in alcoholic hepatitis, have also been implicated in the pathogenesis of
hepatic disease.
The aim of these studies was to
• develop reproducible PCR assays for chemokine genes in human needle liver
biopsies.
• to determine the expression of potential chemoattractant cytokines in patients with
differing liver conditions.
7.2. MATERIALS AND METHODS.
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7.2.1. Liver biopsy, RNA extraction and cDNA synthesis.
These studies were approved by the Royal Infirmary NHS Trust Medical Ethics
Committee. After obtaining informed consent, a laparoscopic liver biopsy was
performed using a Trucut needle or percutaneously using a Menghini needle. Unless
the biopsy was being performed for suspected malignant disease (which was an
exclusion criteria), the biopsy was halved, washed three times in ice-cold sterile saline,
snap frozen in liquid nitrogen and stored at -70°C.
Preliminary experiments lead to the following protocol for RNA isolation and cDNA
synthesis. Liver tissue was thawed, weighed on a torsion balance and immersed in lysis
buffer. The samples were homogenised and 1 x volume of 70% ethanol added. After
mixing, the samples were applied to an RNeasy spin column (Quiagen), centrifuged at
10,000 rpm for 15 seconds, the columns were washed three times and the total RNA
eluted from the column using DEPC treated water. Total RNA (lug) was incubated
with 1 unit DNase (GibcoBRL) in buffer (20 mmol/L Tris HC1, pH 8.3, 50 mmol/L
KC1, 2.5 mmol/L MgCl2) for 15 minutes at room temperature. The RNA was then
reverse transcribed into cDNA using AMV reverse transcriptase (15U) in buffer
(lOmmol/L Tris-HCl, pH 8.8, 50 mmol/L KC1, 5 mmol/L MgCl2, 1% Triton X-100, 20
units RNasin ribonuclease inhibitor, 1 mmol/L dTTP, 1 mmol/L dATP, 1 mmol/L
dGTP, 1 mmol/L dCTP) using oligo(dT)15 (0.5 ug) as a primer. The reverse
transcriptase reaction was continued for 60 minutes at 42°C and terminated by heating
to 95°C for 5 minutes.
7.2.2. Polymerase chain reaction.
Primers were designed for human MCP-1 (Yoshimura et al 1989), MCP-3
(Minty et al 1993), IL-8 (Mukaida et al 1989), MlPla (Nakao et al 1990), MIPip
(Napolitano et al 1991), IP 10 {Luster & Ravetch 1987), RANTES (Schall et al
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1988), ENA-78 (Chang at al 1994) and Gro a (Haskill at al 1990) using published
sequence data. Where possible the primers were designed so that either the sense or
anti-sense primer spanned an intron-exon boundary, thus avoiding amplification of
genomic DNA. In addition, the primers were designed so that within the PCR product
there was a restriction site, which would allow confirmation of the specificity of the
product and allow insertion of further sequences for development of competitive
templates and hence potential quantitation (Table 7.1).
The primers (0.5 umol/L) were added to buffer containing KC1 (50 mmol/L), Tris HC1
(lOmmol/L), pH 9.0, 0.1% triton X-100, MgC^ (2 mmol/L), dNTP (0.2 mmol/L) and
Taq DNA polymerase (2.5 units, Promega) was added after heating the reactions to
95°C for 5 minutes ("hot-start" PCR). A Techne PHC-3 thermal cycler was used. The
annealing, extension and heating temperatures and timings are shown in table 7.2. PCR
reactions were performed in duplicate with 100% concordance. Preliminary
experiments revealed that a positive PCR result was reproducible in over 90% of
repeated cases.
7.2.3. Histological assessment.
The presence or absence of cirrhosis was determine by both macroscopic and
microscopic assessment of liver tissue. The degree of lymphocytic, neutrophilic or
eosinophilic infiltrate was assessed on H & E stained histological sections by two
independent observers and graded on a three point scale as mild, moderate or severe.
7.2.4. Statistical analysis.
Data is presented as expression (% total number of samples in group). Chi
squared tests were used to compare of chemokine gene expression between groups. A






































































































7.3.1. Chemokine gene expression in patients with Hepatitis C infection.
Expression of the lymphocytic chemokines, IL-8, IP 10, MCP-1, MCP-3,
RANTES, MlPla and MIPip were determined in patients with chronic hepatitis C
viral infection (clinical details are shown in table 7.3). In addition, the hepatic
expression of these chemokines in 6 patients at the end of interferon therapy (3 x 106
units, three times per week for 6 months) were studied, all of these patients had
responded to interferon, but relapsed following discontinuing interferon therapy.
Representative pictures of PCR results are shown in Figure 7.1. Similar hepatic
expression of chemokine genes was observed in patients before and following
interferon therapy (Figure 7.2). Compared with chemokine gene expression in "cut-
down" liver tissue (a kind gift from Dr C Benyon, University of Southampton, UK), IP
10 (39% v 100%) and RANTES (14.3% v 100%) genes were expressed at significantly
lower frequency and IL-8 at significantly increased frequency (65% v 12.5%) in
patients with hepatitis C virus infection (Figure 7.2). Compared with another control
group, patients with non-alcoholic fatty liver, patients with hepatitis C virus infection
had significantly increased frequency of IL-8 expression (65% v 0%). There was no
correlation with hepatic chemokine expression and the degree of lymphocytic infiltrate
or presence of cirrhosis.
7.3.2. Hepatic chemokine gene expression in patients with alcoholic liver
disease.
In view of the characteristic neutrophilic infiltrate found in patients with
alcoholic hepatitis, the expression of the CXC chemokines, IL-8, IP 10, Gro a and
ENA-78 was studied. The patients clinical details are presented in table 7.3.
Representative pictures of PCR results of Gro a and ENA-78 are shown in Figure 7.3.
Hepatic CXC chemokine expression was similar in patients with alcoholic liver disease
compared with gene expression found in "cut-down" liver tissue (Figure 7.4).
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Figure 7.3. Clinical details of patients studied.
ALD HCV POST-TP
(N = 21) (N = 24) (N = 22)
Male/Female 9/12 14/10 7/15
Cirrhotic 15 5 N/A
(n)
Bilirubin 50+ 16 12 + 4 201 + 39
(umol/L)
ALT (IU/L) 42 + 8 88 + 13 192 ±35
Alkaline 148 + 27 88 + 12 392 + 66
phosphatase
(IU/L)
GGTP (IU/L) 253 + 71 66+ 14 346 ±46
Albumin (g/L) 37 + 3 40+ 1 31 ± 1
Results are mean + SEM. ALD = alcoholic liver disease, HCV = Hepatitis C infection, Post-
TP = post liver transplantation. ALT = alanine aminotransferase. GGTP = gamma glutamyl
transferase.
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However, IL-8 expression was significantly more common in patients with alcoholic
liver disease (52.4%) compared with patients with non-alcoholic fatty liver (0%).
There was no correlation with hepatic chemokine expression and the degree of
neutrophilic infiltrate or presence of cirrhosis.
7.3.3. Chemokine gene expression in liver tissue from patients following liver
transplantation. .
Expression of the eosinophilic chemokines, MCP-3 and RANTES, was
determined in patients routine day 7 liver biopsies. Although more than 50% of
patients in this group expressed MCP-3, this difference was not significantly different
compared with the two control groups studied (Figure 7.5). RANTES expression was
significantly less frequent in the post-transplant patients (52.2%) compared with
RANTES expression in "cut-down" liver tissue (100%). There was no correlation with
hepatic chemokine expression and the degree of eosinophilic infiltrate or the
histological degree of acute cellular rejection.
7.3.4. Comparison of hepatic chemokine expression in different disease states.
Hepatic chemokine expression was compared in the three disease groups
studied. IP 10 expression was significantly reduced in patients with hepatitis C viral
infection (39.1%) compared with patients with alcoholic liver disease (85.7%). In
addition, the frequency of RANTES (14.3%) and MCP-3 (0%) expression in patients
with hepatitis C viral infection was significantly reduced compared with patients
following liver transplantation (RANTES, 52.5%, MCP-3, 56.5%).
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7.3.6. Figures for Chapter 7.
RANTES
Figure 7.1. PCR results of chemokine genes in human liver tissue. Examples of results










Figure 7.2. Chemokine gene expression in controls (cutdowns, NAF = non-alcoholic
fatty liver) and patients with hepatitis C infection (HCV, HCVPOSTIF = following
interferon alpha). # = significantly different from cutdown livers and * = significantly
different from NAF.
Figure 7.3. ENA-78 and Gro expression in human liver tissue
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Figure 7.4. Chemokine gene expression in controls (cutdowns, NAF = non-alcoholic
fatty liver) and patients with alcoholic liver disease. # = significantly different from
cutdown livers and * = significantly different from NAF.
MCP3 RENTES
Figure 7.5. Chemokine gene expression in controls (cutdowns, NAF = non-alcoholic
fatty liver) and patients after liver transplantation (TP). # = significantly different from
cutdown livers and * = significantly different from NAF.
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7.4. DISCUSSION.
In this chapter the expression of chemokine genes was studied in liver biopsy tissue
from patients with a variety of diseases. A variety of both CXC and CC chemokines
were found to be expressed in the disease groups studied, hepatitis C infection, post
liver transplant and alcoholic liver disease, and also the controls, "cut-down" liver
tissue and non-alcoholic fatty liver. Increased IL-8 expression was noted in both the
hepatitis C virus infected patients and those with alcoholic liver disease compared with
the control groups. The expression of chemokine genes in hepatitis C infected
individuals was found to be unaffected by interferon alpha therapy. Although successful
interferon therapy down regulates the hepatic expression of the adhesion molecule,
ICAM-1, the continued expression of lymphocytic chemokines may explain the rapid
relapse in many patients, once interferon therapy is withdrawn. A reduced frequency of
EP 10 expression was also noted in patents with hepatitis C infection compared with
controls and other disease groups, suggesting the intrahepatic production of interferon
may be deficient in such patients, thus predisposing them to chronic viral infection. In
addition, comparing hepatitis C viral infection, characterised by a lymphocytic
infiltrate, and acute cellular rejection, in which a marked eosinophilia can be found,
increased frequency of expression of the eosinophilic chemokines, MCP-3 and
RANTES was noted in the latter. Others have noted increased expression of IL-5,
MlPla and MIPip in liver tissue of patients with acute liver allograft rejection
(Martinez tit al 1993, Adams et al 1996).
Others have shown increased protein concentrations of the CXC chemokines, Gro and
IL-8, in patients with alcoholic liver disease and have correlated the concentrations
with the degree of neutrophilic hepatitis (Sheron et al 1993, Maltby et al 1996). These
data presented in this chapter confirm the increased IL-8 expression and show that
other CXC chemokines are also expressed in liver tissue from patients with alcoholic
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liver disease. IP 10 was frequently expressed in liver tissue in patients with alcoholic
liver disease. This CXC chemokine lacks the ELR amino acid motif, essential for
neutrophil attraction and activation, and can inhibit the effects on neutrophils of other
ELR positive CXC chemokines (Baggiolini et al 1997). These data suggest that the
balance between ELR positive and ELR negative CXC chemokines may be important
in determining the extent of neutrophilic infiltrate in the liver in disease states.
Both MCP-3 and RANTES are potent eosinophilic chemoattractants and the
lymphocytic chemokines studied in patients with hepatitis C virus infection have some
specificity for different lymphocyte subsets (Bciggiolirii et al 1997). However no
correlation was noted between chemokine gene expression and the degree of
inflammatory cell infiltrate in any of the liver disease groups. These data do not exclude
a role for these chemokines in the development of an inflammatory infiltrate in these
conditions. The relative concentrations and site of production of the various
chemokines and the expression of adhesion molecules on endothelial and other cell
types are likely to be as important in the development of an inflammatory infiltrate. In
addition, as discussed in previous chapters, chemokines have other biological roles, in
cell proliferation, angiogenesis and tissue repair (Baggiolini et al 1997), and so their
expression within the liver may have effects rather than chemoattraction.
In summary, these data presented in this chapter reveal diverse patterns of chemokine
expression in the liver in various disease states. Further understanding of the
pathological role of these chemokines in liver diseases will follow quantitation and




Before starting the work on this thesis, little was known regarding the synthesis
chemokines by liver cells and their potential role in the pathogenesis of liver diseases.
Chapter 2 confirms and expands the published data (Thornton et al 1990, Rowell et al
1997). Human hepatoma cell lines, used in many studies to model the responses of
hepatocytes, were found to express a number of CXC and CC chemokines following
TNFa stimulation. Only protein concentrations in culture supernatant were measured,
but most reports have shown increased protein expression is mediated via increased
mRNA transcription. The stimulatory effects of TNFa on hepatoma cell chemokine
expression were found to be mediated via TNFR1. There after the intracellular
pathways inducing expression of the CXC chemokine, IL-8, diverged from the
pathways inducing the expression of the CC chemokines, RANTES and MCP-1.
Production of IL-8 involved activation of protein kinase C and was inhibited by
staurosporine and calphostin C. In contrast, activation of protein kinase C and tyrosine
kinase pathways were implicated in the expression of RANTES and MCP-1 induced by
TNFa. These data suggest that if certain chemokines were found to play a primary role
in the pathogenesis of a certain liver disorder, that the expression of this chemokine
may be specifically inhibited by targeting the intracellular pathways involved in its
expression.
Chapter 3 aimed to study adhesion mediated chemokine production in cells other than
endothelial cells, such adhesion mediated chemokine production has not been reported
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previously. In contrast with endothelial cells, hepatoma cells do not require
preactivation with proinflammatory cytokines for adhesion mediated chemokine
production to occur. Chemokine production was induced in both the monocyte and
hepatoma cell populations. IL-8 production was mediated via adhesion mediated
production of TNFa and IL-1(3, whereas the production of the CC chemokines MIP1(3
and MCP-1 were mediated via beta integrin mediated activation of intracellular
reactive oxygen generation. Preliminary data in normal human hepatocytes suggests
that small concentrations of IL-8 are produced during monocyte-hepatocyte adhesion,
but no synthesis of CC chemokines occurs. Therefore during tumour development the
hosts immune response may, via the synthesis of the angiogenic chemokine IL-8,
augment tumour growth and metastatic potential. These data suggest that targeted
inhibition of CXC chemokine production may be a novel therapeutic modality in anti-
tumour therapies.
Chapters 4, 5 and 6 studied various aspects of a murine model of paracetamol
poisoning. This model is analogous to the human situation, in that high serum
concentrations of transaminases occur at doses of paracetamol that are hepatotoxic in
humans. In addition, the liver damage is prevented by pretreatment with N-
acetylcysteine, the antidote used in human poison cases. Despite the compelling data
implicating Kupffer cells in the development of hepatocyte necrosis, inhibition of TNF
a had no effect on the degree of liver damage. Similar data have been reported in
models of carbon tetrachloride poisoning. Paracetamol poisoning induces the
expression of CXC chemokines in the liver, inhibiting MIP-2 increased mortality and
increasing hepatic MIP-2 expression with an adenovirus transfection vector accelerated
hepatic regeneration. Although the effect of these treatments on hepatic inflammatory
cell infiltrate were not studied, the published data suggests that the effects of the CXC
chemokines are mediated via their action on cell proliferation and may allow
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development of novel therapies to augment hepatic regeneration following toxic liver
injury. SCF was also induced and was implicated in either injury or repair following
paracetamol poisoning. SCF plays a role in protecting cells against free radical
mediated damage and if subsequent experiments demonstrate this effect also occurs in
paracetamol poisoning, then SCF administration may also be helpful therapeutically.
The final experimental chapter described the expression ofCXC and CC chemokines in
liver tissue, as determined by PCR. Multiple chemokines were found to be expressed,
although there was poor correlation with the inflammatory phenotype. It is likely that
the localisation of expression is as important as the types of chemokines expressed in
dictating the phenotype of an inflammatory infiltrate. In addition the expression and
activation state of adhesion molecules is also important in movement of inflammatory
cells into tissues. Perhaps the chemokines expressed have other actions such as a role
in hepatocyte proliferation or death and is why there is poor correlation with the
inflammatory phenotype.
In summary this thesis has reported data that expands the current knowledge regarding
the production and role of chemokines in hepatic disease. In addition, potentially




Adachi Y, Arii S, Funaki N, Higashitsnji H, Fujita S, Funitani M. Mise M, Zhang WH, Tobe T.
Tumoricidal activity of Kupffer cells augmented by anticancer drugs. Life Sciences, 1992, 51;
177-183
Adams DH, Hubscher S, Fear J, Johnson J, Shaw S, Afford S. Hepatic expression ofMIP1 alpha and
MIP1 beta after liver transplantation. Transplantation, 1996; 61: 817-825.
Adams DH, Lloyd AR. Chemokines: Leucocyte recruitment and activation cytokines. Lancet
1997;349:490-495.
Ahmad F, Goldstein BJ. Effect of tumor necrosis factor-alpha on the phosphorylation of tyrosine
kinase receptors is associated with dynamic alterations in specific protein-tyrosine
phosphatases. J Cell Biochem, 1997; 64: 117-127
Aliuja SK, Murphy PM. The cxc chemokines growth regulated oncogene (gro)alpha, gro-beta, gro-
gamma, neutrophil activating peptide-2, and epithelial cell derived neutrophil activating
peptide-78 are potent agonists for the type-B, but not the type-A. human interleukin-8 receptor.
J Biol Chem 1996;271:20545-20550.
Alcolando R, Arthur MJP, Iredale JP. Pathogenesis of hepatic fibrosis. Clin Sci, 1997; 92: 103-112.
Alonso A, Bayon Y, Crespo MS. The expression of cytokine induced neutrophil chemoattractants
(CINC- 1 and CINC-2) in rat peritoneal macrophages is triggered by Fc-gamma receptor
activation; study of the signaling mechanism. Eur J Immunol 1996;26:2165-2171.
Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Streiter RM. Inhibition of interleukin
8 reduces tumourigenesis of human small cell lung cancer in SCID mice. J Clin Invest. 1996;
97:2792-2802.
Argiles JM, LopezSoriano FJ. Cancer cachexia: A key role for TNF? int J Oncol, 1997: 10: 565-572.
Arnaiz SL, Llesuy S, Cutrin JC, Boveris A. Oxidative stress by acute acetaminophen administration in
mouse liver. Free Radical Biol Med 1995;19:303-310.
Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: Its reaction
with hydrogen peroxide, hydroxyl radical, superoxide and hypochlorous acid. Free Radical Biol
Med 1989;6:593-597.
Asumendi A, Alvarez A, Martinez I, Smedsrod B, Vidal-Vanaclocha F. Hepatic sinusoidal
endothelium heterogeneity with respect to mannose receptor activity is IL1 dependent.
Hepatology, 1996; 23: 1521-1529.
Baggiolini M, Dewald B, Moser B. Human chemokines: An update. Ann Rev Immunol 1997;15:675-
705.
Balach G, Izzo F, Chiao P, Klostergaard J, Curley SA. Activation of human kupffer cells by
thymostimulin to produce cytotoxicity against human hepatocellular carcinoma. Ann Surg
Oncol, 1997; 4: 149-155.
Balemans LTM, Mattijssen V, Steerenberg PA, Vandriel BEM, Demulder PHM, Denotter W.
Locoregional therapy with polyethylene glycol modified interleukin-2 of an intradermally
growing hepatocellular carcinoma in the guinea-pig induces T-cell mediated antitumor activity.
Cancer Immunology Immunotherapy, 1993; 37: 7-14
Banks RE, Forbes MA, Storr M, Higgenson J, Thompson D, Illingworth JM, Perrin TJ, Selby PJ,
Whicher JT. The acute phase response in patients receiving subcutaneous IL6. Clin Exp
Immunol, 1995; 102: 217-223.
Baumann H, Gauldie J. The acute phase response. Immunol Today, 1994; 15: 74-80.
Bautista AP. Chronic alcohol intoxication induces hepatic injury through enhanced macrophage
inflammatory protein-2 production and intercellular adhesion molecule-1 expression in the
liver. Hepatology 1997;25:335-342.
Bazzoni F, Beutler B. How do tumor necrosis factor receptors work. J Inflamm 1995;45:221-238.
Beales LLP, Calam J. Stimulation of IL-8 production in human gastric epithelial cells by Helicobacter
pylori, IL-1 beta and TNF-alpha requires tyrosine kinase activity, but not protein kinase C.
Cytokine 1997;9:514-520.
Benyon RC, Pickering JA, Gaca MDA, Arthur MJP. Interactions between hepatic stellate cells and
mast cells. JHepatology, 1997; 26(S1): 131.
157
Bergelson S, Pinkus R, Daniel V. Intracellular glutathione levels regulate Fos/Jun induction and
activation of GST gene expression. Cancer Res 1994;54:36-40.
Bertoletti A, D'Elios MM, Boni C, DeCarli M, Ziegnego AL, Durazzo M, Missale G. Different
cytokine profiles of intrahepatic T cells in chronic hepatitis B and C vims infections.
Gastroenterology, 1997; 112: 193-199.
Berton G, Laudanna C, Sorio C, Rossi F. Generation of signals activating neutrophil functions by
leukocyte integrins: LFA-1 and gpl50/95, but not CR3, are able to stimulate the respiratory
burst of human eosinophils. J Cell Biol 1992,116:1007-1017.
Bird TA, Kyriakis JM, Tyshler L, Gayle M, Milne A, Virca GD. Interleukin-1 activates p54 mitogen
activated protein (MAP) kinase kinase stress activated protein kinase by a pathway that is
independent of p21(RAS), raf-1, and MAP kinase kinase. J Biol Client, 1994; 269: 31836-
31844
Blazka ME, Elwell MR, Holladay SD, Wilson RE. Luster MI. Histopathology of acetaminophen
induced liver changes: Role of interleukin 1 alpha and tumor necrosis factor alpha. Toxicol
Pathol 1996;24:181-189.
Blazka ME, Wihner JL, Holladay SD, Wilson RE. Luster MI. Role of proinflammatory cytokines in
acetaminophen hepatotoxicity. Toxicol Appl Pharmacol 1995;133:43-52.
Bohlinger I, Leist M, Barsig J, Uhlig S, Tiegs G, Wendel A. Interleukin 1 and nitric oxide protect
against tumor necrosis factor alpha induced liver injury through distinct pathways. Hepatology
1995;22:1829-1837.
Boldin MP, Mett IL, Varfolomeev EE, Chuinakov I, Shemeravni Y, Cainonis JH, Wallach D. Self
association of the death domains of the p55 tumor-necrosis-factor (TNF) receptor and Fas/apol
prompts signaling for TNF and Fas/apol effects. J Biol Chem 1995;270:387-391.
Brennan P. O'Neill LA. Effects of oxidants and antioxidants on nuclear factor kappa B activation in
three different cell lines: Evidence against a universal hypothesis involving oxygen radicles.
Biochem Biophys Acta 1995;1260:167-175.
Brito JM, Borojevic R. Liver granulomas in schistosomiasis: Mast cell dependent induction of SCF
expression in hepatic stellate cells is mediated by TNF-alpha. J Leukocyte Biol 1997;62:389-
396.
Broxmeyer FIE, Cooper S, Cacalano G, Hague NL, Bailish E, Moore MW. Involvement of interleukin
(IL)-8 receptor in negative regulation of myeloid progenitor cells in vivo\ evidence from mice
lacking the murine IL-8 receptor homolog. J Exp Med 1996;184:1825-1832.
Bruccoleri A, Gallucci R, Germolec DR, Blackshear P, Simeonova P, Tluirman RG, Luster MI.
Induction of early immediate genes by tumor necrosis factor alpha contribute to liver repair
following chemical induced hepatotoxicity. Hepatology 1997;25:133-141.
Bruck R, Shirin H, Hershkoviz R, Lider O, Kenet G, Aeed H, Matas Z, Zaidel L, Halpern Z. Analysis
of Arg-Gly-Asp mimetics and soluble receptor of TNF as theraputic modalities for ConA
induced hepatitis in mice. Gut, 1997; 40: 133-138.
Buchner RR, Hugh TE, Ember JA, Morgan EL. Expression of functional receptors for human C5a
anaphylatoxin (CD88) on the human hepatocellular-carcinoma cell line Hep G2; stimulation of
acute phase protein specific mRNA and protein synthesis by human C5a anaphylatoxin. J
Immunol, 1995: 155: 308-315
Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krarns SM. Immunoregulatory cytokines in
chronic hepatits C virus infection. Hepatology, 1996; 24: 6-9.
Campos SP, Wang YP, Baumann H. Insulin modulates STAT3 protein activation and gene
transcription in hepatic cells. J Biol Chem, 1996; 271: 24418-24424
Cao YH, Chen C, Weatherbee JA, Tsang M, Folkman J. Gro-beta, Gro-alpha C-X-C chemokine, is an
angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice. J Exp Med
1995;182:2069-2077.
Cavanaugh VJ, Guidotti LG, Chisari FV. IL12 inhibits hepatitis B viral replication in transgenic
mice. J Virol, 1997; 71: 3236-3243.
Chang M-S, McNich J, Basu R, Simonet S. Cloning and characterisation of the human Neutrophil-
activating peptide (ENA-78) gene. J Biol Chem, 1994; 269: 25277-25282.
Chensue SW, Terebuh PD, Reinick DG, Scales WE, Kunkel SL. In vivo biologic and
immunohistochemical analysis of interleukin 1 alpha, beta and tumor necrosis factor during
158
experimental endotoxemia: Kinetics, Kupffer cell expression and glucocorticoid effects. Am J
Path 1991;138:395-402.
Chisari FV, Ferrari C. Hepatitis B immunopathogenesis. Ann Rev Immunol 1995; 13: 29-60.
Chuang LM, Tai TY, Kahn RC, Wu HP, Lee SC, Lin BJ. Signal-transduction pathways for
interleukin-4 and insulin in human hepatoma-cells. J Biochem 1996; 120: 111-116
Colletti LM, Kunkel SL, Green M, Burdick MD, Streiter RM. C-X-C chemokines may be important
molecules in hepatic regeneration. FASEB J. 1995; 9: A700.
Colletti LM, Kunkel SL, Green M, Burdick MD, Streiter RM. Hepatic inflammation following 70%
hepatectomy may be related to up-regulation of ENA-78. Shock 1996b; 6: 397-402.
Colletti LM, Kunkel SL, Walz A, Burdick MD, Kunkel RG, Wilke CA, StrieterRM. The role of
cytokine networks in the local liver injury following hepatic ischemia/reperfusion in the rat.
Hepatology 1996a;23:506-514.
Costelli P, Carbo N, Tessitore L. Bagby Gj, Lopezsoriano FJ, Argiles JM, Baccino FM. Tumor
necrosis factor alpha mediates changes in tissue protein turnover in a rat cancer cachexia
model. J Clin Invest 1993; 92: 2783-2789
Costelli P, Llovera M, Carbo N, Garciamartinez C, Lopezsorianoq FJ, Argiles JM. Interleukin-1
receptor antagonist (IL-lra) is unable to reverse cachexia in rats bearing an ascites hepatoma
(Yoshida AH-130). Cancer Letters 1995; 95: 33-38
Cressman DE, Diamond RH, Taub R. Rapid activation of the Stat 3 transcription complex in liver
regeneration. Hepatology, 1995; 21: 1443-1449.
Czaja MJ, Geertz A, Xu J, Schmiedeberg P. Ju Y. Monocyte chemoattractant protein 1 (MCP 1)
expression occurs in toxic liver injury and human liver disease. J Leukocyte Biol 1994;55:120-
126.
Czaja MJ, Xu J, Alt E. Prevention of carbon tetrachloride induced rat liver injury by soluble tumor
necrosis factor receptor. Gastroenterology 1995;108:1849-1854.
Damle NK, Klussman K, Linsley PS, Aruffo A. Differential costimulatory effects of adhesion
molecules B7, ICAM-1, LFA-3 and VCAM on resting and antigen primed CD4+ T
lymphocytes. J Immunol 1992;148:1985-1992.
Darnay BG, Aggarwal BB. Early events in TNF signalling. J Leukocyte Biol, 1997; 61: 559-566.
Davatelis G, Tekamp-Olson P, Wolpe SD, Hennsen K, Luedke C, GallEgos C, Coit D, Merryweather
J, Cerami A. Cloning and characterisation of a cDNA for murine macrophage inflammatory
protein (MIP), a novel monokine with inflammatory and chemokinetic properties. J Exp Med
1988;167:1939-1944.
Davis BH, Kresina TF. Hepatic fibrogenesis. Clin Lab Med, 1996; 16: 361-387.
Deaciuc IV, Alappat JM, McDonough KH, D'Souza NB. Effect of chronic alcohol consumption by rats
on TNF alpha and IL6 clearance in vivo and by the isolated perfused liver. Biochem
Pharmacol, 1996; 52: 891-899.
Deutschman CS, Haber BA, Andrejko K, Cressman DE, Harrison R, Elenko E, Taub R. Increased
expression of CINC in septic rat liver. Am J Physiol, 1996; 40: R593-R600.
Diehl AM, Rai RM. Regulation of signal transduction during liver regeneration. FASEB J, 1996b; 10:
215-227.
Diehl AM, Rai RM. Review, regulation of liver regeneration by proinflammatory cytokines. J Gastro
Hepatol, 1996a; 11: 466-470.
Diehl AM, Yang SQ, Yin M, Lin HZ, Nelson S, Bagby G. Tumor necrosis factor alpha modulates
CCAAT/enhancer binding proteins DNA binding activities and promotes hepatocyte specific
gene expression during liver regeneration. Hepatology, 1995; 22: 252-261.
Edwards MJ, Keller BJ, Kaufman FC, Thurman RG. The involvement ofKupffer cells in carbon
tetrachloride toxicity. Toxicol Appl Pharmacol 1993;119:275-279.
Eierman DF, Johnson CE, Haskill JS. Human monocyte inflammatory mediator gene expression is
selectively regulated by adherence substrates. J Immunol 1989;142:1970-1976.
Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE. Remick DG. Anti-tumor necrosis
factor antibody therapy fails to prevent lethality after cecal ligation and puncture or
endotoxemia. J Immunol 1992;148:2724-2730.
EvanoffHL, Burdick MD, Moore SA, Kunkel SL, Stricter RM. A sensitive ELISA for the detection of
human monocyte chemoattractant protein 1. Immunol Invest 1992;21:39-45.
159
Fang JWS, Shen WW, Meager A, Lau JYN. Activation of the TNF alpha system in the liver in
chronic hepatitis B virus infection. Am J Gastro, 1996; 91: 748-753.
Farrell DJ, Hines JE, Walls AF, Kelly PJ, Bennett MK, Burt AD. Intrahepatic mast cells in chronic
liver diseases. Hepatology, 1995; 22: 1175-1181.
Farrell DJ, Hines JE, Walls AF, Kelly PJ, Bennett MK, Burt AD. Intrahepatic mast cells in chronic
liver-diseases. Hepatology 1995;22:1175-1181.
Fausto N, Webber EM. Liver regeneration. In The Liver: Biology and Pathobiology, ppl059-1084, ed
Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA. Raven Press Ltd, NY.
1994.
Ferlazzo G, Scisca C, Lemmo R, Cavaliere R, Quartarone G, Adamo V, Frazzetto G, Costa G, Melioli
G. Intralesional sonographically guided injections of lymphokine activated killer cells and
recombinant IL2 for the treatment of liver tumours. J Immunotherapy, 1997; 20: 158-163.
Fernandezbotran R, Chilton PM, Ma YH. Soluble cytokine receptors. Adv Immunol, 1996; 63: 269-
336.
Foxwell BMJ, Barrett K, Feldmann M. Cytokine receptors, structure and signal transduction. Clin
Exp Immunol, 1992; 90: 161-169.
Frede S, Fandrey J, Jelkmann W. Interleukin 1 beta and phorbol ester induce tumor necrosis factor
alpha production in a hepatic cell line (HepG2). Pflugers Arch Eur J Physiol 1996;431:923-
927.
Fujio K, Evarts RP, Hu ZY, Marsden ER, Thorgeirsson SS. Expression of stem cell factor and its
receptor, c-kit, during liver regeneration from putative stem cells in the adult rat. Lab Invest
1994;70:511-516.
Fukuda R, Ishimura N, Nguyen TX, Chowdhury A, Shihara S, Kohge N. The expression of IL2, IL4
and IFN inRNA using liver biopsies at different phases of acute exacerbation of hepatitis B.
Clin Exp Immunol, 1995; 100: 446-451.
Galimi F, Bagnara GP, Bonsi L, Cottone E, Follenzi A, Simeone A, Comoglio PM. Hepatocyte growth
factor induces proliferation and differentiation of multipotent and erythroid hematopoietic
progenitors. J Cell Biol 1994;127:1743-1754.
Gangopadhyay A, Bajenova O, Kelly TM, Thomas P. Carcinoembryonic antigen induces cytokine
expression in kupffer cells implications for hepatic metastasis for colorectal cancer. Cancer
Research 1996, 56: 4805-4810.
Ganter F, Kusters S, Wendel A, Hatzelmann A, Schudt C, Teigs G. Protection from T cell mediated
murine liver failure by phosphodiesterase inhibitors. J Pharmacol Exp Theraputics, 1997; 280:
53-60.
Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G. Concanavalin A induced T-cell mediated
hepatic injury in mice: Role of tumor necrosis factor. Hepatology 1995 ,21:190-198.
Goetzl EJ, An SZ, Smith WL. Specificity of expression and effects of eicosanoid mediators in normal
physiology and human disease. FASEB J, 1995; 9: 1051-1058
Goldin RD, Ratnayaka ID, Breach CS, Brown IN, Wickrainasinghe SN. Role of macrophages in
acetaminophen (paracetamol) induced hepatotoxicity. J Pathol 1996;179:432-435.
Gorczynski RM, Adams RB, Levy GA, Chung SW. Correlation of peripheral blood lymphocyte and
intragraft cytokine mRNA expression with rejection in orthotopic liver transplantation.
Surgery, 1996; 120: 496-502.
Green RM, Beier D, Gollan JL. Regulation of hepatic bile salt transporters by endotoxin and
inflammatory cytokines in rodents. Gastroenterology, 1996; 111: 193-198.
Gressner AM, Lahme B, Brenzel A. Molecular dissection of the mitogenic effect of hepatocytes on
cultured hepatic stellate cells. Hepatology, 1995; 22: 1507-1518
Grove M, Plumb M. C/EBP, NF-kappa B and c-Ets family members and transcriptional regulation of
the cell specific and inducible macrophage inflammatory protein 1 alpha immediate early gene.
Mol Cell Biol 1993;13:5276-5289.
Guidotti LG, Borrow P, Hobbs MV, Matzke B, Gresser I. Oldstone MBA, Chisari FV. Viral cross talk,
intracellular inactivation of the hepatitis B vims during an unrelated viral infection of the liver.
Proc Natl Acad Sci USA, 1996; 93: 4589-4594.
Guo YJ, Che XY, Shen F, Xie TP, Ma J, Wang XN, Wu SG, Anthony DD, Wu MC. Effective tumor
vaccines generated by in vitro modification of tumor cells with cytokines and bispecific
monoclonal antibodies. Nature Medicine, 1997; 3: 451-455.
160
Haber BA, Mohn KL, Diamond RH, Taub R. Induction patterns of 70 genes during 9 days after
hepatectomy define the temporal course of liver-regeneration. J Clin Invest 1993;91:1319-
1326.
Haeger M, Unander M, Andersson B, Tarkovvski A, Arnestad JP, Bengtsson A. Increased release of
tumor necrosis factor alpha and IL6 in women with the syndrome of hemolysis, elevated liver
enzymes and low platelet count. Acta Obstet Gynecol Scand 1996;75:695-701.
Harada K, Van de Water J, Leung PSC, Coppel RL, Ansari A, Nakanuma Y, Gershwin ME. In situ
nucleic acid hybridisation of cytokines in PBC: predominance of the Till subset. Hepatology,
1997; 25: 791-796.
Harbrecht BG, Wang SC, Simmons RL, Billiar TR. cGMP and guanylate cyclase mediate LPS
induced kupffer cell TNF alpha synthesis. J Leukocyte Biol, 1995; 57: 297-302.
Harrison P, Downs T, Friese P, Wolf R, George JN, Burstein SA. Inhibition of the acute-phase
response in-vivo by anti-gpl30 monoclonal-antibodies. Br J Haematol, 1996; 95: 443-451
Haskill JS, Johnson CE, Eiennan DF, Becker S, Warren K. Adherence induces selective mRNA
expression ofmonocyte mediators and proto-oncogenes. J Immunol 1988;140:1690-1694.
Haskill S, Peace A, Morris J. Identification of three related human Gro genes encoding cytokine
functions. Proc Natl Acad Sci USA 1990; 87: 7732-7736.
Hewett JA, Jean PA, Kunkel SL, Roth RA. Relationship between tumor necrosis factor alpha and
neutrophils in endotoxin induced liver injury. Am J Physiol 1993;265:G 1011 -G1015.
Hill DB, Schmidt J, Shedlofsky SI, Cohen DA, McClain CJ. In-vitro tumor necrosis factor cytotoxicity
in Hep G2 liver cells. Hepatology 1995;21:1114-1119.
Hoffman AL, Rosen HR, Ljubimova JU, Sher L, Podesta LG, Demetriou AA, Makowka L. Hepatic
regeneration. Semin Liver Dis, 1994; 14: 190-210.
Horbach M, Gerber E, Kahl R. Influence of acetaminophen treatment and hydrogen peroxide
treatment on the release of a CINC related protein and TNF-alpha from rat hepatocyte cultures.
Toxicology 1997;121:117-126.
Horuk R. The IL8 receptor family. Immunology Today, 1994; 15: 169-174.
Huang H, Chen SH, Kosai K, Fenegold MJ, Woo SLC. Gene therapy for hepatocellular carcinoma:
long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy
in-vivo. Gene Therapy, 1996; 3: 980-987
Imaizumi TA, Stafforini DM, Yamada Y, Mclntyre TM, Rescott SM, Zimmerman GA. Platelet
activating factor, a mediator for the clinician. J Int Med, 1995; 238: 5-20.
Inagi R, Guntapong R, Nakao M, Ishino Y, Kawanishi K, Isegawa Y, Yamanishi K. Human
herpesvirus-6 induces IL8 gene expression in human hepatoma cell line. Hep G2. J Med Virol,
1996; 49: 34-40
JacobsHelber SM, Penta K, Sun ZH, Lawson A, Sawyer ST. Distinct signaling from stem cell factor
and erythropoietin in HCD57 cells. J Biol Chem 1997;272:6850-6853.
Jaffe HA, Danel C, Longenecker G, Metzger M, Setoguchi Y, Rosenfeld MA, Gant TW, Thorgeirsson
SS, Stratfordperricaudet LD, Perricaudet M, Pavirani A, Lecocq JP, Crystal RG. Adenovirus
mediated invivo gene transfer and expression in normal rat liver. Nature Genetics 1992; 1:372-
378.
Jones DEJ, Palmer JM, Leon MP, Yeaman SJ, Bassendine MF, Diamond AG. T cell responses to
tuberculin PPD in PBC. Gut, 1997; 40: 277-283.
Jordan NJ, Watson ML, Westwick J. The protein phosphatase inhibitor calyculin-A stimulates
chemokine production by human synovial cells. Biochemical J 1995;311:89-95.
Kakumu S, Okumura A, Ishikawa T, Iwata K, Yano M, Yoshioka K. Production of IL10 and 12 by
peripheral blood mononuclear cells in chronic hepatitis C vims infection. Clin Exp Immunol,
1997; 108: 138-143.
Karpoff HM, Tung C, Ng B, Fong YM. Interferon-gamma protects against hepatic tumor-growth in
rats by increasing kupffer cell tumoricidal activity. Hepatology, 1996; 24: 374-379
Kasahara K, Strieter RM, Chensue SW, Standiford TJ, Kunkel SL. Mononuclear cell adherence
induces neutrophil chemotactic factor/interleukin 8 gene expression. J Leukocyte Biol
1991;50:287-295.
Kasahara K, Strieter RM, Standiford TJ, Kunkel SL. Adherence in combination with
lipopolysaccaride, tumour necrosis factor or interleukin lp potentiates the induction of
monocyte derived interlcukin 8. Pathobiology 1993;61:57-66.
161
Kayama F, Yoshida T, Elwell MR, Luster MI. Role of tumor necrosis factor alpha in cadmium
induced hepatotoxicity. Toxicol Appl Pharmacol 1995;13 1:224-234.
Keane HM, Sheron N, Goka J, Hughes RD, Williams R. Plasma inhibitory activity against TNF in
fulminant hepatic failure. Clin Sci 1996; 90: 77-80.
Kimura T, Sakaida I, Terai S, Matsumura Y, Uchida K, Okita K. Inhibition of tumor necrosis factor
alpha production retards liver regeneration after partial hepatectoiny in rats. Biochem Biophys
Res Comm 1997;231:557-560.
Knolle PA, Loser E, Protzer U, Duchmann R, Schmitt E, Rose John S, Gerkin G. Regulation of
endotoxin induced IL6 production in the liver sinusoidal endothelial cells and kupffer cells by
IL10. Clin Exp Immunol, 1997; 107: 555-561.
Knustle G, Leist M, Uhlig S, Revesz L, Feifel R, MacKenzie A. Wendel A. ICE-protease inhibitors
block murine liver injury and apoptosis caused by CD95 or by TNF alpha. Immunol Lett 1997;
55:5-10.
Koj A. Initiation of the acute phase response and synthesis of cytokines. Biochem Biophys Acta, 1996;
1317: 84-94.
Kordula T, Bugno M, Goldstein J, Travis J. Activation of signal transducer and activator of
transcription 3 (STAT3) expression by interferon-gamina and interleukin-6 in hepatoma cells.
Biochem Biophys Res Commun, 1995; 216: 999-1005
Kozak SL, Piatt EJ, Madani N, Ferro FE, Peden K. Kabat D. CD4, CXCR4 and CCR5 dependencies
for infections by primary patient and laboratory adapted isolates of HIV type 1. J Virol, 1997;
71: 873-882.
Kurose I, Miura S, Higuchi H, Watanabe N, Kamegaya Y, Takaishi M, Tomita K, Fukumura D, Kato
S, Ishii H. Increased nitric-oxide synthase activity as a cause of mitochondrial dysfunction in
rat hepatocytes, roles for tumor necrosis factor alpha. Hepatology, 1996; 24: 1185-1192
Kvale D, Brandtzaeg P. Immune modulation of adhesion molecules ICAM-1 (CD54) and LFA-3
(CD58) in human hepatocytic cell lines. J Hepatol 1993;17:347-352.
Larapezzi E, Chirillo P, Morenootero R, Lopezcabrera M. Induction of TNF alpha production in
human hepatocytes by the hepatits B vims HBX protein. Hepatology 1996; 24 (2) SS392.
Laskin DL, Gardner CR, Price VF, Jollovv DJ. Modulation of macrophage functioning abrogates the
acute hepatotoxicity of acetaminophen. Hepatology 1995;21:1045-1050.
Laskin DL, Pilaro AM, Ji SC. Potential role of activated macrophages in acetaminophen
hepatotoxicity. 2. Mechanisms of macrophage accumulation and activation. Toxicol Appl
Pharmacol 1986b;86:216-226.
Laskin DL, Pilaro AM. Potential role of activated macrophages in acetaminophen hepatotoxicity. 1.
Isolation and characterisation of activated macrophages from rat liver. Toxicol Appl Pharmacol
1986a;86:204-215.
Leigh BR, Hancock SL, Knox SJ. The effect of stem cell factor on irradiated human bone marrow.
Cancer Res 1993;53:3857-3859.
Leigh BR, Khan W, Hancock SL, Knox SJ. Stem cell factor enhances the surviva of murine stem cells
after photon irradiation. Radiation Res 1995;142:12-15.
Leigh BR, Khan W, Hancock SL, Knox SJ. Stem cell factor enhances the survival of murine intestinal
stem cells after photon irradiation. Radiation Res 1995; 142:12-15.
Leist M, Gantner F, Bohlinger I, Tiegs G, Gennann PG, Wendel A. Tumor necrosis factor induced
hepatocyte apoptosis preceeds liver failure in experiemental murine shock models. Am J Path
1995;146:1220-1234.
Leist M, Gantner F, Kunstle G, Bohlinger I, Tiegs G, Bluethmann H, Wendel A. The 55-kD tumor
necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and
subsequent liver failure. Molecular Medicine 1996;2:109-124.
Leist M, Gantner F, Naumann, Bluethmann, Vogt K, Brigelius-Flohe R, Nicotera P, Volk H-D,
Wendel A. Tumor necrosis factor induced apoptosis during the poisening of mice with
hepatotoxins. Gastroenterology, 1997; 112: 923-934.
Leist M, Wendel A. A novel mechanism of murine hepatocyte death inducible by ConA. J Hepatol,
1996; 25: 948-959.
Lemoine O, Marchant A, DeGroote D, Azar C, Oldman M, DeViere J. Role of defective monocyte
IL10 release in TNF alpha overproduction in alcoholic cirrhosis. Hepatology 1995; 22: 1436-
1439.
162
Liao W, Floren CH. Up-regulation of low-density-lipoprotein receptor activity by tumor necrosis
factor, a process independent of tumor necrosis factor induced lipid synthesis and secretion.
Lipids, 1994; 29: 679-684
Llorente L, Richaudpatin Y, Alcocastillejos N, Ruizsoto R, Mercado MA, Orozco H, Alcocervarela J.
Cytokine gene expression in cirrhotic and noncirrhotic human liver. J Hepatol, 1996; 24: 555-
563.
Lohr HF, Schlaak JF, Gerken G, Fleischer B, Dienes HP, Zum Buschenfelde KHM. Phenotypical
analysis and cytokine release of liver infiltrating and peripheral blood T lymphocytes from
patients with chronic hepatitis of different aetiologies. Liver, 1994; 14: 161-166.
Lohr HF, Schlaak JF, Kollmannsperger S, Dicnes HP, Zum Buschenfelda KHM, Gerken G. Liver
infiltrating and circulating CD4+ T cells in chronic hepatitis C. Liver, 1996; 16: 174-182.
Louis H, Lemoine O, Peny MO, Gulbis B, Nisol F, Goldman M, Deviere J. Hepatoprotective role of
interleukin 10 in galactosamine/lipopolysaccharide mouse liver injury. Gastroenterology
1997;112:935-942.
Louis H, Moine OL, Peny M-O, Gulbis B, Nisol F, Goldman M, Deviere J. Hepatoprotective role of
interleukin 10 in galactosamine/lipopolysaccaride mouse liver injury. Gastroenterology, 1997,
132; 935-942.
Lukacs NW, Strieter RM, Chensue SW, Widmer M, Kunkel SL. TNF alpha mediates recruitment of
neutrophils and eosinophils during airway inflammation. J Immunol 1995b;154:5411-5417.
Lukacs NW, Strieter RM, Elner VM, Evanoff HL, Burdick MD, Kunkel SL. Intercellular adhesion
molecule-1 mediates the expression of monocyte derived MlP-la during monocyte endothelial
cell interactions. Blood 1994;83:1174-1178.
Lukacs NW, Strieter RM, Elner VM, Evanoff HL, Burdick MD, Kunke! SL. Production of
chemokines, interleukin 8 and monocyte chemoattractant protein 1, during
monocyte:endothelial cell interactions. Blood 1995a;86:2767-2773.
Luster AD, Ravetch JV. Genomic characterisation of a gamma interferon inducible gene (IP-10) and
identification of an interferon inducible hypersensitive site. Mol Cell Biol, 1987; 7: 3723-3731.
Maghazachi AA, Alaoukaty A, Schall TJ. C-C chemokines induce the chemotaxis of NK and IL-2
activated NK cells: role for G proteins. J Immunol 1994;4969-4977.
Maher JJ, Scott MK, Saito JM, Burton MC. Adenovirus mediated expression of CINC in rat liver
induces a neutrophilic hepatitis. Hepatology 1997; 25: 624-630.
Malaguamera M, DiFazio I, Romeo MA, Restuccia S, Laurino A, Trovato BA. Elevation of IL6 levels
in patients with chronic hepatitis due to hepatitis C vims. J Gastro, 1997; 32: 211-215.
Maltby J, Wright S, Bird G, Sheron N. Chemokine levels in human liver homogenates. Hepatol, 1996;
24: 1156-1160.
Martinez OM, Ascher NL, Ferrell L, Villanueva JC, Lake J, Roberts JP, Krams SM, Lorber G.
Evidence for a nonclassical pathway of graft rejection involving IL5 and eosinophils.
Transplantation, 1993; 55: 909-918.
Martinez OM, Villanueva JC, Gershwin ME, Krams SM. Cytokine patterns and cytotoxic mediators
in primary biliary cirrhosis. Hepatology, 1995; 21: 113-119.
Matsuda Y, Kawata S, Nagase T, Maeda Y, Yamasaki E, Kiso S, Ishiguro H, Matsuzawa Y.
Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma
effects of serine protease inhibitor. Cancer, 1994; 73: 53-57
Mawet E, Shiratori Y, Hikiba Y, Takada H, Yoshida H, Kano K, Omata M. CINC release from
hepatocytes is modulated by kupffer cells. Hepatology 1996; 23: 353-358.
McCoy R, Haviland DL, Molmenti EP, Ziambaras T, Wetsel RA. Perlmutter DH. N-fonnylpeptide
and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase
gene-regulation. J Exp Med, 1995; 182: 207-217
Means RT, Mendenhall CL, Worden BD, Moritz TE, Chedid A. EPO and cytokine levels in the
anaemia of severe alcoholic liver disease. Ale Clin Exp Res. 1996; 20: 355-358.
Mendelson KG, Contois LR, Tevosian SG, Davis RJ. Paulson KE. Independent regulation of JNK/P38
MAP kinases by metabolic oxidative stress in the liver. Proc Natl Acad Sci USA, 1996; 93:
12908-12913.
Mendoza EC, Paglieroni TG, Zeldis JB. Decreased PMA induced release of TNF alpha and IL1 beta
from peripheral blood monocytes of patients infected with hepatitis C vims. J Infect Dis, 1996;
174: 842-844.
163
Menegazzi M, DePrati A, Suzuki H, Shinozuka H, Pibiri M, Piga R, Columbano A, Columbano GM.
Liver cell proliferation induced by nafenopin and cyproterone acetate is not associated with
increases in activation of the transcription factors NK-kB and AP-1 or with expression of TNF
alpha. Hepatology, 1997; 25: 585-592.
Meyer M, Schreck R, Baeuerle PA. H202 and antioxidants have opposite effects on activation of NF-
kB and API in intact cells: API as a secondary antioxidant responsive factor. EMBO J
1993;12:2005-15.
Mican JM, Dibisceglie AM, Fong TL, Travis WD, Kleiner DE, Baker B, Metcalfe DD. Hepatic
involvement in mastocytosis; clinicopathological correlations in 41 cases. Hepatology
1995;22:1163-1170.
Milich DR, Schodel F, Hughes JL, Jones JE, Peterson DL. The hepatitis B vims core and e antigens
elicit different Th cell subsets. J Virol, 1997; 71: 2192-2201.
Minty A, Chalon P, Guillemot JC, Kaghad M, Liauzun P, Magazin M, Miloux B, Minty C, Ramond
P, Vita N, Lupker J, Shire D, Ferrara P, Caput D. Molecular cloning of the MCP-3 chemokine
gene and regulation of its expression. Eur Cytokine Netw, 1993; 4: 99-110.
Mitchell JR, Jollow DJ, Potter WZ, Davis D, Gillette JR, Brodie BB. Acetaminophen induced hepatic
necrosis.I. Role of drug metabolism. J Pharmacol Exp Titer 1973;187:185-194.
Mitsui H, Furitsu T, Dvorak AM, Irani AMA, Schwartz LB, Inagaki N, Takei M, Ishizaka K, Zsebo
KM, Gillis S, Ishazaka T. Development of human mast cells from umbilical cord blood cells by
recombinant human and murine c-kit ligand. Proc Natl Acad Sci USA 1993;90:735-739.
Mizuhara H, Uno M, Seki N, Yamashita M. Yainaoka M, Ogawa T, Kaneda K, Fujii T, Senoh H,
Fujiwara H. Critical involvement of interferon gamma in the pathogenesis of T cell activation
associated hepatitis and regulatory mechanisms of IL6 for the manifestations of hepatitis.
Gastroenterology, 1996; 23: 1608-1615.
Morita M, Watanabe Y, Akaike T. Protective effect of HGF on IFN gamma induced cytotoxicity in
mouse hepatocytes. Hepatology 1995; 21: 1585-1593.
Morland CM, Fear J, Joplin R, Adams DH. Inflammatory cytokines stimulate human biliary epithelial
cells to express interleukin-8 and monocyte cheinotactic protein-1. Biochem Soc Trans
1997;25:S232
Moseley RH, Wang W, Takeda H, Lown K, Shick L, Ananthanarayanan M, Suchy FJ. Effect of
endotoxin on bile acid transport in rat liver. Am J Physiol, 1996; 34: G137-G146.
Moshage H. Cytokines and the hepatic acute phase response. J Path, 1997; 181: 257-266.
Mufson RA. The role of serine threonine phosphorylation in hemopoietic cytokine receptor signal
transduction. FASEB J, 1997; 11: 37-44.
Mukaida N, Shiroo M, Matsushima K. Genomic structure of the human monocyte derived neutrophil
chemotactic factor, IL-8. J Immunol, 1989; 143: 1366-1371.
Murray S, Schell K, McCarthy DO, Albertini MR. Tumor growth, weight loss and cytokines in SCID
mice. Cancer Letters, 1997; 111: 111-115
Muto Y, Meager A, Eddleston ALWF, NonriAria KT, Alexander GJM, Williams R. Enhanced tumour
necrosis factor and interleukin 1 in fulminant liver failure. Lancet 1988;2:72-74.
Nagata M, Sedgwick JB, Bates ME, Kita H, Busse WW. Eosinophil adhesion to vascular cell adhesion
molecule 1 activates superoxide anion generation. J Immunol 1995;155:2194-2202.
Nakao M, Nomiyaina H, Shimada K. Structure of human genes coding for cytokine LD78 and their
expression. Mol Cell Biol. 1990; 10: 3646-3658.
Nanney LB, Mueller SG, Bueno R, Peiper SC, Richmond A. Distributions of melanoma growth
stimulatory activity or growth regulated gene and the interleukin-8 receptor-B in human wound
repair. Am J Path 1995;147:1248-1260.
Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in
chronic hepatitis C infection correlates with increased intrahepatic expression of Thl
associated cytokines. Hepatology, 1996: 24: 759-765.
Napolitano M, Modi WS, Cevario SJ, Gnarra JR, Seuanez HN. Leonard WJ. The gene encoding the
Act-2 cytokine. J Biol Chem, 1991; 266: 17531-17536.
Neurath AR, Strick N, Li YY. Cells transfected with human IL6 cDNA aquire binding sites for the
hepatitis B virus envelope protein. J Exp Med, 1992; 176: 1561-1569.
Norgauer J, Metzner B, Schraufstatter I. Expression and growth promoting function of the IL-8
receptor-beta in human melanoma cells. J Immunol 1996; 156:1132-1137.
164
Ohtsuka M, Miyazaki M, Kondo Y, Nakajima N. Neutrophil mediated sinusoidal endothelial cell
injury after extensive hepatectomy in cholestatic rats. Hepatology 1997;25:636-641.
Okamoto T, Furuya M, Yamakawa T, Yamamura KI, Hino O. TNF alpha expression in the liver of
the IFN transgenic mouse with chronic active hepatitis. Biochem Biophys Res Comm, 1996;
226: 762-768.
Omori M, Evarts RP, Omori N, Hu ZY, Marsden ER, Thorgeirsson SS. Expression of alpha
fetoprotein and stem cell factor/c-kit system in bile duct ligatcd young rats. Hepatology
1997;25:1115-1122.
Omori M, Omori N, Evarts RP, Teramoto T, Thorgeirsson SS. Coexpression of flt-3 ligand flt-3 and
SCF/c-kit signal transduction systems in bile duct ligated si and w mice. A J Path
1997;150:1179-1187.
Oppenheim JJ, Zachariae COC, Mukaida N, Matsushima K. Properties of the novel proinflammatory
"intercrine" cytokine family. Annu Rev Immunol 1991;9:617-648.
Pesce M, Farrace MG, Piacentini M, Dolci S, Defelici M. Stem cell factor and leukemia inhibitory
factor promote primordial germ cell survival by suppressing programmed cell death
(apoptosis). Development 1993;118:1089-1094.
Rai RM, Loffreda S, Karp CL, Yang S-Q, Lin H-Z, Diehl AM. Kupffer cell depletion abolishes
induction of interleukin 10 and permits the sustained overcxpression of TNF alpha mRNA in
the regenerating rat liver. Hepatology, 1997; 25: 889-895.
Rao MS, Yukawa M, Oniori M, Thorgeirsson SS, Reddy JK. Expression of transcription factors and
stem cell factor precedes hepatocyte differentiation in rat pancreas. Gene Expression
1996;6:15-22.
Remick DG, Strieter RM, Eskandari MK, Nguyen DT, Genard MA, Raiford CL, Kunkel SL. Role of
TNF alpha in lipopolysaccaride induced pathological alterations. Am J Path 1990;136:49-54.
Rowell DL, Eckmann L, Dwinell MB, Carpenter SP, Raucy JL, Yang SK, Kagnoff MF. Human
hepatocytes express an array of proinflammatory cytokines after agonist stimulation or bacterial
invasion. Am J Physiol (GI/Liver) 1997;36:G322-G332.
Ruttinger D, Vollmar B, Wanner GA, Messmer K. In vivo assesment of hepatic alterations following
gadolinium chloride induced Kupffer cell blockade. J Hepatol 1997;25:960-967.
Sakamoto K, Masuda T, Mita S, Ishiko T, Nakashima Y, Arakawa H, Egami H, Harada S,
Matsushima K, Ogawa M. Interleukin-8 is constitutively and commonly produced by various
human carcinoma cell-lines. Int J Clin Lab Res, 1992; 22: 216-219
Santucci L, Fiorucci S, Chiorean M, Brunori PM, Di Matteo FM, Sidoni A, Migliorati G, Morelli A.
Interleukin 10 reduces lethality and hepatic injury induced by lipopolysaccaride in
galactosamine sensitised mice. Gastroenterology 1996;111:736-744.
Sato T, Asanuma Y, Masaki Y, Sato Y, Hatakeyaina Y, Kusano T, Koyama K. Changes in TNF alpha
and IL1 beta production following liver surgery on cirrhotic patients. Hepato-Gastroenterol,
1996; 43: 1148-1153.
Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, Krensky AM. A human T cell
specific molecule is a member of a new gene family. J Immunol, 1988; 141: 1018-1025.
Schaper F, Siewert E, GomezLechon MJ, Gatsios P, Sachs M, Birchmeier W, Heinrich PC, Castell J.
Hepatocyte growth factor scatter factor (HGF/SF) signals via the STAT3/APRF transcription
factor in human hepatoma cells and hepatocytes. FEBS Letters, 1997; 405: 99-103.
Schindeler C, Darnell JE. Transcriptional responses to polypeptide ligands, the JAK/STAT pathway.
Ann Rev Biochem, 1995; 64: 621-651.
Schreck R, Meier B, Mannel DN, Droge W, Baeuerie PA. Dithiocarbamates as potent inhibitors of
NF-kB activation in intact cells. J Exp Med 1992; 175:1181-1193.
Schreck, R Reber P, Baeuerie PA. Reactive oxygen intermediates as apparently widely used
messangers in the activation of the NF-kB transcription factor and HIV-1. EMBO J
1991;10:2247-2258.
Sekiyama KD, Yoshiba M, Thomson AW. Circulating proinflammatory cytokines (IL-1 bata, TNF-
alpha and IL-6) and IL-1 receptor antagonist in fulminant hepaticx failure and acute hepatitis.
Clin Exp Immunol 1994;98:71-77.
Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J, 1996; 10: 709-
720.
165
Serizawa A, Nakamura S, Suzuki S, Baba S, Nakano M. Involvement of PAF in cytokine production
and neutrophil activation after hepatic ischaemia-reperfusion. Hepatology, 1996; 23: 1656-
1663.
Sheron N, Bird G, Koskinas J, Portmann B, Ceska M. Lindley I, Williams R. Circulating and tissue
levels of the neutrophil chemotaxin IL8 are elevated in severe acute alcoholic hepatitis.
Hepatology, 1993; 18: 41-46.
Shibata F, Konishi K, Kato H, Komorita N, Almokdad M, Fujioka M, Nakagawa H. Recombinant
production and biological properties of rat cytokine induced neutrophil chemoattractants,
gro/CINC-2-alpha, CINC-2-beta and CINC-3. Eur J Biochem 1995;231:306-311.
Shiratori Y, Takada H, Hai K, Kiriyama H, Mawet E, Komatsu Y, Nivva Y, Matsumura M, Shiina S.
Effect of antiallergic agents on chemotaxis of neutrophils by stimulation of chemotactic factor
released from hepatocytes exposed to ethanol. Dig Dis Sci, 1994; 39: 1569-1575.
Shiratori Y, Takada H, Hikiba Y, Nakata R, Okano K. Komatsu Y, Niwa Y, Matsumura M, Shiina S,
Omata M, Kamii K. Production of chemotactic factor, interleukin 8 from hepatocytes exposed
to ethanol. Hepatology, 1993; 18: 1477-1482.
Shito M, Wakabayashi G, Ueda M, Shimazu M, Shirasugi N, Endo M, Mukai M, Kitajima M. IL1
receptor blockade reduces TNF production, tissue injury and mortality after hepatic
ischaemia/reperfusion in the rat. Transplantation, 1997; 63: 143-148.
Simonet S, Hughes TM, Nguyen HQ, Trebasky LD, Danilenko DM. Madlock ES. Long-term impaired
neutrophil migration in mice overexpressing human IL8. J Clin Invest, 1994; 94: 1310-1319.
Skretting G, Gjernes E, Prydz H. Regulation of LCAT by TGF and IL6. Biochem Biophys Acta, 1995;
1255: 267-272.
Spengler U, Zachoval R, Gallati H, Jung MC, Hoffman R, Reithmuller G, Pape G. Serum levels and
in situ expression of TNF alpha and TNF alpha binding proteins in inflammatoiy liver
diseases. Cytokine, 1996; 8: 864-872.
Staal FJT, Roederer M, Herzenberg LA, Herzenberg LA. Intracellular thiols regulate activation of
nuclear factor kappa B and transcription of human immunodeficiency virus. Proc Natl Acad
Sci USA 1990;87:9943-9947.
Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL. Neutralisation of IL10 increases lethality in
endotoxemia: Cooperative effects of macrophage inflammatory protein 2 and tumor necrosis
factor. J Immunol 1995;155:2222-2229.
Streiter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, VanDamme J,
Walz A, Marriott D, Chan SY, Roczniak S, Shanafelt AB. The functional role of the ELR
motif in CXC chemokine mediated angiogenesis. J Biol Chem. 1995;270:27348-27357.
Suzuki S, Toledopereyra LH. IL1 and TNF production as the initial stimulants of liver ischaemia and
reperfusion injury. J Surg Res, 1994; 57: 253-258.
Takafuji S, Ohtoshi T, Takizawa H, Tadokoro K, Ito K. Eosinophil degranulation in the presence of
bronchial epithelial cells: Effects of cytokines and the role of adhesion. J Immunol
1996;156:3980-3985.
Tanaka Y, Adams DH, Hubscher S Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by
proteoglycan-inunobilised cytokine MIP-1 beta. Nature 1993;361:79-82.
Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ. Preferential migration of activated CD4+
and CD8+ T cells in response to MlP-la and MIP-ip. Science 1993;260:355-358.
Taub R. Transcriptional control of liver regeneration. FASEB J, 1996; 10: 413-427.
Thornton AJ, Ham J, Kunkel SL. Kupffer cell derived cytokines induced the synthesis of a leukocyte
chemotactic peptide, interlukin 8, in human hepatoma and primary hepatocyte cultures.
Hepatology, 1992; 15: 1112-1122.
Thornton AJ, Strieter RM, Lindley I, Baggiolini M, Kunkel SL. Cytokine induced gene expression of
a neutrophil chemotactic factor/IL8 in human hepatocytes. J Immunology, 1990; 144: 2609-
2613.
Tilg H. New insights into the mechanisms of interferon alpha. Gastroenterology, 1997; 112: 1017-
1021.
Tsai M, Takeishi T, Thompson H, Langley KE, Zsebo KM, Metcalfe DD, Geissler EN, Galli SJ.
Induction of mast cell proliferation, maturation and heparin synthesis by the rat c-kit ligand,
stem cell factor. Proc Natl Acad Sci USA 1991;88:6382-6386.
166
Tsuruta J, Sugisaki K, Dannenberg AM, Yoshimura T, Abe Y, Mounts P. The cytokines NAP-1 (IL-
8), MCP-1, IL-l-beta, and gro in rabbit inflammatory skin lesions produced by the chemical
irritant sulfur mustard. Inflammation 1996;20:293-318.
Van Den Abeele P, DeCIercq W, Beyaert R, Fiers W. 2 TNF receptors, structure and function. Trends
Cell Biol, 1995; 5: 392-399.
Van Gool J, VanVugt H, Helle M, Aarden LA. The relation among stress, adrenaline, interleukins
and acute phase proteins in the rat. Clin Immunol Immunopath 1990; 57: 200-210.
Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA-1 ligand ICAM-1 provides an important
costimulatory signal for T cell receptor mediated activation of resting T cells. J Immunol
1990;144:4579-4586.
Vilcek J, Lee TH. Tumor necrosis factor - new insights into the molecular mechanisms of its multiple
actions. J Biol Chem 1991;266:7313-7316.
Volpes R, van den Oord JJ, Desmet VJ, Yap S-H. Induction of intracellular adhesion molecule-1
(CD54) on human hepatoma cell line Hep G2: Influence of cytokines and Hepatitis B virus
DNA transfection. Clin Exp Immunol 1992;87:71-75.
Vonschweinitz D, Schmidt D, Fuchs J, Welte K, Pietsch T. Extramedullary heinatopoiesis and
intratumoral production of cytokines in childhood hepatoblastoma. Pediatric Res 1995;38:555-
563.
Waddell TK, Fialkow L, Chan CK, Kishimoto TK, Downey GP. Potentiation of the oxidative burst of
human neutrophils: A signaling role for L-selectin. J Biol Chem. 1994;269:18485-18491.
Walley KR, Lukacs NW, Standiford TJ, Strieter RM. Kunkel SL. Balance of inflammatory cytokines
related to the severity and mortality of murine sepsis. Infect Immunity 1996;64:4733-4738.
Watanabe Y, Morita M, Akaike T. ConA induces perforin but not Fas mediated hepatic injury.
Hepatology, 1996; 24: 702-710.
Wolpe SD, Davatelis G, Sherry B, Beutler B, Hesse DG, Nguyen HT, Moldawer LL, Nathen CF,
Lowry SF, Cerami A. Macrophages secrete a novel heparin binding protein with inflammatory
and neutrophil chemokinetic properties. J Exp Med 1988;167:570-581.
Wu J, Zern MA. Modification of liposomes for liver targetting. J Hepatol, 1996; 24: 757-763.
Xu Y, Rojkind M, Czaja MJ. Regulation of monocyte chemoattractant protein 1 by cytokines and
oxygen free radicals in rat hepatic fat storing cells. Gastroenterology, 1996; 110: 1870-1877.
Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by TNF: Deficient liver
regeneration in mice lacking type 1 TNF receptor. Proc Natl Acad Sci USA 1997;94:1441-
1446.
Yang R, Lin Q, Rescorla FJ, Grosfeld JL. Experimental liver cancer, improved response after hepatic
artery ligation and infusion of tumor necrosis factor alpha and interferon-gamma. Surgery,
1995;118:768-774
Yeung AW, Pang YK, Tsang YC, Wong SW, Leung JS. Short duration invitro interleukin-2 activated
mononuclear cells for advanced cancer, a Hong-Kong biotherapy pilot study trial. Cancer,
1993;71:3633-3639
Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, Leonard EJ. Human monocyte
chemoattractant protein 1 (MCP-l). FEBS Lett, 1989; 244: 487-493.
Zesbo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL. Hsu RY, Birkett NC,
Okino KH, Murdock DC, Jacobsen FW, Langley KE, Smith KA, Takeishi T, Cattanach BM,
Galli SJ, Suggs SV. Stem cell factor is encoded at the si-locus of the mouse and is the ligand
for the c-kit tyrosine kinase receptor. Cell 1990;63:213-224.
Zhou M, Brown EJ. Leukocyte response integrins and integrin associated protein act as a signal
transduction unit in generation of a phagocytic respiratory burst. J Exp Med. 1993 178:1165-
1174.
Ziegler-Heitbrock HWL, Sterndorf T, Liese J, Belohradsky B, Weber C, Wedel A, Schreck R, Bauerle
P, Strobel M. Pyrrolidine dithiocarbamate inhibits NF-kB mobilisation and TNF production in
human monocytes. J Immunol 1993;151:6986-6993.
167
